+

WO2000012708A2 - Nouveaux pro-polypeptides et sequences correspondantes - Google Patents

Nouveaux pro-polypeptides et sequences correspondantes Download PDF

Info

Publication number
WO2000012708A2
WO2000012708A2 PCT/US1999/020111 US9920111W WO0012708A2 WO 2000012708 A2 WO2000012708 A2 WO 2000012708A2 US 9920111 W US9920111 W US 9920111W WO 0012708 A2 WO0012708 A2 WO 0012708A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
polypeptide
sequence identity
amino acid
sequence
Prior art date
Application number
PCT/US1999/020111
Other languages
English (en)
Other versions
WO2000012708A3 (fr
Inventor
Kevin Baker
Audrey Goddard
Austin L. Gurney
Victoria Smith
Colin K. Watanabe
William I. Wood
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Priority to IL14142099A priority Critical patent/IL141420A0/xx
Priority to AU55908/99A priority patent/AU759150B2/en
Priority to EP99942557A priority patent/EP1144629A3/fr
Priority to JP2000567695A priority patent/JP2003518361A/ja
Priority to JP2000584912A priority patent/JP3695642B2/ja
Priority to KR1020047012987A priority patent/KR100543857B1/ko
Priority to CA002347835A priority patent/CA2347835A1/fr
Priority to MXPA01005169A priority patent/MXPA01005169A/es
Priority to PCT/US1999/028313 priority patent/WO2000032221A2/fr
Priority to AU17482/00A priority patent/AU771751C/en
Priority to AT99960624T priority patent/ATE458050T1/de
Priority to EP06014175A priority patent/EP1734051A3/fr
Priority to KR10-2001-7006818A priority patent/KR100529270B1/ko
Priority to CA002503475A priority patent/CA2503475A1/fr
Priority to NZ535590A priority patent/NZ535590A/en
Priority to IL14274299A priority patent/IL142742A0/xx
Priority to EP99960624A priority patent/EP1135485B1/fr
Priority to ES05019849T priority patent/ES2324876T3/es
Priority to AT05019849T priority patent/ATE427319T1/de
Priority to JP2000603371A priority patent/JP2003525585A/ja
Priority to CA002367334A priority patent/CA2367334A1/fr
Priority to EP05019846A priority patent/EP1642967A3/fr
Priority to EP05019850A priority patent/EP1634892A3/fr
Priority to ES05019847T priority patent/ES2329689T3/es
Priority to AT05019847T priority patent/ATE439431T1/de
Priority to EP05019849A priority patent/EP1642907B1/fr
Priority to KR1020017011361A priority patent/KR100566839B1/ko
Priority to EP99965090A priority patent/EP1159422A1/fr
Priority to EP05019848A priority patent/EP1642906A3/fr
Priority to EP05019847A priority patent/EP1642968B1/fr
Priority to DE69941273T priority patent/DE69941273D1/de
Priority to DE69940681T priority patent/DE69940681D1/de
Priority to PCT/US1999/028551 priority patent/WO2000053750A1/fr
Priority to AU31077/00A priority patent/AU773055C/en
Priority to MXPA01006345A priority patent/MXPA01006345A/es
Priority to KR1020017007877A priority patent/KR20010102960A/ko
Priority to EP99966374A priority patent/EP1141289A2/fr
Priority to IL14321299A priority patent/IL143212A0/xx
Priority to PCT/US1999/030095 priority patent/WO2000037640A2/fr
Priority to AU21928/00A priority patent/AU2192800A/en
Priority to CA002353775A priority patent/CA2353775A1/fr
Priority to JP2000589694A priority patent/JP2003524390A/ja
Priority to PCT/US2000/000219 priority patent/WO2000053753A2/fr
Priority to AU26008/00A priority patent/AU2600800A/en
Priority to EP05018353A priority patent/EP1626084B1/fr
Priority to ES05018355T priority patent/ES2289630T3/es
Priority to EP05018354A priority patent/EP1632499B9/fr
Priority to AT05018355T priority patent/ATE364628T1/de
Priority to AU28794/00A priority patent/AU756400B2/en
Priority to PT05018355T priority patent/PT1623989E/pt
Priority to AT05018353T priority patent/ATE422536T1/de
Priority to CA002365610A priority patent/CA2365610A1/fr
Priority to EP00907270A priority patent/EP1173563A1/fr
Priority to ES05018353T priority patent/ES2321954T3/es
Priority to ES05018356T priority patent/ES2279473T3/es
Priority to AT05018356T priority patent/ATE348108T1/de
Priority to AT05018358T priority patent/ATE380195T1/de
Priority to PCT/US2000/003565 priority patent/WO2001053486A1/fr
Priority to CA002479494A priority patent/CA2479494C/fr
Priority to DK05018358T priority patent/DK1623990T3/da
Priority to KR10-2001-7011391A priority patent/KR100512819B1/ko
Priority to DK05018354T priority patent/DK1632499T3/da
Priority to PT05018356T priority patent/PT1607402E/pt
Priority to EP05018356A priority patent/EP1607402B1/fr
Priority to AT05018354T priority patent/ATE363489T1/de
Priority to CA002479498A priority patent/CA2479498A1/fr
Priority to PT05018354T priority patent/PT1632499E/pt
Priority to CA002479476A priority patent/CA2479476C/fr
Priority to AT05018357T priority patent/ATE377025T1/de
Priority to EP05018355A priority patent/EP1623989B1/fr
Priority to CA002479511A priority patent/CA2479511A1/fr
Priority to DK05018356T priority patent/DK1607402T3/da
Priority to EP05018358A priority patent/EP1623990B1/fr
Priority to ES05018354T priority patent/ES2290834T3/es
Priority to PT05018358T priority patent/PT1623990E/pt
Priority to ES05018357T priority patent/ES2296029T3/es
Priority to JP2001553947A priority patent/JP2004520003A/ja
Priority to PT05018357T priority patent/PT1626058E/pt
Priority to DK05018355T priority patent/DK1623989T3/da
Priority to ES05018358T priority patent/ES2298896T3/es
Priority to DK05018357T priority patent/DK1626058T3/da
Priority to EP05018357A priority patent/EP1626058B1/fr
Priority to AU28837/00A priority patent/AU2883700A/en
Priority to PCT/US2000/004342 priority patent/WO2000078961A1/fr
Priority to PCT/US2000/005004 priority patent/WO2000053757A2/fr
Priority to KR1020017011378A priority patent/KR100553300B1/ko
Priority to KR1020017011378D priority patent/KR20010104373A/ko
Priority to EP00912015A priority patent/EP1159419A1/fr
Priority to JP2000603378A priority patent/JP2003531811A/ja
Priority to CA002361849A priority patent/CA2361849A1/fr
Priority to AU33816/00A priority patent/AU768694B2/en
Priority to PCT/US2000/005841 priority patent/WO2000053758A2/fr
Priority to KR1020017011406A priority patent/KR20010103046A/ko
Priority to EP00913764A priority patent/EP1220905A2/fr
Priority to AU35144/00A priority patent/AU3514400A/en
Priority to JP2000603379A priority patent/JP2004516227A/ja
Priority to CA002362427A priority patent/CA2362427A1/fr
Publication of WO2000012708A2 publication Critical patent/WO2000012708A2/fr
Priority to CA002376116A priority patent/CA2376116A1/fr
Priority to AT00939307T priority patent/ATE393825T1/de
Priority to ES00939307T priority patent/ES2307515T3/es
Priority to AU54412/00A priority patent/AU5441200A/en
Priority to DE60038740T priority patent/DE60038740T2/de
Priority to DK00939307T priority patent/DK1212417T3/da
Priority to PCT/US2000/013705 priority patent/WO2000073445A2/fr
Priority to EP00939307A priority patent/EP1212417B1/fr
Priority to PT00939307T priority patent/PT1212417E/pt
Priority to JP2001500757A priority patent/JP4297317B2/ja
Priority to EP07025118A priority patent/EP1956030B1/fr
Priority to AT07025116T priority patent/ATE449109T1/de
Priority to AU51527/00A priority patent/AU5152700A/en
Priority to PCT/US2000/014042 priority patent/WO2000077037A2/fr
Priority to CA2372511A priority patent/CA2372511C/fr
Priority to JP2001503894A priority patent/JP2003529324A/ja
Priority to AT07025118T priority patent/ATE448246T1/de
Priority to DE60043322T priority patent/DE60043322D1/de
Priority to EP07025117A priority patent/EP1978029A3/fr
Priority to DE60043367T priority patent/DE60043367D1/de
Priority to EP07025116A priority patent/EP1953173B1/fr
Priority to EP00936172A priority patent/EP1208195A2/fr
Priority to AT00941164T priority patent/ATE357518T1/de
Priority to ES00941164T priority patent/ES2287020T3/es
Priority to DK00941164T priority patent/DK1185648T3/da
Priority to JP2001500672A priority patent/JP2003524406A/ja
Priority to EP07005022A priority patent/EP1870464A3/fr
Priority to DE60034036T priority patent/DE60034036T2/de
Priority to AU55911/00A priority patent/AU5591100A/en
Priority to EP07005023A priority patent/EP1867719A3/fr
Priority to EP07005021A priority patent/EP1873244A3/fr
Priority to CA002373915A priority patent/CA2373915A1/fr
Priority to PCT/US2000/014941 priority patent/WO2000073348A2/fr
Priority to EP07004855A priority patent/EP1820860A3/fr
Priority to EP00941164A priority patent/EP1185648B1/fr
Priority to PCT/US2000/015264 priority patent/WO2000073452A2/fr
Priority to AU54601/00A priority patent/AU5460100A/en
Priority to EP00959474A priority patent/EP1208201B9/fr
Priority to DE60041266T priority patent/DE60041266D1/de
Priority to AT00959474T priority patent/ATE419348T1/de
Priority to ES00959474T priority patent/ES2317847T3/es
Priority to AU70793/00A priority patent/AU7079300A/en
Priority to CA002384055A priority patent/CA2384055A1/fr
Priority to JP2001520865A priority patent/JP3988821B2/ja
Priority to PCT/US2000/023522 priority patent/WO2001016319A2/fr
Priority to EP05019537A priority patent/EP1637541B1/fr
Priority to ES05019537T priority patent/ES2341257T3/es
Priority to EP07019808A priority patent/EP1892249A1/fr
Priority to EP05019538A priority patent/EP1623992A3/fr
Priority to EP05019539A priority patent/EP1623993A3/fr
Priority to CA002645727A priority patent/CA2645727A1/fr
Priority to CA002481691A priority patent/CA2481691A1/fr
Priority to AT05019537T priority patent/ATE459645T1/de
Priority to CA002481685A priority patent/CA2481685A1/fr
Priority to CA002481756A priority patent/CA2481756A1/fr
Priority to CA002380355A priority patent/CA2380355A1/fr
Priority to EP05019540A priority patent/EP1621620A3/fr
Priority to EP00964919A priority patent/EP1208202A2/fr
Priority to CA2481731A priority patent/CA2481731C/fr
Priority to JP2001520864A priority patent/JP3951035B2/ja
Priority to DE60043951T priority patent/DE60043951D1/de
Priority to CA002481788A priority patent/CA2481788A1/fr
Priority to PCT/US2000/023328 priority patent/WO2001016318A2/fr
Priority to EP05019536A priority patent/EP1623991A3/fr
Priority to AU75730/00A priority patent/AU7573000A/en
Priority to US09/888,257 priority patent/US20030060612A1/en
Priority to US09/929,769 priority patent/US6914130B2/en
Priority to US09/938,418 priority patent/US20020161199A1/en
Priority to US09/946,374 priority patent/US20030073129A1/en
Priority claimed from US09/946,374 external-priority patent/US20030073129A1/en
Publication of WO2000012708A3 publication Critical patent/WO2000012708A3/fr
Priority to US09/990,456 priority patent/US20020137890A1/en
Priority to US10/002,796 priority patent/US20030032057A1/en
Priority to US10/001,054 priority patent/US20020192209A1/en
Priority to US10/006,130 priority patent/US7098312B2/en
Priority to US10/006,041 priority patent/US6951921B2/en
Priority to US10/006,172 priority patent/US7081514B2/en
Priority to US10/006,485 priority patent/US7026448B2/en
Priority to US10/006,867 priority patent/US7160985B2/en
Priority to US10/006,063 priority patent/US20030114652A1/en
Priority to US10/007,194 priority patent/US7041805B2/en
Priority to US10/006,768 priority patent/US6936697B2/en
Priority to US10/006,818 priority patent/US20030054406A1/en
Priority to US10/006,117 priority patent/US7071304B2/en
Priority to US10/006,116 priority patent/US20030082626A1/en
Priority to US10/007,236 priority patent/US7034123B2/en
Priority to US10/006,856 priority patent/US7538086B2/en
Priority to US10/006,746 priority patent/US7026449B2/en
Priority to US10/011,833 priority patent/US6951920B2/en
Priority to US10/012,753 priority patent/US7488796B2/en
Priority to US10/012,752 priority patent/US7026455B2/en
Priority to US10/012,755 priority patent/US20030096955A1/en
Priority to US10/012,137 priority patent/US20030187189A1/en
Priority to US10/011,692 priority patent/US20030109672A1/en
Priority to US10/011,671 priority patent/US20030096954A1/en
Priority to US10/012,237 priority patent/US20030191281A1/en
Priority to US10/012,149 priority patent/US7038019B2/en
Priority to US10/012,121 priority patent/US7022817B2/en
Priority to US10/012,101 priority patent/US20030187239A1/en
Priority to US10/012,754 priority patent/US7375184B2/en
Priority to US10/011,795 priority patent/US7012131B2/en
Priority to US10/012,064 priority patent/US6953841B2/en
Priority to US10/012,231 priority patent/US6924355B2/en
Priority to US10/012,754 priority patent/US20030187191A1/en
Priority to US10/013,907 priority patent/US20030064925A1/en
Priority to US10/013,913 priority patent/US20030083462A1/en
Priority to US10/013,911 priority patent/US20030187193A1/en
Priority to US10/013,912 priority patent/US7399834B2/en
Priority to US10/013,910 priority patent/US7057018B2/en
Priority to US10/013,430 priority patent/US20030092883A1/en
Priority to US10/013,915 priority patent/US20030204053A1/en
Priority to US10/013,906 priority patent/US20030191282A1/en
Priority to US10/013,909 priority patent/US20030186318A1/en
Priority to US10/015,822 priority patent/US20030130491A1/en
Priority to US10/015,519 priority patent/US7033785B2/en
Priority to US10/015,869 priority patent/US7189530B2/en
Priority to US10/015,389 priority patent/US6936436B2/en
Priority to US10/015,653 priority patent/US20030187195A1/en
Priority to US10/015,869 priority patent/US20030073130A1/en
Priority to US10/015,671 priority patent/US6946263B2/en
Priority to US10/015,480 priority patent/US7074912B2/en
Priority to US10/015,393 priority patent/US6951737B2/en
Priority to US10/015,499 priority patent/US20030065142A1/en
Priority claimed from US10/015,480 external-priority patent/US7074912B2/en
Priority to US10/015,388 priority patent/US20030191299A1/en
Priority to US10/015,386 priority patent/US7022498B2/en
Priority to US10/015,387 priority patent/US20030135034A1/en
Priority to US10/015,385 priority patent/US20030195347A1/en
Priority to US10/015,390 priority patent/US20030216562A1/en
Priority to US10/015,610 priority patent/US7087404B2/en
Priority to US10/015,391 priority patent/US20030120053A1/en
Priority to US10/015,715 priority patent/US7033786B2/en
Priority to US10/015,392 priority patent/US6972186B2/en
Priority to US10/015,395 priority patent/US7083946B2/en
Priority to US10/017,527 priority patent/US20030082628A1/en
Priority to US10/017,867 priority patent/US20030180792A1/en
Priority to US10/017,306 priority patent/US20030170718A1/en
Priority to US10/017,407 priority patent/US20030125535A1/en
Priority to US10/017,610 priority patent/US20030113795A1/en
Priority to US10/020,063 priority patent/US20030119097A1/en
Priority to US10/017,253 priority patent/US7029875B2/en
Priority to US10/028,072 priority patent/US20030004311A1/en
Priority to US10/052,586 priority patent/US20020127584A1/en
Priority to US10/053,107 priority patent/US20020192752A1/en
Priority to US10/066,198 priority patent/US20030170721A1/en
Priority to US10/066,211 priority patent/US20030044844A1/en
Priority to US10/066,500 priority patent/US20020177165A1/en
Priority to US10/066,273 priority patent/US7317092B2/en
Priority to US10/066,269 priority patent/US20030040014A1/en
Priority to US10/066,193 priority patent/US20030044902A1/en
Priority to US10/066,203 priority patent/US20030180796A1/en
Priority to US10/066,494 priority patent/US20030032063A1/en
Priority to US10/081,056 priority patent/US20040043927A1/en
Priority to US10/119,480 priority patent/US20040087769A1/en
Priority to US10/121,044 priority patent/US20030190717A1/en
Priority to US10/121,042 priority patent/US20030096386A1/en
Priority to US10/121,059 priority patent/US20030190721A1/en
Priority to US10/121,040 priority patent/US20030082759A1/en
Priority to US10/121,045 priority patent/US20030073210A1/en
Priority to US10/121,041 priority patent/US20030077776A1/en
Priority to US10/121,046 priority patent/US20030194791A1/en
Priority to US10/121,047 priority patent/US20030077778A1/en
Priority to US10/121,051 priority patent/US20030092147A1/en
Priority to US10/121,061 priority patent/US20030082761A1/en
Priority to US10/121,052 priority patent/US20030199052A1/en
Priority to US10/121,043 priority patent/US7220831B2/en
Priority to US10/121,050 priority patent/US20030054516A1/en
Priority to US10/121,056 priority patent/US20030082760A1/en
Priority to US10/121,048 priority patent/US20030199051A1/en
Priority to US10/121,055 priority patent/US20030190718A1/en
Priority to US10/121,058 priority patent/US20030190720A1/en
Priority to US10/121,063 priority patent/US20030199055A1/en
Priority to US10/121,054 priority patent/US20030199054A1/en
Priority to US10/121,062 priority patent/US20030077779A1/en
Priority to US10/121,060 priority patent/US20030190722A1/en
Priority to US10/121,049 priority patent/US20030022239A1/en
Priority to US10/121,053 priority patent/US20030199053A1/en
Priority to US10/121,057 priority patent/US20030190719A1/en
Priority to US10/123,213 priority patent/US7193048B2/en
Priority to US10/123,154 priority patent/US20030190724A1/en
Priority to US10/123,156 priority patent/US20030194792A1/en
Priority to US10/123,261 priority patent/US20030068796A1/en
Priority to US10/123,109 priority patent/US20030190723A1/en
Priority to US10/123,235 priority patent/US20030082762A1/en
Priority to US10/123,771 priority patent/US20030199060A1/en
Priority to US10/123,292 priority patent/US20030073211A1/en
Priority to US10/123,212 priority patent/US7276577B2/en
Priority to US10/123,291 priority patent/US20030199058A1/en
Priority to US10/123,262 priority patent/US20030049816A1/en
Priority to US10/123,236 priority patent/US20030068795A1/en
Priority to US10/123,213 priority patent/US20030199057A1/en
Priority to US10/123,215 priority patent/US7291329B2/en
Priority to US10/123,108 priority patent/US7635478B2/en
Priority to US10/123,322 priority patent/US20030199059A1/en
Priority to US10/123,157 priority patent/US20030190725A1/en
Priority to US10/123,214 priority patent/US7343721B2/en
Priority to US10/123,155 priority patent/US20030068794A1/en
Priority to US10/123,905 priority patent/US7285625B2/en
Priority to US10/123,904 priority patent/US20030022328A1/en
Priority to US10/123,913 priority patent/US20030203462A1/en
Priority to US10/123,902 priority patent/US20030077781A1/en
Priority to US10/123,903 priority patent/US20030073212A1/en
Priority to US10/123,905 priority patent/US20030087344A1/en
Priority to US10/123,907 priority patent/US7084258B2/en
Priority to US10/123,912 priority patent/US20030100087A1/en
Priority to US10/123,908 priority patent/US7335728B2/en
Priority to US10/123,906 priority patent/US20030190726A1/en
Priority to US10/123,910 priority patent/US7329404B2/en
Priority to US10/123,911 priority patent/US7408032B2/en
Priority to US10/123,909 priority patent/US7193049B2/en
Priority to US10/125,795 priority patent/US7304131B2/en
Priority to US10/124,818 priority patent/US20030082763A1/en
Priority to US10/124,820 priority patent/US20030190729A1/en
Priority to US10/124,814 priority patent/US7105335B2/en
Priority to US10/124,819 priority patent/US7285626B2/en
Priority to US10/124,823 priority patent/US20030199062A1/en
Priority to US10/125,805 priority patent/US20030194794A1/en
Priority to US10/124,821 priority patent/US20030199023A1/en
Priority to US10/125,704 priority patent/US7357926B2/en
Priority to US10/124,822 priority patent/US7109305B2/en
Priority to US10/124,816 priority patent/US20030190728A1/en
Priority to US10/124,817 priority patent/US20030077786A1/en
Priority to US10/124,824 priority patent/US20030077659A1/en
Priority to US10/124,813 priority patent/US7312307B2/en
Priority to US10/125,932 priority patent/US7317079B2/en
Priority to US10/125,927 priority patent/US20030190731A1/en
Priority to US10/125,931 priority patent/US20030199063A1/en
Priority to US10/125,922 priority patent/US7309762B2/en
Priority to US10/125,924 priority patent/US7342097B2/en
Priority to US10/127,831 priority patent/US20030082689A1/en
Priority to US10/128,689 priority patent/US20030087365A1/en
Priority to US10/131,833 priority patent/US7141652B1/en
Priority to US10/131,820 priority patent/US7312314B2/en
Priority to US10/131,825 priority patent/US7282566B2/en
Priority to US10/131,828 priority patent/US7309777B2/en
Priority to US10/131,823 priority patent/US7304132B2/en
Priority to US10/131,817 priority patent/US7291701B2/en
Priority to US10/063,612 priority patent/US7399828B2/en
Priority to US10/137,865 priority patent/US20030032155A1/en
Priority to US10/063,586 priority patent/US7244817B2/en
Priority to US10/063,587 priority patent/US7244428B2/en
Priority to US10/063,591 priority patent/US7196174B2/en
Priority to US10/137,867 priority patent/US20030207349A1/en
Priority to US10/063,615 priority patent/US7405269B2/en
Priority to US10/063,609 priority patent/US7402661B2/en
Priority to US10/137,868 priority patent/US20030082764A1/en
Priority to US10/063,592 priority patent/US7220841B2/en
Priority to US10/140,474 priority patent/US20030032156A1/en
Priority to US10/140,023 priority patent/US20030207416A1/en
Priority to US10/140,020 priority patent/US20030207415A1/en
Priority to US10/139,980 priority patent/US7247710B2/en
Priority to US10/140,024 priority patent/US20040058424A1/en
Priority to US10/140,470 priority patent/US20030022331A1/en
Priority to US10/139,963 priority patent/US7288625B2/en
Priority to US10/063,647 priority patent/US7193046B2/en
Priority to US10/140,921 priority patent/US7317080B2/en
Priority to US10/140,865 priority patent/US20030207420A1/en
Priority to US10/140,805 priority patent/US20030207417A1/en
Priority to US10/063,639 priority patent/US7081520B2/en
Priority to US10/140,860 priority patent/US7307151B2/en
Priority to US10/063,644 priority patent/US7196167B2/en
Priority to US10/063,648 priority patent/US7193062B2/en
Priority to US10/140,864 priority patent/US20030207419A1/en
Priority to US10/140,925 priority patent/US20030073215A1/en
Priority to US10/140,808 priority patent/US7425621B2/en
Priority to US10/063,646 priority patent/US7189821B2/en
Priority to US10/140,809 priority patent/US20030207418A1/en
Priority to US10/063,651 priority patent/US7193057B2/en
Priority to US10/140,928 priority patent/US20030068798A1/en
Priority to US10/141,754 priority patent/US7361732B2/en
Priority to US10/141,756 priority patent/US7488586B2/en
Priority to US10/141,755 priority patent/US7297764B2/en
Priority to US10/141,701 priority patent/US20030207421A1/en
Priority to US10/141,760 priority patent/US7342104B2/en
Priority to US10/142,417 priority patent/US7304133B2/en
Priority to US10/143,113 priority patent/US7329730B2/en
Priority to US10/142,425 priority patent/US20030207424A1/en
Priority to US10/143,114 priority patent/US20030036180A1/en
Priority to US10/142,430 priority patent/US7309766B2/en
Priority to US10/142,419 priority patent/US7153941B2/en
Priority to US10/142,423 priority patent/US20030049817A1/en
Priority to US10/143,032 priority patent/US7408033B2/en
Priority to US10/142,431 priority patent/US7285629B2/en
Priority to US10/146,792 priority patent/US20030207428A1/en
Priority to US10/146,730 priority patent/US20030207427A1/en
Priority to US10/147,528 priority patent/US20030219885A1/en
Priority to US10/147,492 priority patent/US20030082765A1/en
Priority to US10/147,536 priority patent/US20040077064A1/en
Priority to US10/147,519 priority patent/US20030077791A1/en
Priority to US10/152,395 priority patent/US7189534B2/en
Priority to US10/153,934 priority patent/US20030129695A1/en
Priority to US10/156,843 priority patent/US20030207805A1/en
Priority to US10/157,782 priority patent/US20030077792A1/en
Priority to US10/157,786 priority patent/US20030208055A1/en
Priority to US10/158,782 priority patent/US20030082766A1/en
Priority to US10/160,498 priority patent/US20030073216A1/en
Priority to US10/158,791 priority patent/US20030207429A1/en
Priority to US10/173,707 priority patent/US20030166110A1/en
Priority to US10/173,708 priority patent/US20030040053A1/en
Priority to US10/173,706 priority patent/US20030022293A1/en
Priority to US10/173,690 priority patent/US20030166105A1/en
Priority to US10/173,699 priority patent/US20030166109A1/en
Priority to US10/173,691 priority patent/US20030166106A1/en
Priority to US10/173,698 priority patent/US20030166108A1/en
Priority to US10/173,704 priority patent/US20030170795A1/en
Priority to US10/173,695 priority patent/US20030032101A1/en
Priority to US10/173,701 priority patent/US20030104538A1/en
Priority to US10/173,694 priority patent/US20030166107A1/en
Priority to US10/173,692 priority patent/US20030166188A1/en
Priority to US10/173,705 priority patent/US20030032103A1/en
Priority to US10/173,697 priority patent/US20030032102A1/en
Priority to US10/173,702 priority patent/US20030170793A1/en
Priority to US10/173,696 priority patent/US20030082767A1/en
Priority to US10/173,700 priority patent/US20030027262A1/en
Priority to US10/173,689 priority patent/US20030166104A1/en
Priority to US10/173,703 priority patent/US20030170794A1/en
Priority to US10/173,693 priority patent/US20030073169A1/en
Priority to US10/174,590 priority patent/US20030008352A1/en
Priority to US10/174,578 priority patent/US20030073170A1/en
Priority to US10/174,586 priority patent/US20030032106A1/en
Priority to US10/174,569 priority patent/US20030166111A1/en
Priority to US10/174,581 priority patent/US7153939B2/en
Priority to US10/174,585 priority patent/US20030032105A1/en
Priority to US10/174,579 priority patent/US20030027264A1/en
Priority to US10/174,574 priority patent/US20030170796A1/en
Priority to US10/174,591 priority patent/US20030166115A1/en
Priority to US10/174,588 priority patent/US20030027266A1/en
Priority to US10/174,570 priority patent/US20030211572A1/en
Priority to US10/174,583 priority patent/US7211645B2/en
Priority to US10/174,582 priority patent/US20030027265A1/en
Priority to US10/175,740 priority patent/US20030027268A1/en
Priority to US10/174,589 priority patent/US20030166114A1/en
Priority to US10/174,587 priority patent/US20030166113A1/en
Priority to US10/174,576 priority patent/US7125962B2/en
Priority to US10/174,572 priority patent/US20030027263A1/en
Priority to US10/175,739 priority patent/US20030027267A1/en
Priority to US10/175,746 priority patent/US20030027270A1/en
Priority to US10/175,743 priority patent/US20030027269A1/en
Priority to US10/175,744 priority patent/US20030166119A1/en
Priority to US10/175,754 priority patent/US20030166123A1/en
Priority to US10/175,736 priority patent/US20030166117A1/en
Priority to US10/175,750 priority patent/US20030073172A1/en
Priority to US10/175,752 priority patent/US20030022295A1/en
Priority to US10/175,738 priority patent/US20030022294A1/en
Priority to US10/175,742 priority patent/US20030166118A1/en
Priority to US10/175,748 priority patent/US20030166121A1/en
Priority to US10/175,741 priority patent/US20030073171A1/en
Priority to US10/175,747 priority patent/US20030032107A1/en
Priority to US10/175,753 priority patent/US20030077732A1/en
Priority to US10/175,751 priority patent/US20030166122A1/en
Priority to US10/175,735 priority patent/US20030082715A1/en
Priority to US10/175,737 priority patent/US20030013153A1/en
Priority to US10/175,749 priority patent/US20050196832A1/en
Priority to US10/175,745 priority patent/US20030166120A1/en
Priority to US10/176,914 priority patent/US20030017543A1/en
Priority to US10/176,990 priority patent/US20030036119A1/en
Priority to US10/176,759 priority patent/US20030166128A1/en
Priority to US10/176,483 priority patent/US20030017541A1/en
Priority to US10/176,921 priority patent/US20030027276A1/en
Priority to US10/176,482 priority patent/US20030022296A1/en
Priority to US10/176,490 priority patent/US20030170798A1/en
Priority to US10/176,484 priority patent/US20030059876A9/en
Priority to US10/176,919 priority patent/US20030032114A1/en
Priority to US10/176,920 priority patent/US20030166129A1/en
Priority to US10/176,981 priority patent/US20030170800A1/en
Priority to US10/176,487 priority patent/US20030032110A1/en
Priority to US10/176,993 priority patent/US20030027280A1/en
Priority to US10/176,757 priority patent/US7317082B2/en
Priority to US10/176,749 priority patent/US20030017542A1/en
Priority to US10/176,479 priority patent/US20030040054A1/en
Priority to US10/176,746 priority patent/US20030068680A1/en
Priority to US10/176,913 priority patent/US20030022298A1/en
Priority to US10/176,988 priority patent/US20030170802A1/en
Priority to US10/176,747 priority patent/US20030027273A1/en
Priority to US10/176,989 priority patent/US20030170803A1/en
Priority to US10/176,911 priority patent/US20030032113A1/en
Priority to US10/176,917 priority patent/US20030044918A1/en
Priority to US10/176,493 priority patent/US20030032111A1/en
Priority to US10/176,754 priority patent/US7709602B2/en
Priority to US10/176,485 priority patent/US20030032109A1/en
Priority to US10/176,918 priority patent/US7495083B2/en
Priority to US10/176,753 priority patent/US20030044917A1/en
Priority to US10/176,491 priority patent/US20030087373A1/en
Priority to US10/176,752 priority patent/US20030170799A1/en
Priority to US10/176,760 priority patent/US7339033B2/en
Priority to US10/176,481 priority patent/US20030032108A1/en
Priority to US10/176,923 priority patent/US20030068681A1/en
Priority to US10/176,480 priority patent/US20030166124A1/en
Priority to US10/176,922 priority patent/US20030166130A1/en
Priority to US10/176,489 priority patent/US20030166125A1/en
Priority to US10/176,486 priority patent/US7354999B2/en
Priority to US10/176,979 priority patent/US20030087374A1/en
Priority to US10/176,985 priority patent/US20030027277A1/en
Priority to US10/176,924 priority patent/US20030166131A1/en
Priority to US10/176,982 priority patent/US20030044919A1/en
Priority to US10/176,925 priority patent/US20030032115A1/en
Priority to US10/176,492 priority patent/US20030027272A1/en
Priority to US10/176,755 priority patent/US20030166127A1/en
Priority to US10/176,983 priority patent/US20030170801A1/en
Priority to US10/176,758 priority patent/US20030008353A1/en
Priority to US10/176,915 priority patent/US20030017544A1/en
Priority to US10/176,986 priority patent/US20030073173A1/en
Priority to US10/176,978 priority patent/US20030032116A1/en
Priority to US10/176,756 priority patent/US20030032112A1/en
Priority to US10/176,987 priority patent/US20030027278A1/en
Priority to US10/176,751 priority patent/US20030036117A1/en
Priority to US10/176,992 priority patent/US20030027279A1/en
Priority to US10/176,916 priority patent/US20030040056A1/en
Priority to US10/176,488 priority patent/US20030027271A1/en
Priority to US10/176,748 priority patent/US20030040055A1/en
Priority to US10/176,991 priority patent/US20030027324A1/en
Priority to US10/176,750 priority patent/US20030027274A1/en
Priority to US10/179,507 priority patent/US20030040057A1/en
Priority to US10/179,510 priority patent/US20030032117A1/en
Priority to US10/179,506 priority patent/US20030044920A1/en
Priority to US10/179,512 priority patent/US20030166134A1/en
Priority to US10/179,513 priority patent/US20030044921A1/en
Priority to US10/179,520 priority patent/US20030096353A1/en
Priority to US10/179,519 priority patent/US7339024B2/en
Priority to US10/179,526 priority patent/US20030100061A1/en
Priority to US10/179,514 priority patent/US20030044922A1/en
Priority to US10/179,517 priority patent/US20030170805A1/en
Priority to US10/179,525 priority patent/US20030040060A1/en
Priority to US10/179,518 priority patent/US20030104540A1/en
Priority to US10/179,508 priority patent/US20030166133A1/en
Priority to US10/179,522 priority patent/US20030044923A1/en
Priority to US10/179,515 priority patent/US20030166135A1/en
Priority to US10/179,509 priority patent/US20030207392A1/en
Priority to US10/179,521 priority patent/US20030170806A1/en
Priority to US10/179,516 priority patent/US20030040058A1/en
Priority to US10/179,523 priority patent/US20030215909A1/en
Priority to US10/179,511 priority patent/US20030104539A1/en
Priority to US10/180,546 priority patent/US20030032120A1/en
Priority to US10/180,552 priority patent/US7348415B2/en
Priority to US10/180,559 priority patent/US20030032124A1/en
Priority to US10/180,548 priority patent/US7696319B2/en
Priority to US10/180,560 priority patent/US20030044925A1/en
Priority to US10/180,545 priority patent/US20030040062A1/en
Priority to US10/180,540 priority patent/US20030040061A1/en
Priority to US10/180,553 priority patent/US7365156B2/en
Priority to US10/180,555 priority patent/US20030032123A1/en
Priority to US10/180,544 priority patent/US20030032119A1/en
Priority to US10/180,541 priority patent/US20030036120A1/en
Priority to US10/180,543 priority patent/US20030032118A1/en
Priority to US10/180,542 priority patent/US20030036121A1/en
Priority to US10/180,554 priority patent/US20050202526A1/en
Priority to US10/180,557 priority patent/US20030022301A1/en
Priority to US10/180,547 priority patent/US20030032121A1/en
Priority to US10/180,549 priority patent/US20030032122A1/en
Priority to US10/180,556 priority patent/US7355000B2/en
Priority to US10/180,550 priority patent/US20030064440A1/en
Priority to US10/180,551 priority patent/US20030036123A1/en
Priority to US10/183,011 priority patent/US20030068682A1/en
Priority to US10/183,019 priority patent/US7425605B2/en
Priority to US10/183,012 priority patent/US7718770B2/en
Priority to US10/183,005 priority patent/US7317093B2/en
Priority to US10/180,999 priority patent/US7297767B2/en
Priority to US10/183,013 priority patent/US7309769B2/en
Priority to US10/183,006 priority patent/US7297776B2/en
Priority to US10/183,002 priority patent/US20030054454A1/en
Priority to US10/183,008 priority patent/US20030040064A1/en
Priority to US10/183,003 priority patent/US20030082716A1/en
Priority to US10/183,010 priority patent/US20030032126A1/en
Priority to US10/180,998 priority patent/US7087421B2/en
Priority to US10/183,009 priority patent/US7339034B2/en
Priority to US10/183,018 priority patent/US20030104541A1/en
Priority to US10/183,015 priority patent/US20030044926A1/en
Priority to US10/183,001 priority patent/US7084255B2/en
Priority to US10/183,017 priority patent/US20030040065A1/en
Priority to US10/181,000 priority patent/US7319137B2/en
Priority to US10/183,014 priority patent/US20030064441A1/en
Priority to US10/183,016 priority patent/US20030082717A1/en
Priority to US10/184,619 priority patent/US20030049738A1/en
Priority to US10/184,642 priority patent/US7332573B2/en
Priority to US10/184,639 priority patent/US7291703B2/en
Priority to US10/184,618 priority patent/US7393917B2/en
Priority to US10/184,613 priority patent/US20030119105A1/en
Priority to US10/184,641 priority patent/US20030073174A1/en
Priority to US10/184,615 priority patent/US20030044927A1/en
Priority to US10/184,614 priority patent/US20030032128A1/en
Priority to US10/184,627 priority patent/US20030040070A1/en
Priority to US10/184,612 priority patent/US20030036127A1/en
Priority to US10/184,640 priority patent/US7271250B2/en
Priority to US10/184,652 priority patent/US20030032134A1/en
Priority to US10/184,631 priority patent/US20030036134A1/en
Priority to US10/184,651 priority patent/US7291704B2/en
Priority to US10/184,616 priority patent/US20030036128A1/en
Priority to US10/184,633 priority patent/US20030068683A1/en
Priority to US10/184,630 priority patent/US7304143B2/en
Priority to US10/184,654 priority patent/US7378486B2/en
Priority to US10/184,630 priority patent/US20030036133A1/en
Priority to US10/184,627 priority patent/US7282569B2/en
Priority to US10/184,638 priority patent/US20030054456A1/en
Priority to US10/184,628 priority patent/US7309770B2/en
Priority to US10/184,635 priority patent/US20030032130A1/en
Priority to US10/184,637 priority patent/US20030032131A1/en
Priority to US10/184,624 priority patent/US20030104542A1/en
Priority to US10/184,657 priority patent/US20030104543A1/en
Priority to US10/184,645 priority patent/US7291718B2/en
Priority to US10/184,629 priority patent/US20030036132A1/en
Priority to US10/184,644 priority patent/US20030044930A1/en
Priority to US10/184,647 priority patent/US20030032133A1/en
Priority to US10/184,621 priority patent/US20030054455A1/en
Priority to US10/184,626 priority patent/US20030040069A1/en
Priority to US10/184,655 priority patent/US20030040073A1/en
Priority to US10/184,656 priority patent/US20030044931A1/en
Priority to US10/184,634 priority patent/US20030068684A1/en
Priority to US10/184,617 priority patent/US20030036129A1/en
Priority to US10/184,646 priority patent/US20030032132A1/en
Priority to US10/184,658 priority patent/US20030027281A1/en
Priority to US10/184,625 priority patent/US20030040068A1/en
Priority to US10/184,643 priority patent/US20030044929A1/en
Priority to US10/184,632 priority patent/US20030036135A1/en
Priority to US10/184,636 priority patent/US20030036136A1/en
Priority to US10/184,650 priority patent/US20030036138A1/en
Priority to US10/184,623 priority patent/US20030032129A1/en
Priority to US10/184,620 priority patent/US20030044928A1/en
Priority to US10/184,622 priority patent/US20030036130A1/en
Priority to US10/187,591 priority patent/US7709603B2/en
Priority to US10/187,588 priority patent/US7351795B2/en
Priority to US10/187,887 priority patent/US7285645B2/en
Priority to US10/187,886 priority patent/US7291708B2/en
Priority to US10/187,739 priority patent/US7291706B2/en
Priority to US10/187,884 priority patent/US20030036155A1/en
Priority to US10/187,597 priority patent/US20030036141A1/en
Priority to US10/187,747 priority patent/US7291707B2/en
Priority to US10/187,601 priority patent/US7291705B2/en
Priority to US10/187,594 priority patent/US7294335B2/en
Priority to US10/187,598 priority patent/US20030036142A1/en
Priority to US10/188,767 priority patent/US7312310B2/en
Priority to US10/187,745 priority patent/US7250490B2/en
Priority to US10/188,766 priority patent/US7351804B2/en
Priority to US10/187,741 priority patent/US20030036147A1/en
Priority to US10/188,780 priority patent/US7268217B2/en
Priority to US10/187,753 priority patent/US20030036152A1/en
Priority to US10/187,602 priority patent/US20030036145A1/en
Priority to US10/187,743 priority patent/US20030036148A1/en
Priority to US10/188,770 priority patent/US7358340B2/en
Priority to US10/187,754 priority patent/US20030036153A1/en
Priority to US10/187,885 priority patent/US20030032138A1/en
Priority to US10/187,747 priority patent/US20030036150A1/en
Priority to US10/187,746 priority patent/US20030036149A1/en
Priority to US10/187,603 priority patent/US20030036146A1/en
Priority to US10/188,774 priority patent/US20030040074A1/en
Priority to US10/187,600 priority patent/US20030036143A1/en
Priority to US10/188,769 priority patent/US20030036157A1/en
Priority to US10/188,781 priority patent/US20030036160A1/en
Priority to US10/187,596 priority patent/US20030032136A1/en
Priority to US10/188,773 priority patent/US20030036159A1/en
Priority to US10/188,775 priority patent/US20030040075A1/en
Priority to US10/187,757 priority patent/US7276578B2/en
Priority to US10/187,751 priority patent/US20030036151A1/en
Priority to JP2002194555A priority patent/JP2003274977A/ja
Priority to JP2002194919A priority patent/JP2003274980A/ja
Priority to JP2002194814A priority patent/JP2003274979A/ja
Priority to JP2002194702A priority patent/JP2003274978A/ja
Priority to US10/192,010 priority patent/US20030044932A1/en
Priority to US10/194,423 priority patent/US7339025B2/en
Priority to US10/194,462 priority patent/US7388073B2/en
Priority to US10/194,365 priority patent/US7381791B2/en
Priority to US10/194,461 priority patent/US20030054459A1/en
Priority to US10/194,361 priority patent/US20030036161A1/en
Priority to US10/195,889 priority patent/US7534856B2/en
Priority to US10/195,893 priority patent/US20030206188A1/en
Priority to US10/195,897 priority patent/US20030036164A1/en
Priority to US10/195,892 priority patent/US7385033B2/en
Priority to US10/195,894 priority patent/US20030043176A1/en
Priority to US10/195,902 priority patent/US20030038826A1/en
Priority to US10/195,883 priority patent/US20060073544A1/en
Priority to US10/195,901 priority patent/US20030036165A1/en
Priority to US10/195,888 priority patent/US20060073545A1/en
Priority to US10/196,756 priority patent/US7304145B2/en
Priority to US10/196,762 priority patent/US20030040078A1/en
Priority to US10/196,759 priority patent/US20030071835A1/en
Priority to US10/196,745 priority patent/US7423120B2/en
Priority to US10/196,743 priority patent/US20030038827A1/en
Priority to US10/196,760 priority patent/US7408034B2/en
Priority to US10/197,942 priority patent/US20030175882A1/en
Priority to US10/198,768 priority patent/US20030049756A1/en
Priority to US10/199,316 priority patent/US20030068726A1/en
Priority to US10/199,464 priority patent/US20030032140A1/en
Priority to US10/199,462 priority patent/US20030054468A1/en
Priority to US10/205,904 priority patent/US20030073813A1/en
Priority to US10/213,181 priority patent/US7282570B2/en
Priority to US10/213,199 priority patent/US7381809B2/en
Priority to US10/212,912 priority patent/US7344880B2/en
Priority to US10/219,528 priority patent/US20030096963A1/en
Priority to US10/219,471 priority patent/US20030100720A1/en
Priority to US10/226,739 priority patent/US7390879B2/en
Priority to US10/272,051 priority patent/US20030108544A1/en
Priority to JP2002378692A priority patent/JP2004201653A/ja
Priority to JP2002378517A priority patent/JP2004201652A/ja
Priority to JP2002379406A priority patent/JP2004229503A/ja
Priority to JP2002380537A priority patent/JP2004229504A/ja
Priority to JP2002379711A priority patent/JP2004201654A/ja
Priority to AU2003200731A priority patent/AU2003200731C1/en
Priority to AU2003200740A priority patent/AU2003200740C1/en
Priority to JP2003420475A priority patent/JP2004154140A/ja
Priority to US10/758,377 priority patent/US20040126807A1/en
Priority to JP2004212340A priority patent/JP3803681B2/ja
Priority to US10/972,317 priority patent/US7208321B2/en
Priority to US11/021,329 priority patent/US20050159591A1/en
Priority to US11/021,330 priority patent/US20050159588A1/en
Priority to US11/025,607 priority patent/US20050181478A1/en
Priority to US11/038,549 priority patent/US20060246461A1/en
Priority to US11/042,889 priority patent/US20050272058A1/en
Priority to US11/060,652 priority patent/US20050136475A1/en
Priority to JP2005054646A priority patent/JP2005224245A/ja
Priority to US11/090,729 priority patent/US20060068413A1/en
Priority to JP2005118817A priority patent/JP2005245460A/ja
Priority to JP2005118968A priority patent/JP2005270107A/ja
Priority to JP2005118579A priority patent/JP2005253468A/ja
Priority to JP2005118701A priority patent/JP2005253469A/ja
Priority to JP2005119030A priority patent/JP2005261437A/ja
Priority to JP2005180188A priority patent/JP4358159B2/ja
Priority to US11/189,442 priority patent/US20060246465A1/en
Priority to US11/191,669 priority patent/US7414112B2/en
Priority to JP2005229454A priority patent/JP4145314B2/ja
Priority to JP2005235120A priority patent/JP2006068006A/ja
Priority to JP2005238244A priority patent/JP2006061156A/ja
Priority to JP2005238274A priority patent/JP2006051032A/ja
Priority to JP2005238266A priority patent/JP2006025795A/ja
Priority to JP2005238217A priority patent/JP2006051031A/ja
Priority to US11/240,891 priority patent/US20060246540A1/en
Priority to US11/258,348 priority patent/US7462692B2/en
Priority to US11/258,349 priority patent/US7470774B2/en
Priority to US11/323,117 priority patent/US20070092941A1/en
Priority to US11/341,175 priority patent/US7468427B2/en
Priority to US11/367,172 priority patent/US20060257897A1/en
Priority to US11/457,750 priority patent/US20070031901A1/en
Priority to JP2006225771A priority patent/JP4074645B2/ja
Priority to JP2006225772A priority patent/JP2007029098A/ja
Priority to JP2006225770A priority patent/JP4072181B2/ja
Priority to JP2006225879A priority patent/JP2007037552A/ja
Priority to US11/537,235 priority patent/US7504484B2/en
Priority to US11/538,754 priority patent/US20070098634A1/en
Priority to US11/796,725 priority patent/US20090197301A1/en
Priority to US11/929,190 priority patent/US20080050758A1/en
Priority to US11/929,465 priority patent/US7728108B2/en
Priority to JP2008145176A priority patent/JP2009019032A/ja
Priority to JP2008163394A priority patent/JP2009039097A/ja
Priority to JP2008166460A priority patent/JP2009000114A/ja
Priority to JP2008256822A priority patent/JP2009095345A/ja
Priority to US12/364,329 priority patent/US20090142786A1/en
Priority to IL202176A priority patent/IL202176A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates generally to the identification and isolation of novel DNA and to the recombinant production of novel polypeptides.
  • Extracellular proteins play important roles in, among other things, the formation, differentiation and maintenance of multicellular organisms.
  • secreted polypeptides or signaling molecules normally pass through the cellular secretory pathway to reach their site of action in the extracellular environment.
  • Secreted proteins have various industrial applications, including as pharmaceuticals, diagnostics, biosensors and bioreactors.
  • Most protein drugs available at present, such as thrombolytic agents, interferons, interleukins, erythropoietins, colony stimulating factors, and various other cytokines, are secretory proteins.
  • Their receptors, which are membrane proteins, also have potential as therapeutic or diagnostic agents.
  • Efforts are being undertaken by both industry and proficient to identify new, native secreted proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted proteins. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., Proc. Natl. Acad. Sci. 93:7108-7113 (1996); U.S. Patent No. 5,536,637)].
  • Membrane-bound proteins and receptors can play important roles in, among other things, the formation, differentiation and maintenance of multicellular organisms.
  • membrane-bound proteins and cell receptors include, but are not limited to, cytokine receptors, receptor kinases, receptor phosphatases, receptors involved in cell-cell interactions, and cellular adhesin molecules like selectins and integrins. For instance, transduction of signals that regulate cell growth and differentiation is regulated in part by phosphorylation of various cellular proteins. Protein tyrosine kinases, enzymes that catalyze that process, can also act as growth factor receptors. Examples include fibroblast growth factor receptor and nerve growth factor receptor.
  • Membrane-bound proteins and receptor molecules have various industrial applications, including as pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance, can be employed as therapeutic agents to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.
  • the tetraspan family of proteins has grown to include approximately 20 known genes from various species, including drosophila.
  • the tetraspans are also known as the transmembrane 4 (TM4) superfamily and are proposed to have an organizing function in the cell membrane. Their ability to interact with other molecules and function in such diverse activities as cell adhesion, activation and differentiation, point to a role of aggregating large molecular complexes. Skubitz, et al., J. Immunology. 157:3617-3626 (1996).
  • the tetraspan group has also emerged as a set of proteins with prominent functions in Schwann cell biology. Mirsky and Jessen, Curr. Opin. Neurobiol., 6(l):89-96 (1996).
  • Tetraspans also sometimes called tetraspanins
  • Maecker et al., FASEB. 11 :428-442 (1997).
  • members of the tetraspan family are of interest.
  • PRQ1018 Efforts are being undertaken by both industry and proficient to identify new, native transmembrane and receptor proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel transmembrane proteins. We herein describe the identification and characterization of a novel transmembrane polypeptide designated herein as PRO1018.
  • Retinol dehydrogenase proteins are enzymes which function to recognize holo-cellular retinol-binding protein as a substrate, thereby catalyzing the first step of retinoic acid biogenesis from its substrate.
  • Various retinol dehydrogenase genes have been cloned and characterized, wherein the products of these genes are suggested as potentially being useful for the treatment of retinitis pigmentosa, psoriasis, acne and various cancers (Chai et al., J. Biol. Chem.
  • PRQ1477 Glycosylation is an important mechanism for modulating the physiochemical and biological properties of proteins in a stage- and tissue-specific manner.
  • One of the important enzymes involved in glycosylation in Saccharomyces cerevisiae is alpha 1,2-mannosidase, an enzyme that catalyzes the conversion of Man9GlcNAc2 to Man8GlcNAc2 during the formation of N-linked oligosaccharides.
  • the Saccharomyces cerevisiae alpha 1,2- mannosidase enzyme of is a member of the Class I alpha 1 ,2-mannosidases that are conserved from yeast to mammals.
  • PRQ831 Efforts are being undertaken by both industry and academia to identify new, native secreted proteins.
  • Protein-proteininter actions include receptor and antigen complexes and signaling mechanisms . As more is known about the structural and functional mechanisms underlying protein-protein interactions, protein-protein interactions can be more easily manipulated to regulate the particular result of the protein-protein interaction. Thus, the underlying mechanisms of protein-protein interactions are of interest to the scientific and medical community.
  • Leucine-rich repeats are short sequence motifs present in a number of proteins with diverse functions and cellular locations.
  • the crystal structure of ribonuclease inhibitor protein has revealed that leucine-rich repeats correspond to beta-alpha structural units. These units are arranged so that they form a parallel beta-sheet with one surface exposed to solvent, so that the protein acquires an unusual, nonglubular shape.
  • IGF insulin like growth factor
  • ALS acid labile subunit of IGF
  • LIG- 1 a membrane glycoprotein that is expressed specifically in glial cells in the mouse brain, and has leucine rich repeats and immunoglobulin-like domains. Suzuki, et al., J. Biol. Chem. (U.S.), 271(37):22522 (1996).
  • PRQ1194 The nuclear genes PET117 and PET 119 are required for the assembly of active cytochrome c oxidase in S. Cerevisiae, and therefore, are of interest. Also of interest are nucleic acids which have sequence identity with these genes. PET genes are further described in McEwen, et al., Curr. Genet.. 23(1):9-14 (1993). 10. PROl 110
  • the bone marrow plays many important roles in the mammal. One of those roles is to provide a source of various progenitor cells that differentiate into important cells and other components of the blood and immune systems. As such, the function of the myeloid system is of extreme interest.
  • PROl 110 polypeptides having homology to myeloid upregulated protein
  • PRO 1378 a novel secreted protein designated herein as PRO 1378.
  • PRQ1189 There has been much interest in the identification of receptor proteins on stem cells and progenitor cells which may be involved in triggering proliferation or differentiation.
  • a type II transmembrane protein was identified in proliferating progenitor cells in the outer perichondrial rim of the postnatal mandibular condyle proliferation.
  • the investigators concluded that E25 could be a useful marker for chondro-osteogenic differentiation (Deleersnijder, et al. J. Biol. Chem. 271(32): 19475-19482 (1996)).
  • PR01411 a novel secreted protein designated herein as PR01411. 16. PRQ1295
  • PRO 1295 a novel secreted protein designated herein as PRO 1295.
  • Enzymes such as hyaluronidase, sialyltransferase, urokinase-type plasminogenactivator, plasmin, matrix metalloproteinases, and others, play central roles in the catabolism of extracellular matrix molecules. As such, these enzymes and inhibitors thereof, may play roles in metastatic cancer and the treatment thereof. Van Asplatz and du Plessis, Med. Hypotheses. 48(5):443-447 (1997).
  • sialyltransferases are of particular interest.
  • a peptide of interest is the GalNAc alpha 2, 6-sailytransferase as described in Kurosawa, et al., J.
  • sialyltransferases such as this one, and peptides related by sequence identity, are of interest. Sialyltransferases are further described in the literature, see for example, Sjoberg, et al, J. Biol. Chem.. 271(13):7450-7459 (1996), Tsuji, J. Biochem.. 120(1): 1-13 (1996) and Harduin-Lepers, et al., Glvcobiology. 5(8):741-758 (1995).
  • Kang et al. reported the identification a novel cell surface glycoprotein of the lg superfamily (J. Cell biol. (1997) 138(1):203-213).
  • Cell adhesion molecules of the lg superfamily are implicated in a wide variety of biological processes, including cell migration, growth control, and tumorigenesis.
  • the Kang et al. studies suggest that loss of CDO function may play a role in oncogenesis. Accordingly, the identification of additional CDO-like molecules, and more generally, cell adhesion molecules of the lg superfamily, is of interest.
  • Peptidases are enzymatic proteins that function to cleave peptide substrates either in a specific or nonspecific manner. Peptidases are generally involved in a large number of very important biological processes in mammalian and non-mammalian organisms. Numerous different peptidase enzymes from a variety of different mammalian and non-mammalian organisms have been both identified and characterized. The mammalian peptidase enzymes play important roles in many different biological processes including, for example, protein digestion, activation, inactivation, or modulation of peptide hormone activity, and alteration of the physical properties of proteins and enzymes.
  • Putative protein-2 (PUT-2) is a homolog of the human disease genes LI CAM, G6PD and P55 (Riboldi Tunnicliffe et al. , Genome Analysis, submitted). As such, there is interest in identifying novel polypeptides and encoding DNA having homology to the PUT-2 protein.
  • PR01248 polypeptides We herein describe the identification and characterization of novel polypeptides having homology to PUT-2 protein, designated herein as PR01248 polypeptides.
  • Dickkopf is a family of secreted proteins having a high degree of homology in the cysteine-rich domains (i.e., 80-90%).
  • Dkk-1 the first discovered member, of this family has potent head-inducgin activity on the Spemann organizer. Glinka et al., Nature 391 (6665): 357-362 (1988).
  • the Spemann organizer of the amphibian embryo can be subdivided into two discrete activities, namely trunk organizer and head organizer.
  • Dkk-1 has been found to be both sufficient and necessary to cause head induction in Xenopus embryos and is further a potent antagonist of Wnt signaling, suggesting that the Dkk genes encode an entire family of Wnt inhibitors.
  • Wnt genes encode a family of secreted glycoproteins that modulate cell fate and behavior in embryos through activation of receptor-mediated signaling pathways.
  • wingless encodes a Wnt-related gene (Rijsewik et al., Cell, 50: 649-657 (1987)) and wg mutations alter the pattern of embryonic ectoderm, neurogenesis, and imaginal disc outgrowth.
  • wg wingless
  • Morata and Lawerence Dev. Biol., 56: 227-240 (1977); Baker, Dev. Biol., 125: 96-108 (1988); Klingensmith and Nusse, Dev. Biol., 166: 396-414 (1994).
  • lin-44 encodes a Wnt homolog which is required for asymmetric cell divisions.
  • Knock-out mutations in mice have shown Wnts to be essential for brain development (McMahon and Bradley, Cell, 62: 1073-1085 (1990); Thomas and Cappechi, Nature, 346: 847-850 (1990)), and the outgrowth of embryonic primordia for kidney (Stark et al., Nature, 372: 679-683 (1994)), tail bud (Takada et al., Genes Dev., 8: 174-189 (1994)), and limb bud.
  • the Wnt/Wg signal transduction pathway plays an important role in the biological development of the organism and has been implicated in several human cancers. This pathway also includes the tumor suppressor gene, APC. Mutations in the APC gene are associated with the development of sporadic and inherited forms of human colorectal cancer. For example, elevated levels of Wnt-2 have been observed in colorectal cancers. Vider, B-Z. et al., Oncogene 12: 153-158 (1996).
  • Immunoglobulins are antibody molecules, the proteins that function both as receptors for antigen on the B-cell membrane and as the secreted products ofthe plasma cell. Like all antibody molecules, immunoglobulins perform two major functions: they bind specifically to an antigen and they participate in a limited number of biological effector functions. Therefore, new members of the lg superfamily and fragments thereof are always of interest. Molecules which act as receptors by various viruses and those which act to regulate immune function are of particular interest. Also of particular interest are those molecules which have homology to known lg family members which act as virus receptors or regulate immune function. Thus, molecules having homology to lg superfamily members and fragments thereof (i.e., heavy and light chain fragments) are of particular interest.
  • novel secreted proteins involved in physiological and metabolic pathways is of interest because of their potential use as pharmaceutical agents.
  • novel polypeptides that are potentially involved in immxme response and inflammation mechanisms.
  • a novel polypeptide has recently been identified that is expressed in mouse B cells in response to IL-4. The gene encoding this polypeptide is referred to as interleukin-four induced gene 1 , or "Figl” (Chu et al. Proc. Natl. Acad. Sci (1997) 94(6): 2507-2512).
  • Long chain fatty acid CoA ligase is an enzymatic protein that functions to ligate together long chain fatty acids, a function that plays important roles in a variety of different physiological processes. Given the importance of this enzymatic protein, efforts are currently being undertaken to identify novel long chain fatty acid CoA ligase homologs. We herein describe the identification and characterization of novel polypeptides having homology to long chain fatty acid CoA ligase, designated herein as PRO 1250 polypeptides.
  • N-acetylglucosaminyltransferase proteins comprise a family of enzymes that provide for a variety of important biological functions in the mammalian organism.
  • 2-N-acetylglucosaminyltransferase I is an enzymatic protein that catalyzes an essential first step in the conversion of high-mannose N-glycans to hybrid and complex N-glycans (Sarkar et al. , Proc. Natl. Acad. Sci. USA. 88:234-238 (1991).
  • cytokine receptor family includes the interferon receptors, the interleukin-10 receptor and the tissue factor CRFB4 (Spencer et al., J. Exp. Med. 187:571-578 (1998) and Kotenko et al., EMBO J. 16:5894-5903 (1997)).
  • CRF2 class II cytokine receptor family
  • cytokine receptor family-4 proteins designated herein as PRO 1315 polypeptides.
  • Granzyme M is a natural killer cell serine protease.
  • the human gene is 7.5 kilobases, has an exon- intron structure identical to other serine proteases, and is closely linked to the serine protease gene cluster on chromosome 19pl3.3. (Pilat et al., Genomics. 24:445-450 (1994)).
  • Granzyme M has been found in two human natural killer leukemia cell lines, unstimulated human peripheral blood monocytes and untreated purified CD3-
  • Reductases form a large class of enzymatic proteins found in a variety of mammalian tissues and play many important roles for the proper functioning of these tissues. They are antioxidant enzymes that catalyze the conversion of reactive oxygen species to water. Abnormal levels or functioning of reductases have been implicated in several diseases and disorders including strokes, heart attacks, oxidative stress, hypertension and the development of both benign and malignant tumors. For example, malignant prostate epithelium may have lowered expression of such antioxidant enzymes [Baker et al., Prostate 32(4): 229-233 (1997)].
  • International patent application no. WO9622360-A1 describes a prostate specific reductase that is useful for diagnosing and treating prostate cancer and screening new antagonists.
  • Inhibitors of alpha-reductase have been used in the treatment of benign prostatic hyperplasia (Anderson, Drugs Aging (1996) 6(5):388-396). For these reasons, the identification of new members of the reductase family has been of interest for the treatment and diagnosis of cancers and other diseases and disorders.
  • Prolyl 4-hyr oxylase catalyzes the formation of 4-hydroxyproline in collagens .
  • the tetraspan family of proteins also referred to as the "transmembrane 4 (TM4) superfamily" are proposed to have an organizing function in the cell membrane. It is believed that they interact with large molecular complexes and function in such diverse activities as cell adhesion, activation and differentiation (see Maecker et al. FASEB (1997) JT:428-442). Accordingly, the identification of new members of the tetraspan family of proteins is of interest. Efforts are being undertaken by both industry and proficient to identify new, native transmembrane proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel receptor proteins.
  • Ebnerin is a cell surface protein associated with von Ebner glands in mammals. Efforts are being undertaken by both industry and proficient to identify new, native proteins and specifically those which possess sequence homology to cell surface proteins such as ebnerin or other salivary gland-associated proteins. Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel receptor proteins. We herein describe the identification of novel polypeptides having significant homology to the von Ebner minor salivary gland-associated protein, designated herein as PR01357 polypeptides.
  • transmembrane protein One type of transmembrane protein that has received attention is implantation-associated uterine protein. Deficiencies or abnormalities of this protein may be a cause of miscarriage. Therefore, the identification and characterization of implantation-associated proteins is of interest.
  • Bone-related sulphatase is an enzymatic protein that has been shown to degrade sulphate groups of proteoglycan sugar chains in bone tissue (Australian Patent Publication No. AU 93/44921-A, March 3, 1994). Because of its specific sulphatase activity, it has been suggested that bone-related sulphatase may find use in the treatment of bone metabolic diseases. As such, there is significant interest in identifymg and characterizing novel polypeptides having sequence similarity to bone-related sulphatase. We herein describe the identification and characterization of novel polypeptides having homology to bone-related sulphatase, designated herein as PR01246 polypeptides.
  • Clostridium perfringens enterotoxin (CPE) is considered to be the virulence factor responsible for causing the symptoms of C. perfringens type A food poisoning and may also be involved in other human and veterinary illnesses (McClane, Toxicon. 34:1335-1343 (1996)).
  • CPE carries out its adverse cellular functions by binding to an approximately 50 kD cell surface receptor protein designated the Clostridium perfringens enterotoxin receptor (CPE-R) to form an approximately 90,000 kD complex on the surface of the cell.
  • CPE-R Clostridium perfringens enterotoxin receptor
  • PRO 1275 a novel secreted protein designated herein as PRO 1275.
  • PRO 1274 a novel secreted protein designated herein as PRO 1274.
  • Chordin protein which has been isolated from Xenopus, is a potent dorsalizing factor that regulates cell-cell interactions in the organizing centers of Xenopus head, trunk and tail development (Sasai et al. , (1994) Cell 79(5):779-790: see also Mullins, (1998) Trends Genet. 14(4): 127-129: and Kessel et al. (1998) ) Trends Genet. 14(5):169-171). It may be used as a component of culture medium for culturing nerve and muscle cells, and may have use in the treatment of neurodegenerative diseases and neural injury (U.S. Pat. No. 5,679,783).
  • the extracellular mucous matrix of olfactory neuroepithelium is a highly organized structure in intimate contact with chemosensory cilia that house the olfactory transduction machinery.
  • the major protein component of this extracellular matrix is olfactomedin, a glycoprotein that is expressed in olfactory neuroepithelium and which form intermolecular disulfide bonds so as to produce a polymer (Yokoe et al. , Proc. Natl. Acad. Sci. USA 90:4655-4659 (1993), Bal et al., Biochemistry 32:1047-1053 (1993) and Snyder et al., Biochemistry 30:9143- 9153 (1991)).
  • olfactomedin may influence the maintenance, growth or differentiation of chemosensory cilia on the apical dendrites of olfactory neurons.
  • olfactomedin may influence the maintenance, growth or differentiation of chemosensory cilia on the apical dendrites of olfactory neurons.
  • Butyrophilin is a milk glycoprotein that constitutes more than 40% of the total protein associated with the fat globule membrane in mammalian milk. Expression of butyrophilin mRNA has been shown to correlate with the onset of milk fat production toward the end pregnancy and is maintained throughout lactation. Butyrophilin has been identified in bovine, murine and human (see Taylor et al., Biochim. Biophvs. Acta 1306:1-4 (1996), Ishii et al., Biochim. Biophvs. Acta 1245:285-292 (1995), Mather et al., J. Dairy Sci. 76:3832-3850 (1993), Ogg, et al., Mamm. Genome.
  • butyrophilin may play a role as the principle scaffold for the assembly of a complex with xanthine dehydrogenase/oxidase and other proteins that function in the budding and release of milk-fat globules from the apical surface during lactation (Banghart et al. , supra). Given that butyrophilin plays a role in mammalian milk production, there is substantial interest in identifying novel butyrophilin homologs.
  • the lipocalin protein family is a large group of small extracellular proteins. The family demonstrates great diversity at the sequence level; however, most lipocalins share characteristic conserved sequence motifs.
  • Lipocalins are known to be involved in retinol transport, invertebrate cryptic coloration, olfaction and pheromone transport, and prostaglandin synthesis.
  • the lipocalins have also been implicated in the regulation of cell homoeostasis and the modulation of the immune response, and as carrier proteins, to act in the general clearance of endogenous and exogenous compounds.
  • novel members of the lipocalin protein family are of interest.
  • PRO1302 CD33 is a cell-surface protein that is a member of the sialoadhesin family of proteins that are capable of mediating sialic-acid dependent binding with distinct specificities for both the type of sialic acid and its linkage to subterminal sugars.
  • CD33 is specifically expressed in early myeloid and some monocyte cell lineages and has been shown to be strongly associated with various myeloid tumors including, for example, acute non-lymphocytic leukemia (ANLL).
  • ANLL acute non-lymphocytic leukemia
  • CD33 has been suggested as a potential target for the treatment of cancers associated with high level expression of the protein.
  • One CD33 homolog (designated CD33L) is described in Takei et al., Cvtogenet. Cell Genet. 78:295-300 (1997).
  • Another study describes the use of CD33 monoclonal antibodies in bone marrow transplantation for acute myeloid leukemia. Robertson, et al., Prog. Clin.
  • Olfactory reception occurs via the interaction of odorants with the chemosensory cilia of the olfactory receptor cells located in the nasal epithelium.
  • the mammalian olfactory system is capable of recognizing and discriminating a large number of different odorant molecules.
  • numerous different odorant binding proteins and their encoding DNA have recently been identified and characterized (Dear etal., Biochemistry 30: 10376-10382 (1991). Pevsner et al., Science 241:336-339 (1988), Buck et al., Cell 65:175-187 (1991) andBreer et al., J. Recept. Res.
  • protease enzymes are enzymatic proteins which are involved in a large number of very important biological processes in mammalian and non-mammalian organisms. Numerous different protease enzymes from a variety of different mammalian and non-mammalian organisms have been both identified and characterized, including the serine proteases which exhibit specific activity toward various serine-containing proteins. The mammalian protease enzymes play important roles in biological processes such as, for example, protein digestion, activation, inactivation, or modulation of peptide hormone activity, and alteration of the physical properties of proteins and enzymes.
  • Neuropsin is a novel serine protease whose mRNA is expressed in the central nervous system. Mouse neuropsin has been cloned, and studies have shown that it is involved in the hippocampal plasticity. Neuropsin has also been indicated as associated with extracellular matrix modifications and cell migrations. See, generally, Chen, et al., Neurosci.. 7(2): 5088-5097 (1995) and Chen, et al., J. Histochem. Cvtochem.. 46:313-320 (1998).
  • PR01279 polypeptides having homology to neuropsin protein
  • the immunophilins are a family of proteins that function as receptors for immunosuppressant drugs, such as cyclosporin A, FK506, and rapamycin.
  • the immunophilins occur in two separate classes, (1) the FK506-binding proteins (FKBPs), which bind to FK506 and rapamycin, and (2) the cyclophilins, which bind to cyclosporin A.
  • FKBPs FK506-binding proteins
  • the FK506/FKBP complex functions to inhibit the activity of the serine/threonine protein phosphatase 2B (calcineurin), thereby providmg immunosuppressant activity (Gold, Mol. Neurobiol.
  • FK506 binding protein designated herein as PRO 1304 polypeptides.
  • CD97 a cell surface antigen that is rapidly upregulated upon activation on lymphocytes
  • Leukocytes strongly positive for CD97 are concentrated at sites of inflammation relative to CD97 expression in normal lymphoid tissue.
  • a soluble subunit of CD97, CD97alpha has been found in the body fluids from inflamed tissues (Gray et al. J. Immunol. (1996) 157(12):5438-5447).
  • Proteases are enzymatic proteins which are involved in a large number of very important biological processes in mammalian and non-mammalian organisms. Numerous different protease enzymes from a variety of different mammalian and non-mammalian organisms have been both identified and characterized, including the serine proteases which exhibit specific activity toward various serine-containing proteins. The mammalian protease enzymes play important roles in biological processes such as, for example, protein digestion, activation, inactivation, or modulation of peptide hormone activity, and alteration ofthe physical properties of proteins and enzymes.
  • Neuropsin is a novel serine protease whose mRNA is expressed in the central nervous system.
  • Mouse neuropsin has been cloned, and studies have shown that it is involved in the hippocampal plasticity. Neuropsin has also been indicated as associated with extracellular matrix modifications and cell migrations. See, generally, Chen, et al., J. Neurosci., 7(2):5088-5097 (1995) and Chen, et al., J. Histochem. Cvtochem.. 46:313-320 (1998).
  • Other studies have reported that kindling induces neuropsin mRNA in the mouse brain. Okabe, et al., Brain Res. , 728(1): 116-120 (1996).
  • neuropsins and related proteins and agents, including agonists and antagonists are of interest.
  • daintain/AIFl daintain allograft inflammatory factor 1
  • daintain/AIFl may have a role in connection with the pathogenesis of insulin-dependent diabetes mellitus (Chen et al. Proc. Natl Acad. Sci. (1997) 94(25): 13879- 13884).
  • AIF-1 has also been implicated in both rat and human allogenic heart transplant rejection (Utans et al. Transplantation (1996) 61(9): 1387-1392), and may play a role in macrophage activation and function (Utans et al. J. Clin. Invest. (1995. 95(6):2954-2962).
  • Protein-protein interactions include receptor and antigen complexes and signalingmechanisms. As more is known about the structural and functional mechanisms underlying protein-protein interactions, protein-protein interactions can be more easily manipulated to regulate the particular result of the protein-protein interaction. Thus, the underlying mechanisms of protein-protein interactions are of interest to the scientific and medical community.
  • Leucine-rich proteins are known to be involved in protein-protein interactions.
  • a study has been reported on leucine-rich proteoglycans which serve as tissue organizers, orienting and ordering collagen fibrils during ontogeny and are involved in pathological processes such as wound healing, tissue repair, and tumor stroma formation. Iozzo, R. V., Crit. Rev. Biochem. Mol. Biol .. 32(2): 141-174 (1997).
  • Others studies implicating leucine rich proteins in wound healing and tissue repair are De La Salle, C, et al., Vouv. Rev. Fr. Hematol.
  • slit protein Another protein of particular interest which has been reported to have leucine-rich repeats is the slit protein which has been reported to be useful in treating neuro-degenerative diseases such as Alzheimer's disease, nerve damage such as in Parkinson's disease, and for diagnosis of cancer, see, Artavanistsakonas, S. and Rothberg, J. M., WO9210518-A1 by Yale University.
  • the slit protein has been characterized and reported to be secreted by glial cells and involved in the formation of axonal pathways in Drosophila as well as the mediation of extracellular protein interactions. Wharton and Crews, Mech. Dev.. 40(3): 141-154 91993); Rothberg and Artavanis-Tsakonas, J. Mol. Biol.. 227(2):367-370 (1992); Rothberg, et al., Genes Dev.. 4(12A):2169-2187 (1990); and Rothberg, et al., CeJ 55(6): 1047
  • Lysozymes are secretedenzymes that preferentially hydrolyze the [beta] -1 ,4 glucosidic linkages between N-acetylmuramic acid and N-acetylgucosamine which occur in the mucopeptide cell wall structure of certain microoganisms. Lysozyme is of widespread distribution in animals and plants. It has been found in mammalian secretions and tissues including saliva, tears, milk, cervical mucus, leucocytes, kidneys, etc. The identification of new members of the lysozyme family of proteins is of interest because of the variety of roles lysozymes play in metabolic function and dysfunction. Abnormal levels of lysozymes have been implicated in various disease states. Lysozymes have been reported to have anti-microbial, analgesic, and antinociceptive properties. Additional characteristics and possible uses of lysozymes are described in U.S. Pat. No. 5,618,712.
  • glycosylation can determine the fate of a protein, for example, whether it is secreted or not. Also, glycoproteins play many structural and functional roles, particularly as part of the cell membrane. Therefore, glycosylation is of interest. Studies have reported on the growth-related coordinate regulation of the early N- glycosylation genes in yeast. Kukuruzinska and Lennon, Glvcobiologv. 4(4): 437-443 (1994). Moreover, the relationship between protein glycosylation and fatty acylation of glycoproteins was studied in the wild-type and asparagine-linked glycosylation-deficient mutants in yeast. Appukuttan, FEBS Lett.. 255(1): 139-142 (1989).
  • Cytochrome P450 proteins form a large class of monooxygenase enzymes involved in hydroxylation.
  • cytochrome P450 Hydroxylation reactions are important in the synthesis of cholesterol and steroid hormones. Enzymes of the cytochrome P450 family play an important role in the metabolism endogenous compounds such as arachidonic acid. These enzymes are also important in the metabolism of foreign substances such as the elimination of drugs from the body [see, for example, Peterson, Aliment. Pharmacol. Ther.. 9: 1-9 (1995).]. In addition, metabolites generated through the cytochrome P450 pathway may play a role in carcinogenesis, blood pressure regulation and renal function [see, for example, Rahman et al., Am. J. Hypertens.. 10:356-365 (1997)].
  • PRQ1269 Granulocytes the most common type of white blood cell, have the ability to mediate immunologic cytotoxicity against tumor cells and microorganisms. Accordingly, there has been interest in identifying various factors that are produced by these cells because of their potential use as pharmaceutical agents.
  • Patent publication no. W09729765-A1 to Selsted, describes the identification of granulocyte peptide A which was isolated from bovine and murine granulocytes. Several uses for this peptide were identified including, a therapeutic use, use as an agricultural agent, use as a preservative for food, and use as a water treatment agent.
  • Neurexophilin is a protein that was discovered as a neuronal glycoprotein that was copurified with neurexin I alpha during affinity chromatography on immobilized alpha-latrotoxin (Missler et al., J. Neurosci. 18:3630-3638 (1998)).
  • the mammalian brain contains four genes for neurexophilins the products of which share a common structure composed of five domains: (1) an N-terminal signal peptide, (2) a variable N-terminal domain, (3) a highly conserved central domain that is N-glycosylated, (4) a short linker region and (5) a conserved C-terminal domain that is cysteine-rich (Missler et al., supra).
  • These data further demonstrate that the neurexophilins are proteolytically processed after synthesis and bind to alpha-neurexins.
  • the structure and characteristics of neurexophilins indicate that they may function as neuropeptides that may signal via alpha-neurexins. Therefore, there is significant interest in identifying and characterizing novel polypeptides having homology to the neurexophilins.
  • PRO 1327 polypeptides having homology to neurexophilin protein, designated herein as PRO 1327 polypeptides.
  • Cerebellin is a secreted, postsynaptic neuroprotein found throughout the brain. The highest concentrations of this protein have been found in the cerebellum. It has also been detected in the pituitary, spinal cord, and adrenal glands (Satoh etal. J. Endocrinol. (1997) 15491):27-34). The feasibility of using cerebellum as a quantifiable marker for the investigation of the maturation of Purkinje cells of the cerebellum and to chart neurodevelopment has been reported (see Slemmon et al. Proc. Natl. Acad. Sci (1985) 82(20):7145-7148).
  • Cadherins are known as the principal mediators of homotypic cellular recognition and play a demonstrated role in the morphogenic direction of tissue development.
  • Cadherins are a diverse family of proteins that have been identified in various tissues including nervous tissue (Suzuki et al., Cell Regul.. 2:261- 270 (1991)).
  • Ksp-cadherin is a kidney-specific member of the cadherin multigene family (Thomson et al., Biol. Chem. 270: 17594-17601 (1995)).
  • Cadherins are thought to play an important role in human cancer (Yap, Cancer Invest.. 16:252-261 (1998)).
  • Carboxypeptidases are of interest. Carboxypeptidase E appears to be involved in the biosynthesis of a wide range of peptide hormones. Fricker, Annu. Rev. Physiol.. 50:309-321 (1988). This carboxypeptidase has been associated with obesity. Leiter. J. Endocrinol.. 155(2):211-214 (1997). Carboxypeptidase M has been reported as being a marker of macrophage maturation. Krause, et al., Immunol. Rev.. 161: 119-127 (1998).
  • carboxypeptidases of particular interest which are known in the art include human pancreatic carboxypeptidase 2, carboxypeptidase al and carboxypeptidase B. Therefore, novel members of the carboxypeptidase family are of interest. 68. PRQ1337
  • Thyroxine-binding globulin is synthesized by the liver and secreted into the bloodstream. It is the principal thyroid hormone transport protein in human serum (Refetoff et al. Horm. Res. (1996) 45(3-5): 128-138). High serum levels of TBG have been found to cause hyperthyroxinaemia (Leahy etal. Postgrad Med. J. (1984) 60(703): 324-327). Accordingly, the identification and characterization of TBG proteins is of interest (see Flink et al. Proc. Natl Acad Sci.
  • PRQ1343 Efforts are being undertaken by both industry and academia to identify new, native secreted proteins.
  • PRO 1343 a novel secreted protein designated herein as PRO 1343.
  • Semaphorins are a large family of transmembrane and secreted proteins, many of which are expressed in the nervous system. Members of the semaphorin family include both ligands and receptors. (Eckhardt et al. , Mol. Cell. Neurosci.. 9: 409-419 (1997)). Studies have revealed a role for semaphorins in embryonic motor and central nervous system axon guidance and synapse formation. (Catalano et al., Mol. Cell. Neurosci.. : 173-182 (1998); Kitsukawa et al., Neuron. .19: 995-1005 (1997); Yu et al., Neuron. 20: 207-220 (1998)).
  • Semaphorins have been shown to induce neuronal growth cone collapse and alter their pathway in vivo. (Shoji et al., Development. 125: 1275-1283 (1998)). Members of the semaphorin family have been shown to be immunologically active, inducing cytokine production in human monocytes. (Comeau et al. , Immunity. 8: 473- 482 (1998)). Semaphorins may also play a role in cancer. Expression of a mouse semaphorin gene is known to correlate with metastatic ability in mouse tumor cell lines. (Christensen et al., Cancer Res.. 58: 1238-1244 (1998)). 72. PRQ1487
  • Fringe is a protein which specifically blocks serrate-mediated activation of notch in the dorsal compartment of the Drosophila wing imaginal disc (see Fleming et al. , Development. 124(15):2973-81 (1997); Wu et al. Science (1996) 273(5273) : 355-358) .
  • Fringe protein is also involved in vertebrate development where a thickening of the apical ectodermal ridge essential for limb bud outgrowth involves an interaction between dorsal cells that express radical fringe and those that do not (see Wolpert, L. Philos Trans R Soc Lond B Biol Sci 1998) 353(1370):871-875: Kengaku et al.
  • fringe protein is of interest for both its role in development as well as its ability to regulate serrate, particularly serrate 's signaling abilities. Also of interest are novel polypeptides which may have a role in development and/or the regulation of serrate-like molecules. Of particular interest are novel polypeptides having homology to fringe protein.
  • PRQ1418 Efforts are being undertaken by both industry and academia to identify new, native secreted proteins.
  • Butyrophilin is a milk glycoprotein that constitutes more than 40% of the total protein associated with the fat globule membrane in mammalian milk. Expression of butyrophilin mRNA has been shown to correlate with the onset of milk fat production toward the end pregnancy and is maintained throughout lactation. Butyrophilin has been identified in bovine, murine and human (see Taylor et al., Biochim. Biophvs. Acta 1306:1-4 (1996), Ishii et al., Biochim. Biophvs. Acta 1245:285-292 (1995), Mather et al., J. Dairy Sci. 76:3832-3850 (1993), Ogg, et al., Mamm. Genome.
  • butyrophilin plays a role in mammalian milk production, there is substantial interest in identifying novel butyrophilin homologs.
  • Members of the butyrophilin family are further described in Tazi-Ahnini, et al., Immunogenetics. 47(l):55-63 (1997); Davey, et al., Gene. 199(l-2):57-62 (1997); and Mather and Jack, J. Dairy Sci.. 76(12):3832-3850 (1993).
  • Proteases are enzymatic proteins which are involved in many biological processes in mammalian and non-mammalian organisms including digestion, protein activation and inactivation, modulation of peptide hormone activity, and alteration of the physical properties of proteins and enzymes.
  • Serine proteases comprise a large class of enzymes that exhibit specific activity toward various serine-containing proteins. Trypsin, which is synthesized by the pancreas and secreted to the small intestine, is a well-characterized serine protease that hydrolyzes peptide bonds of ingested proteins. Trypsin-like proteases have been characterized that are cell- surface proteins (see Farley etal.
  • the tetraspanin (or tetraspan) family of proteins has grown to include approximately twenty known genes from various species.
  • the tetraspanins are four transmembrane domain membrane-bound molecules which include for example, CD81, CD82, CD9, CD63, CD37 and CD53.
  • Many of these proteins have a flair for promiscuous associations with other molecules, including lineage-specific proteins, integrins, and other transpanins. In terms of function, they are involved in diverse processes such as cell activation and proliferation, adhesion and motility, differentiation and cancer.
  • Proteases are enzymatic proteins which are involved in many biological processes in mammalian and non-mammalian organisms including digestion, protein activation and inactivation, modulation of peptide hormone activity, and alteration of the physical properties of proteins and enzymes.
  • Serine proteases comprise a large class of enzymes that exhibit specific activity toward various serine-containing proteins. Trypsin, which is synthesized by the pancreas and secreted to the small intestine, is a well-characterized serine protease that hydrolyzes peptide bonds of ingested proteins. Trypsin-like proteases have been characterized that are cell- surface proteins (see Farley etal.
  • semaphorins have been identified in the human immune system, where they are believed to play functional roles including B-cell signaling (Hall et al. Proc. Natl. Acad. Sci (1996) 93(21): ! 1780-50).
  • a human semaphorin gene, useful in the diagnosis of nervous system an immune disorders, is disclosed in Japanese Pat. No. J10155490-A, published June 16, 1998. The identification of additional members of the semaphorin family if of interest.
  • Enzymatic proteins that may be implicated in metabolic diseases or disorders are of particular interest.
  • the enzymatic addition of sugars to fat-soluble chemicals is an important process that increases their solubility in water and aids in their excretion.
  • glucuronic acid is the main sugar that is used to prevent the waste products of metabolism and fat-soluble chemicals from reaching toxic levels in the body.
  • the UDP glucuronosyltransferases that carry out this reaction are part of a super family of UDP glycosyltransferases found in animals, plants and bacteria. In the liver, UDP-glucuronosyltransferase conjugates bilirubin.
  • the cerebellum contains a hexadecapeptide, termed cerebellin, that is conserved in sequence from human to chicken.
  • cerebellin a hexadecapeptide
  • Three independent, overlapping cDNA clones have been isolated from a human cerebellum cDNA library that encode the cerebellin sequence.
  • the longest clone codes for a protein of 193 amino acids generally termed precerebellin, or a cerebellin precursor.
  • This protein has a significant similarity to the globular region of the B chain of human complement component C lq.
  • the region of .elatedness extends approximately over 145 amino acids located in the carboxyl terminus of both proteins.
  • no collagen-like motifs are present in the amino-terminal regions of precerebellin.
  • cerebellin is not liberated from precerebellin by the classical dibasic amino acid protealytic cleavage mechanism seen in many neuropeptide precursors.
  • the cerebellin precursor has been associated with synaptic physiology. Urade, et al., PNAS. USA. 88(3): 1069-1073 (1991). Cerebellin, its precursor, and related molecules, particularly those having sequence identity with cerebellin, are therefore of interest.
  • Enzymatic proteins play important roles in the chemical reactions involved in the digestion of foods, the biosynthesis of macromolecules, the controlled release and utilization of chemical energy, and other processes necessary to sustain life.
  • Acyltransferases are enzymes which acylate moieties.
  • acyl-glycerol- phosphate acyltransferases can act on lysophosphatidic acid as a substrate. The lysophosphatidic acid is converted to phophatidic acid and thus plays a role in forming phosphatidylethanolamme found in membranes. See, Brown, et al., Plant Mol. Biol.. 26(l):211-223 (1994).
  • LPAAT l-acyl-sn-glycerol-3-phosphate acyltransferase
  • PRO1490 polypeptides having homology to a l-acyl-sn-glycerol-3-phosphate acyltransferase protein, designated herein as PRO1490 polypeptides.
  • Methyltransferase enzymes catalyze the transfer of methyl groups from a donor molecule to an acceptor molecule. Methyltransferase enzymes play extremely important roles in a number of different biological processes including, for example, in the electron transport chain in the plasma membrane in prokaryotes and in the inner mitochondrial membrane in eukaryotic cells (see , e . g . , Barkovich et al . , J. Biol. Chem. 272 : 9182-9188 (1997), Dibrov et al., J. Biol. Chem. 272:9175-9181 (1997), Lee et al., J. Bacteriol..
  • Methyltransferase enzymes have been shown to be essential for the biosynthesis of ubiquinone (coenzyme Q) and menaquinone (vitamin K2), both of which are essential isoprenoid quinone components of the respiratory electron transport chain. Given the obvious importance of the methyltransferase enzymes, there is substantial interest in identifying novel polypeptide homologs of the methyltransferases. We herein describe the identification and characterization of a novel polypeptide having homology to methyltransferase enzymes, designated herein as PR01558 polypeptides.
  • novel growth factors is of particular interest because of the roles they play in inducing cellular growth, proliferation and differentiation in both normal states and abnormal states.
  • the identification of growth factors that are over- or under-expressed in abnormal tissues may lead to the development of diagnostic tools and therapeutic agents.
  • Growth factors have been isolated from hepatoma- derived cell lines. Hepatoma-derived growth factors have been isolated from mouse (Japanese Pat. No. J09313185-A, published December 9, 1997) and human (Japanese Pat. No. J06343470-A, published December 20, 1994) tissues.
  • a hepatoma-derived growth factor isolated from a human hepatoma-derived cell line, has been found to be ubiquitously expressed in several tumor-derived cell lines, as well as in normal tissues (Nakamura et al , J. Biol. Chem (1994) 269(40):25143-9).
  • the growth factor was determined to be a novel heparin-binding protein that is mitogenic for fibroblasts.
  • the neuronal cell body is usually round like any other cell. However, these cells have structures, also referred to as "processes", which grow from them to form synaptic connections. Some of these processes carry information away from the cell body; sometimes over very long distances. These long and thin processes are axons. The axon is a thin, static tube. Other processes carry information either towards the cell body, or both towards and away from the cell body. These shorter and usually thicker processes are called dendrites. Both axons and dendrites are called neurites.
  • a growth cone is the growing tip of a neurite.
  • the growth cone is flattened and highly motile. It is where new material is added and further extension ofthe axon originates. Controlling where the growth cone crawls controls were the axon will be laid down and thus where it will be present.
  • the growth cone has several definable parts.
  • the thin, flattened, veil-like processes that stick out and retract from the leading edge are called lamellipodia.
  • the needle-like processes that stick out and retract from the leading edge are called microspikes or filopodia. These are the structures involved in pushing the leading edge of the growth cone forward.
  • the accurate navigation of growth cones to their appropriate targets requires that they recognize and respond to navigational cues in their immediate environment. Some of these cues encourage extension into certain areas whereas others discourage extension into others.
  • Well characterized molecules that encourage neurite outgrowth in vitro include the extracellular matrix molecule laminin and the neuronal cell surface molecule L1/G4/8D9. These molecules which promote neurite extension are generally widely distributed throughout the body. Laminin immunoreactivity is reasonably widespread in the developing central and peripheral nervous systems. Similarly, L1/G4/8D9 is present on a wide variety of neuronal processes in the developing central nervous system, particularly long projecting axons. It is, therefore, unclear whether the known outgrowth promoting molecules play an important role in self-specific choices growth cones make as they decide between possible routes. Instead, their function is believed to provide a generally permissive environment in which growth cones extend and respond to more specific navigational cues.
  • Collapsins are proteins that function to modulate the activity of molecules which modulate growth cone extension.
  • PR01491 polypeptides we herein describe the identification and characterization of novel polypeptides having homology to a collapsin protein, designated herein as PR01491 polypeptides.
  • signal transduction is crucial to cell processing such as differentiation, motility and division.
  • signal transduction is believed to occur throughout the cell in the form of complex interactions between proteins.
  • protein-protein interactions are often mediated by modular domains within signaling proteins.
  • signal transduction is now modeled as a system in which molecules act in a combination, and the composition of that combination, determines the signal.
  • Src homology domains are two domains found in regions of sequence similarity of proteins involved in signal transduction. Early work on the oncogenic tyrosine kinase Src identified the SH2 domain. Since then, SH2 and SH3 domains have been found in many diverse proteins, making them among the most common type of structural motif. SH2 and SH3 domains are modular in that they fold independently of the protein that contains them, their secondary structure places N- and C- termini close to one another in space, and they appear at variable locations (anywhere from N- to C-terminal) from one protein ot the next (Cohen et al., Cell 80: 237-348, 1995).
  • SH3 domains have a more general function than that which is purported for SH2.
  • SH3 binding proteins have been isolated by screening bacteriophage expression libraries with labeled SH3 domains. The results of these experiments showed that SH3 domains would bind to short proline-rich peptides, in particular the motif PxxP. Based on the level of knowledge present at the time of the preparation of the present patent application, all of the SH3 binding sites identified have the property of being proline rich. Binding of an SH3 domain is independent of covalent modification ofthe binding site, such as phosphorylation as occurs with the SH2 domain. As a result, SH3-ligand interactions are usually constitutive and not inducible, although exceptions do exist.
  • SH3 domains are less likely to act as signal "switches” than as a means of assembling protein complexes via moderate-affinity interactions. Such moderate affinity interactions also imply that the SH3-mediated interactions will be relatively short in duration and remodeled in response to changes in concentration of binding partners.
  • Peptidomimetic ligands based on the sequence of target proteins for SH2 and SH3 domains may represent new lead compounds for the therapy of proliferative diseases that are dependent upon constitutively activated tyrosine kinases (e.g., BCR ABL in chronic myelogenous and acute lymphocytic leukemias or HER-2/Neu in breast and ovarian cancer).
  • constitutively activated tyrosine kinases e.g., BCR ABL in chronic myelogenous and acute lymphocytic leukemias or HER-2/Neu in breast and ovarian cancer.
  • ADAMs Cellular disintegrin and metalloproteinase
  • the ADAMTS-1 gene encodes a new type of ADAM protein with respect to possessing the thrombospondin (TSP) type I motifs, the expression of which is associated with the inflammatory process (Kuno et al., J. Biol. Chem. 273: 13912-13917 (1998), Kuno et al., Genomics 46:466-471 (1997) and Kuno et al., J. Biol. Chem. 272:556-562 (1997)).
  • TSP thrombospondin
  • ADAMTS-1 ADAMTS-1 protein
  • the ADAMTS-1 protein has been suggested as playing a possible role in various inflammatory processes as well as in the development of cancer cachexia (Kuno et al., 1998, supra).
  • PRO 1563 polypeptides novel polypeptides having homology to ADAMTS-1 protein, designated herein as PRO 1563 polypeptides.
  • Chondromodulin proteins are cartilage-generated matrix components that synergistically stimulate the growth and differentiation of chondrocytes (Suzuki, Connect. Tissue Res. 35:303-307 (1996)). More specifically, chondromodulin-I functions to inhibit the proliferation of vascular endothelial cells and tube formation, thereby functioning to stimulate cartilage growth and inhibiting replacing cartilage by bone in an early stage. Chondromodulin-II, while not capable of inhibiting vascularization like chondromodulin-I, also functions to stimulate osteoclast differentiation and cartilage growth. As such, these two polypeptides are essential for the regulation of the formation of cartilage and endochondral bone structures.
  • Clostridium perfringens enterotoxin is considered to be the virulence factor responsible for causing the symptoms of C. perfringens type A food poisoning and may also be involved in other human and veterinary illnesses (McClane, Toxicon. 34: 1335-1343 (1996)).
  • CPE carries out its adverse cellular functions by binding to an approximately 50 kD cell surface receptor protein designated the Clostridium perfringens enterotoxin receptor (CPE-R) to form an approximately 90,000 kD complex on the surface of the cell.
  • CPE-R Clostridium perfringens enterotoxin receptor
  • Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. Human and mouse cDNAs showing homology to the Clostridium enterotoxin receptor (CPE-
  • Vero cell CPE receptor homologues and rat androgen withdrawal apoptosis protein (RVP1). These receptors are thus of interest as are related molecules. Of particular interest is the use of these receptors and related molecules in the identification of modulators of these receptors.
  • Claudius are integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. Furuse, et al. , J. Cell Biol.. 141(7): 1539-50 (1998).
  • Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo.
  • Human and mouse cDNAs showing homology to the Clostridium enterotoxin receptor (CPE- R) gene have previously been cloned as described in Katahira, et al. , J. Biol. Chem.. 272(42): 26652-8 (1997). They have been classified into two groups, the Vero cell CPE receptor homologues and rat androgen withdrawal apoptosis protein (RVP1). These receptors are thus of interest as are related molecules. Of particular interest is the use of these receptors and related molecules in the identification of modulators of these receptors.
  • ventral prostate.1 protein (RVP. l) which is transcriptionally induced in the regressing rat prostate after castration. This protein is further described in Peacock, et al., Genomics. 46(3):443-9 (1997).
  • Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo.
  • Human and mouse cDNAs showing homology to the Clostridium enterotoxin receptor (CPE-R) gene have previously been cloned as described in Katahira, et al., J. Biol. Chem.. 272(42): 26652-8 (1997), and Katahira, etal . J. Cell Biol.. 136(6): 1239-1247 (1997). They have been classified into two groups, the Vero cell CPE receptor homologues and rat androgen withdrawal apoptosis protein (RVP1). These receptors are thus of interest as are related molecules. Of particular interest is the use of these receptors and related molecules in the identification of modulators of these receptors. Efforts are being undertaken by both industry and academia to identify new, native receptor proteins.
  • Clostridium perfringens enterotoxin (CPE) is considered to be the virulence factor responsible for causing the symptoms of C. perfringens type A food poisoning and may also be involved in other human and veterinary illnesses (McClane, Toxicon. 34:1335-1343 (1996)).
  • CPE carries out its adverse cellular functions by binding to an approximately 50 kD cell surface receptor protein designated the Clostridium perfringens enterotoxin receptor (CPE-R) to form an approximately 90,000 kD complex on the surface of the cell.
  • CPE-R Clostridium perfringens enterotoxin receptor
  • Bioactive egg whites are a rich source of protein inhibitors of proteinases belonging to all four mechanistic classes.
  • Ovomucoid and ovoinhibitor are multidomain Kazal-type inhibitors with each domain containing an actual or putative reactive site for a serine proteinase.
  • Cystatin is a cysteine proteinase inhibitor, while ovostatin inhibits proteinases of all four mechanistic classes.
  • New members of protein inhibitors of proteinases are of interest, particularly those having sequence identity with known inhibitors such as ovomucoid.
  • Serine protease inhibitors in general are of interest. Serine proteases such as neuropsin have been indicated as associated with extracellular matrix modifications and cell migrations. See, generally, Chen, et al., Neurosci., 7(2):5088-5097 (1995) and Chen, et al. , J. Histochem. Cvtochem.. 46:313-320 (1998). Another serine protease, the enamel matrix serine proteinase, is associated with the degradation of organic matrix in teeth. Simmer, et al., J. Dent. Res.. 77(2):377-386 (1998), Overall and Limeback, Biochem J.. 256(3): 965-972 (1988), andMoradian-Oldak, Connect. Tissue Res.. 35(l-4):231-238 (1996). Thus, inhibitors of these proteases are of interest in the case that these mechanisms require control.
  • PRO 1508 a novel secreted protein designated herein as PRO 1508.
  • Lysozymes are secreted enzymes that preferentially hydrolyze the [beta] -1,4 glucosidic linkages between N-acetylmuramic acid and N-acetylgucosamine which occur in the mucopeptide cell wall structure of certain microoganisms. Lysozyme is of widespread distribution in animals and plants. It has been found in mammalian secretions and tissues including saliva, tears, milk, cervical mucus, leucocytes, kidneys, etc. The identification of new members of the lysozyme family of proteins is of interest because of the variety of roles lysozymes play in metabolic function and dysfunction. Abnormal levels of lysozymes have been implicated in various disease states. Lysozymes have been reported to have anti-microbial, analgesic, and antinociceptive properties. Additional characteristics and possible uses of lysozymes are described in U.S. Pat. No. 5,618,712.
  • lysozyme C which has been recruited as a digestive enzyme in the stomachs of creatures needing to retrieve nutrients from microorganisms in fermented food.
  • the history of lysozyme C and related proteins are further described in Qasba and Kumar, Crit. Rev. Biochem. Mol. Biol.. 32(4):255-306 (1997); Irwin, EXS, 75:347-361 (1996)
  • Glycosylation is a common and complex form of post-translational protein modification. Although a large and increasing number of unique structures is known to exist, most arise from a series of common synthetic intermediates and differ at their periphery glycosyltransferases, which recognize both the oligosaccharide acceptor and features of the underlying protein.
  • UDP-N-acetyl-alpha-D-galactosamine:polypeptide N- acetylgalactosaminyltransferase is an enzymatic protein that initiates O-glycosylation of specific serine and threonine amino acids in proteins by adding N-acetylgalactosamine to the hydroxy group of these amino acids.
  • PRQ1755 Efforts are being undertaken by both industry and academia to identify new, native transmembrane proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel transmembrane proteins. We herein describe the identification and characterization of a novel transmembrane protein designated herein as PRO 1755.
  • Protein Disulfide Isomerase enhances formation of disulfide bonds in human serum albumin (HSA). Consequently, PDI assists in the formation of the overall structure of human serum albumin. Co- expression of PDI with human serum albumin increases secretion of HSA by reducing the chance of HSA structural instability and destruction by cellular proteases. Co-expression of PDI and HSA improved localization in the endoplasmic reticulum of eukaryotic cells . (Hayano et al . , EP-50941 -A ( 1992)) . PDI and the beta-subunit of human prolyl 4-hydroxylase have been shown to be products of the same gene. (Pihlajaniemi et al.
  • Myelin glycoprotein P0 has been reported on in a number of other studies as well (Blanquet-Grossard, et al., Clin. Genet., 48(6):281-3 (1995), Hayasaka, et al., Nat. Genet., 5(l):31-4 (1993) and Saavedra, et al., J. Mol. Evol., 29(2):149-56 (1989).
  • proteins which may belong to the myelin pO family are of interest.
  • PRO 1760 a novel secreted protein designated herein as PRO 1760.
  • Phospholipase A2 is a protein which hydrolyzes a 2-acyl ester bond of phospholipids, and examples thereof include cytosolic PLA2 and secretory PLA2 which can be clearly distinguished from each other. It has been known that the cytosolic PLA2 (cPLA2) selectively hydrolyzes phospholipids containing arachidonic acid of which 2-position is esterified. Given these important biological activities, there is significant interest in identifying and characterizing novel plypeptides having homology to phospholipase A2 proteins. We herein describe the identification and characterization of novel polypeptides having homology to human phospholipase A2 protein, designated herein as PRO 1561 polypeptides.
  • CSGs Colon specific genes
  • They are useful diagnostic markers for colon cancer and for colon cancer metastasis and can also be used to screen for potential pharmaceutical and diagnostic agents. The identification of new members of the CSG family is of interest.
  • Insulin-like growth factors have both growth-promoting and insulin-like activities.
  • the larger protein is an acid-labile protein of 53K which circulates mostly as a 125 to 150 kD complex thought to be composed of IGF-I or IGF-II, the binding protein itself and an acid-labile non-IGF-binding protein with an approximate molecular mass of 100K kD.
  • the smaller protein has an apparent molecular mass of 28K in the non-reduced form and 34K when reduced.
  • N-acetylglucosaminyltransferase proteins comprise a family of enzymes that provide for a variety of important biological functions in the mammalian organism.
  • UDP-N-acetylglucosamine: alpha-3- D-mannoside beat-l,2-N-acetylglucosarninyltransferase I is an enzymatic protein that catalyzes an essential first step in the conversion of high-mannose N-glycans to hybrid and complex N-glycans (Sarkar et al., Proc. Natl. Acad. Sci. USA. 88:234-238 (1991).
  • Protein-protein interactions include receptor and antigen complexes and signaling mechanisms. As more is known about the structural and functional mechanisms underlying protein-protein interactions, protein-protein interactions can be more easily manipulated to regulate the particular result of the protein-protein interaction. Thus, the underlying mechanisms of protein-protein interactions are of interest to the scientific and medical community.
  • Leucine-rich repeats are short sequence motifs present in a number of proteins with diverse functions and cellular locations.
  • the crystal structure of ribonuclease inhibitor protein has revealed that leucine-rich repeats correspond to beta-alpha structural units. These units are arranged so that they form a parallel beta-sheet with one surface exposed to solvent, so that the protein acquires an unusual, nonglobular shape.
  • IGF insulin like growth factor
  • the acid labile subunit of IGF is also of interest in that it increases the half-life of IGF and is part of the IGF complex in vivo.
  • SLIT protein Another protein which has been reported to have leucine-rich repeats is the SLIT protein which has been reported to be useful in treating neurodegenerative diseases such as Alzheimer's disease, nerve damage such as in Parkinson's disease, and for diagnosis of cancer, see, Artavanistsakonas, S. and Rothberg, J. M., WO9210518-A1 by Yale University.
  • LIG-1 a membrane glycoprotein that is expressed specifically in glial cells in the mouse brain, and has leucine rich repeats and immunoglobulin-like domains. Suzuki, et al., J. Biol. Chem. (U.S.), 271(37):22522 (1996).
  • Interleukin-10 is a pleiotropic immunosuppressive cytokine that has been implicated as an important regulator of the functions of myeloid and lymphoid cells. It has been demonstrated that IL-10 functions as a potent inhibitor of the activation of the synthesis of various inflammatory cytokines including, for example, IL-1, IL-6, IFN- ⁇ and TNF- ⁇ (Gesser et al., Proc. Natl. Acad. Sci. USA 94: 14620-14625 (1997)).
  • IL-10 has been demonstrated to strongly inhibit several of the accessory activities of macrophages, thereby functioning as a potent suppressor of the effector functions of macrophages, T-cells and NK cells (Kuhn et al., Cell 75:263-274 (1993)). Furthermore, IL-10 has been strongly implicated in the regulation of B-cell, mast cell and thymocyte differentiation. IL-10 was independently identified in two separate lines of experiments.
  • cDNA clones encoding murine IL-10 were identified based upon the expression of cytokine synthesis inhibitory factor (Moore et al., Science 248: 1230-1234 (1990)), wherein the human IL-10 counterpart cDNAs were subsequently identified by cross-hybridization with the murine IL-10 cDNA (Viera et al., Proc. Natl. Acad. Sci. USA 88:1172-1176 (1991)). Additionally, IL-10 was independently identified as a B-cell-derived mediator which functioned to co- stimulate active thymocytes (Suda et al., Cell Immunol. 129:228 (1990)).
  • IL-19 is a 177 amino acid polypeptide having a molecular weight of approximately 20.4 kD (see WO 98/08870, published March 5, 1998). It has been reported that IL-19 is specifically expressed by activated monocytes, wherein increased and/or decreased levels of IL-19 may be associated with one or more physiological disorders that are associated with increased or decreased levels of cytokine production (see WO 98/08870). Specifically, IL-19 is suggested as being capable of inhibiting the synthesis of inflammatory cytokines by cells of the immune system.
  • Uncoupling proteins or "UCPs” believed to play a role in the metabolic process, have been reported in the literature. UCPs were first found and described in the brown fat cells of hibernating animals, such as bears. UCPs were believed to help such hibernators and other cold-weather adapted animals maintain core body temperatures in cold weather by raising their body's resting metabolic rate. Because humans possess relatively small quantities of brown adipose tissue, UCPs were originally thought to play a minor role in human metabolism.
  • UCP1 human uncoupling protein
  • UCP2 Another human UCP, referred to as UCPH or UCP2, has also been described.
  • Fleury et al. teach that the UCP2 protein has 59% amino acid identity to UCP1 , and that UCP2 maps to regions of human chromosome 11 which have been linked to hyperinsulinaemia and obesity. [Fleury et al., supra].
  • UCP2 is expressed in a variety of adult tissues, such as brain and muscle and fat cells. [Gimeno et al., supra, and Fleury et al., supra].
  • Polypeptides such as the human 2-19 protein may function as cytokines.
  • Cytokines are low molecular weight proteins which function to stimulate or inhibit the differentiation, proliferation or function of immune cells. Cytokine proteins often act as intercellular messengers and have multiple physiological effects. Given the physiological importance of immune mechanisms in vivo, efforts are currently being undertaken to identify new, native proteins which are involved in effecting the immune system. We describe herein the identification of a novel polypeptide which has sequence similarity to the human 2-19 protein.
  • Carbonic anhydrase is an enzymatic protein that which aids carbon dioxide transport and release in the mammalian blood system by catalyzing the synthesis (and the dehydration) of carbonic acid from (and to) carbon dioxide and water.
  • the actions of carbonic anhydrase are essential for a variety of important physiological reactions in the mammal.
  • novel polypeptides having homology to carbonic anhydrase there is significant interest in the identification and characterization of novel polypeptides having homology to carbonic anhydrase.
  • novel polypeptides having homology to carbonic anhydrase designated herein as PRO 1335 polypeptides.
  • PRO 1329 a novel secreted protein designated herein as PRO 1329.
  • PRO 1550 a novel secreted protein designated herein as PRO 1550.
  • PRO1560 a novel secreted protein designated herein as PRO 1550.
  • a cDNA clone (DNA 19902- 1669) has been identified that encodes a novel polypeptide believed to be a novel member of the tetraspan family, designated in the present application as "PRO1560.”
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO1560 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO1560 polypeptide having the sequence of amino acid residues from 1 or about 43 to about 245, inclusive of Figure 2 (SEQ ID NO:4), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PRO 1560 polypeptide comprising DNA hybridizing to the complement ofthe nucleic acid between about residues 167 and about 775, inclusive, of Figure 1 (SEQ ID NO:3). Preferably, hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No.
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203454 (DNA 19902- 1669).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 1 or about 43 to about 245, inclusive of Figure 2
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1560 polypeptide having the sequence of amino acid residues from about 1 or about 43 to about 245, inclusive of Figure 2 (SEQ ID NO:4), or (b) the complement ofthe DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1560 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e. transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 42 in the sequence of Figure 2 (SEQ ID NO:4).
  • the transmembrane domains have been tentatively identified as at about amino acid positions 19-42, 61-83, 92-114 and 209-230 in the PRO1560 amino acid sequence ( Figure 2, SEQ ID NO:4).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 43 to about 245, inclusive of Figure 2 (SEQ ID NO: 4), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PRO 1560 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PRO 1560 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 or about 43 through 245 of Figure 2 (SEQ ID NO:4).
  • the invention concerns an isolated PRO1560 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 43 to about 245, inclusive of Figure 2 (SEQ ID NO:4).
  • the invention concerns an isolated PRO1560 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 43 through 245 of Figure 2 (SEQ ID NO:4).
  • the invention concerns an isolated PRO 1560 polypeptide, comprising the sequence of amino acid residues 1 or about 43 to about 245, inclusive of Figure 2 (SEQ ID NO:4), or a fragment thereof sufficient to provide a binding site for an anti-PRO1560 antibody.
  • the PRO1560 fragment retains a qualitative biological activity of a native PRO1560 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO1560 polypeptide having the sequence of amino acid residues from about 1 or about 43 to about 245, inclusive of Figure 2 (SEQ ID NO:4), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PRO 1560 polypeptide.
  • the agonist or antagonist is an anti-PRO1560 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PRO1560 polypeptide, by contacting the native PRO1560 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PRO1560 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA26846-1393) has been identified that encodes a novel secreted polypeptide, designated in the present application as "PR0444.”
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR0444 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PR0444 polypeptide having the sequence of amino acid residues from about 1 or about 17 to about 117, inclusive of Figure 4 (SEQ ID NO: 1)
  • the invention concerns an isolated nucleic acid molecule encoding a PR0444 polypeptide comprising DNA hybridizing to the complement ofthe nucleic acid between about residues 656 and about 958, inclusive, of Figure 3 (SEQ ID NO:5).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203406 (DNA26846-1397), or (b) the complement ofthe DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 1 or about 17 to about 117, inclusive of Figure 4
  • the invention concerns an isolated nucleic acid molecule having at least about 10 nucleotides, more preferably at least about 20 nucleotides, and most preferably at least about 40 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a
  • PR0444 polypeptide having the sequence of amino acid residues from about 1 or about 17 to about 117, inclusive of Figure 4 (SEQ ID NO:6), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR0444 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 16 in the sequence of Figure 4 (SEQ ID NO: 1
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 17 to about 117, inclusive of Figure 4 (SEQ ID NO: 6), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PR0444 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PR0444 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 or about 17 to 117 of Figure 4 (SEQ ID NO:6).
  • the invention concerns an isolated PR0444 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 17 to about 117, inclusive of Figure 4 (SEQ ID NO:6).
  • the invention concerns an isolated PR0444 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 or about 17 to 117 of Figure 4 (SEQ ID NO: 6).
  • the invention concerns an isolated PR0444 polypeptide, comprising the sequence of amino acid residues 1 or about 17 to about 117, inclusive of Figure 4 (SEQ ID NO:6), or a fragment thereof sufficient to provide a binding site for an anti-PR0444 antibody.
  • the PR0444 fragment retains a qualitative biological activity of a native PR0444 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR0444 polypeptide having the sequence of amino acid residues from about 1 or about 17 to about 117, inclusive of Figure 4 (SEQ ID NO:6), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • a cDNA clone (DNA56107-1415) has been identified that encodes a novel transmembrane polypeptide, designated in the present application as "PRO1018".
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO1018 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO1018 polypeptide having the sequence of amino acid residues from about 1 or about 25 to about 189, inclusive of Figure 6 (SEQ ID NO: 8), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PRO1018 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 129 or about 201 and about 695, inclusive, of Figure 5 (SEQ ID NO:7).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203405 (DNA56107-1415) or (b) the complement of the nucleic acid molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203405 (DNA56107-1415).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 25 to about 189, inclusive of Figure62 (SEQ ID NO:8), or (b) the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least 10 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1018 polypeptide having the sequence of amino acid residues from 1 or about 25 to about 189, inclusive of Figure 6 (SEQ ID NO:8), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO1018 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e., transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 24 in the sequence of Figure 6 (SEQ ID NO:8).
  • the transmembrane domains have been tentatively identified as extending from about amino acid position 86 to about amino acid position 103 and from about amino acid position 60 to about amino acid position 75 in the PRO 1018 amino acid sequence ( Figure 6, SEQ ID NO: 8).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 25 to about 189, inclusive of Figure 6 (SEQ ID NO:8), or (b) the complement of the DNA of (a).
  • Another embodiment is directed to fragments of a PRO 1018 polypeptide coding sequence that may find use as hybridization probes.
  • Such nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 5 (SEQ ID NO:7).
  • the invention provides isolated PRO1018 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention provides isolated native sequence PRO1018 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 25 to about 189 of Figure 6 (SEQ ID NO:8).
  • the invention concerns an isolated PRO1018 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 25 to about 189, inclusive of Figure 6 (SEQ ID NO:8).
  • the invention concerns an isolated PRO1018 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 or about 25 to about 189, inclusive of Figure 6 (SEQ ID NO:8).
  • the invention concerns an isolated PRO1018 polypeptide, comprising the sequence of amino acid residues 1 or about 25 to about 189, inclusive of Figure 6 (SEQ ID NO: 8), or a fragment thereof sufficient to provide a binding site for an anti-PRO1018 antibody.
  • the PRO1018 fragment retains a qualitative biological activity of a native PRO 1018 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO1018 polypeptide having the sequence of amino acid residues from about 1 or about 25 to about 189, inclusive of Figure 6 (SEQ ID NO:8), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • a cDNA clone (DNA56406-1704) has been identified, having homology to nucleic acid encoding a retinol dehydrogenase protein that encodes a novel polypeptide, designated in the present application as
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1773 polypeptide.
  • the invention concerns an isolated nucleic acid molecule encoding a PRO 1773 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 111 or about 162 and about 1067, inclusive, of Figure 7 (SEQ ID NO:9).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203478 (DNA56406-1704) or (b) the complement of the nucleic acid molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in
  • the invention concerns an isolated nucleic acid molecule having at least 525 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR01773 polypeptide having the sequence of amino acid residues from 1 or about 18 to about 319, inclusive of Figure 8 (SEQ ID NO: 10), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1773 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e., transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 17 in the sequence of Figure 8 (SEQ ID NO: 10).
  • the transmembrane domain has been tentatively identified as extending from about amino acid position 136 to about amino acid position 152 in the PR01773 amino acid sequence ( Figure 8, SEQ ID NO: 10).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 18 to about 319, inclusive of Figure 8 (SEQ ID NO: 10), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 7 (SEQ ID NO: 9).
  • the invention provides isolated PRO 1773 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention provides isolated native sequence PR01773 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 18 to about 319 of Figure 8 (SEQ ID NO: 10).
  • the invention concerns an isolated PR01773 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 18 to about 319, inclusive of Figure 8 (SEQ ID NO: 10).
  • the invention concerns an isolated PR01773 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 or about 18 to about 319, inclusive of Figure 8 (SEQ ID NO:10).
  • the invention concerns an isolated PRO 1773 polypeptide, comprising the sequence of amino acid residues 1 or about 18 to about 319, inclusive of Figure 8 (SEQ ID NO: 10), or a fragment thereof sufficient to provide a binding site for an anti-PR01773 antibody.
  • the PR01773 fragment retains a qualitative biological activity of a native PR01773 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1773 polypeptide having the sequence of amino acid residues from about 1 or about 18 to about 319, inclusive of Figure 8 (SEQ ID NO: 10), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PR01773 polypeptide.
  • the agonist or antagonist is an anti-PRO 1773 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PR01773 polypeptide by contacting the native PR01773 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PRO 1773 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • PRQ1477 A cDNA clone (DNA56529-1647) has been identified, having homology to nucleic acid encoding a mannosidase protein that encodes a novel polypeptide, designated in the present application as "PR01477".
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1477 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1477 polypeptide having the sequence of amino acid residues from about 1 to about 699, inclusive of Figure 10 (SEQ ID NO: 12), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PRO 1477 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 23 and about 2119, inclusive, of Figure 9 (SEQ ID NO: 11).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203293
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 to about 699, inclusive of Figure 10 (SEQ ID NO: 12), or (b) the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least 540 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1477 polypeptide having the sequence of amino acid residues from 1 to about 699, inclusive of Figure 10 (SEQ ID NO: 12), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01477 polypeptide, with or without and/or the initiating methionine, and its soluble, i.e., transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the transmembrane domains have been tentatively identified as extending from about amino acid position 21 to about amino acid position 40 and from about amino acid position 84 to about amino acid position 105 in the PRO 1477 amino acid sequence ( Figure 10, SEQ ID NO: 12).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to about 699, inclusive of Figure 10 (SEQ ID NO: 12), or (b) the complement of the DNA of (a).
  • Another embodiment is directed to fragments of a PRO 1477 polypeptide coding sequence that may find use as hybridization probes.
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 9 (SEQ ID NO: 11).
  • the invention provides isolated PRO 1477 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention provides isolated native sequence PR01477 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 to about 699 of Figure 10 (SEQ ID NO: 12).
  • the invention concerns an isolated PRO 1477 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 to about 699, inclusive of Figure 10 (SEQ ID NO: 12).
  • the invention concerns an isolated PRO 1477 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to about 699, inclusive of Figure 10 (SEQ ID NO: 12).
  • the invention concerns an isolated PRO 1477 polypeptide, comprising the sequence of amino acid residues 1 to about 699, inclusive of Figure 10 (SEQ ID NO: 12), or a fragment thereof sufficient to provide a binding site for an anti-PR01477 antibody.
  • the PR01477 fragment retains a qualitative biological activity of a native PRO 1477 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1477 polypeptide having the sequence of amino acid residues from about 1 to about 699, inclusive of Figure 10 (SEQ ID NO: 12), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PRO 1477 polypeptide.
  • the agonist or antagonist is an anti-PR01477 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PRO 1477 polypeptide by contacting the native PRO 1477 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PR01477 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA56531-1648) has been identified that encodes a novel polypeptide having sequence identity with galactosyltransferase and designated in the present application as "PRO 1478.”
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01478 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1478 polypeptide having the sequence of amino acid residues from about 1 to about 327, inclusive of Figure 12 (SEQ ID NO: 17), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01478 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 77 and about 1057, inclusive, of Figure 11 (SEQ ID NO: 16).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203286 (DNA56531-1648), or (b) the complement of the DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203286 (DNA56531-1648).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1478 polypeptide having the sequence of amino acid residues from about 1 to about 327, inclusive of Figure 12 (SEQ ID NO: 17), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01478 polypeptide in its soluble form, i.e. transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the transmembrane domain (type II) has been tentatively identified as extending from about amino acid position 29 through about amino acid position 49 in the PR01478 amino acid sequence ( Figure 12, SEQ ID NO: 17). Therefore, a peptide including amino acids 50-327, with or without amino acids 1-28, is specifically embodied herein, as well as the nucleic acid encoding such a peptide.
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to about 327, inclusive of Figure 12 (SEQ ID NO: 17), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PRO 1478 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PR01478 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 through 327 of Figure 12 (SEQ ID NO: 17).
  • the invention concerns an isolated PRO 1478 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 to about 327, inclusive of Figure 12 (SEQ ID NO: 17).
  • the invention concerns an isolated PRO 1478 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 through 327 of Figure 12 (SEQ ID NO: 17).
  • the invention concerns an isolated PRO 1478 polypeptide, comprising the sequence of amino acid residues 1 to about 327, inclusive of Figure 12 (SEQ ID NO: 17), or a fragment thereof sufficient to provide a binding site for an anti-PRO 1478 antibody.
  • the PRO 1478 fragment retains a qualitative biological activity of a native PR01478 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1478 polypeptide having the sequence of amino acid residues from about 1 to about 327, inclusive of Figure 12 (SEQ ID NO: 17), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PRO 1478 polypeptide.
  • the agonist or antagonist is an anti-PR01478 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PR01478 polypeptide, by contacting the native PR01478 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PR01478 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA56862-1343) has been identified that encodes a novel secreted polypeptide, designated in the present application as "PR0831".
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR0831 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PR0831 polypeptide having the sequence of amino acid residues from about 1 or about 16 to about 73, inclusive of Figure 14 (SEQ ID NO: 22), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR0831 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 40 or about 85 and about 258, inclusive, of Figure 13 (SEQ ID NO:21).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203174 (DNA56862-1343) or (b) the complement of the nucleic acid molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203174 (DNA56862-1343).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 16 to about 73, inclusive of Figure 14 (SEQ ID NO:22), or (b) the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least 470 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR0831 polypeptide having the sequence of amino acid residues from 1 or about 16 to about 73, inclusive of Figure 14 (SEQ ID NO: 22), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR0831 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 15 in the sequence of Figure 14 (SEQ ID NO:22).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 16 to about 73, inclusive of Figure 14 (SEQ ID NO:22), or (b) the complement of the DNA of (a).
  • Another embodiment is directed to fragments of a PR0831 polypeptide coding sequence that may find use as hybridization probes.
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 13 (SEQ ID NO:21).
  • the invention provides isolated PR0831 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention provides isolated native sequence PR0831 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 16 to about 73 of Figure 14 (SEQ ID NO:22).
  • the invention concerns an isolated PR0831 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 16 to about 73, inclusive of Figure 14 (SEQ ID NO:22).
  • the invention concerns an isolated PR0831 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 or about 16 to about 73, inclusive of Figure 14 (SEQ ID NO:22).
  • the invention concerns an isolated PR0831 polypeptide, comprising the sequence of amino acid residues 1 or about 16 to about 73, inclusive of Figure 14 (SEQ ID NO: 22), or a fragment thereof sufficient to provide a binding site for an anti-PR0831 antibody.
  • the PR0831 fragment retains a qualitative biological activity of a native PR0831 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR0831 polypeptide having the sequence of amino acid residues from about 1 or about 16 to about 73, inclusive of Figure 14 (SEQ ID NO:22), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • a cDNA clone (DNA57254-1477) has been identified that encodes a novel polypeptide having sequence identity with leucine rich repeat proteins and designated in the present application as "PROl 113. "
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PROl 113 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PROl 113 polypeptide having the sequence of amino acid residues from about 1 to about 616, inclusive of Figure 16 (SEQ ID NO:24), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PROl 113 polypeptide comprising DNA hybridizing to the complement ofthe nucleic acid between about residues 214 and about 2061, inclusive, of Figure 15 (SEQ ID NO:23).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encodmg the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203289 (DNA57254-1477), or (b) the complement ofthe DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203289 (DNA57254-1477).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 1 to about 616, inclusive of Figure 16 (SEQ ID NO: 24), or the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PROl 113 polypeptide having the sequence of amino acid residues from about 1 to about 616, inclusive of Figure 16 (SEQ ID NO:24), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PROl 113 polypeptide in its soluble, i.e. transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the transmembrane domain has been tentatively identified as extending from about amino acid position 13 through about amino acid position 40 in the PROl 113 amino acid sequence ( Figure 16, SEQ ID NO:24).
  • Figure 16 SEQ ID NO:24
  • a peptide comprising amino acids 41-616, and optionally 1-12 of SEQ ID NO:24, and the nucleic acids encoding the same.
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to about 616, inclusive of Figure 16 (SEQ ID NO:24), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PROl 113 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PRO 1113 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 through 616 of Figure 16 (SEQ ID NO:24).
  • the invention concerns an isolated PROl 113 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 to about 616, inclusive of Figure 16 (SEQ ID NO:24).
  • the invention concerns an isolated PROl 113 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 through 616 of Figure 16 (SEQ ID NO:24).
  • the invention concerns an isolated PROl 113 polypeptide, comprising the sequence of amino acid residues 1 to about 616, inclusive of Figure 16 (SEQ ID NO: 24), or a fragment thereof sufficient to provide a binding site for an anti-PROl 113 antibody.
  • the PROl 113 fragment retains a qualitative biological activity of a native PROl 113 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PROH 13 polypeptide having the sequence of amino acid residues from about 1 to about 616, inclusive of Figure 16 (SEQ ID NO: 24), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PROl 113 polypeptide.
  • the agonist or antagonist is an anti-PROl 113 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PROl 113 polypeptide, by contacting the native PROl 113 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PROl 113 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA57841-1522) has been identified that encodes a novel secreted polypeptide designated in the present application as "PROl 194.”
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1194 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PROl 194 polypeptide having the sequence of amino acid residues from 1 or about 22 to about 81, inclusive of Figure 18 (SEQ ID NO:29), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PROl 194 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 72 and about 251, inclusive, of Figure 17 (SEQ ID NO:28).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203458 (DNA57841-1522), or (b) the complement of the DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203458 (DNA57841-1522).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 22 to about 81, inclusive of Figure 18 (SEQ ID NO:29), or the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PROl 194 polypeptide having the sequence of amino acid residues from about 22 to about 81, inclusive of Figure 18 (SEQ ID NO:29), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 22 to about 81, inclusive of Figure 18 (SEQ ID NO: 29), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PROl 194 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PRO 1194 polypeptide , which in one embodiment, includes an amino acid sequence comprising residues 22 through 81 of Figure 18 (SEQ ID NO: 29).
  • the invention concerns an isolated PROl 194 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 22 to about 81 , inclusive of Figure 18 (SEQ ID NO:29).
  • the invention concerns an isolated PROl 194 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 22 through 81 of Figure 18 (SEQ ID NO:29).
  • the invention concerns an isolated PRO 1194 polypeptide, comprising the sequence of amino acid residues 22 to about 81 , inclusive of Figure 18 (SEQ ID NO: 29), or a fragment thereof sufficient to provide a binding site for an anti-PROl 194 antibody.
  • the PROl 194 fragment retains a qualitative biological activity of a native PRO 1194 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1194 polypeptide having the sequence of amino acid residues from about 22 to about 81, inclusive of Figure 18 (SEQ ID NO:29), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PRO 1194 polypeptide.
  • the agonist or antagonist is an anti-PROl 194 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PROl 194 polypeptide, by contacting the native PROl 194 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PROl 194 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA58727-1474) has been identified, having homology to nucleic acid encoding myeloid upregulated protein that encodes a novel polypeptide, designated in the present application as "PROll lO".
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PROl 110 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PROl 110 polypeptide having the sequence of amino acid residues from about 1 to about 322, inclusive of Figure 20 (SEQ ID NO:31), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PROlllO polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 131 and about 1096, inclusive, of Figure 19 (SEQ ID NO:30).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203171 (DNA58727-1474) or (b) the complement of the nucleic acid molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203171 (DNA58727-1474).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 to about 322, inclusive of Figure 20 (SEQ ID NO:31), or (b) the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least 10 nucleotides and produced by hybridizmg a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PROll lO polypeptide having the sequence of amino acid residues from 1 to about 322, inclusive of Figure 20 (SEQ ID NO:31), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PROlllO polypeptide, with or without the initiating methionine and its soluble, i.e., transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • transmembrane domains have been tentatively identified as extending from about amino acid position 41 to about amino acid position 60, from about amino acid position 66 to about amino acid position 85, from about amino acid position 101 to about amino acid position 120, from about amino acid position 137 to about amino acid position 153, from about amino acid position 171 to about amino acid position 192, from about amino acid position 205 to about amino acid position 226, from about amino acid position 235 to about amino acid position 255, and from about amino acid position 294 to about amino acid position 312 in the PROl l lO amino acid sequence (Figure 20, SEQ ID NO:31).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to about 322, inclusive of Figure 20 (SEQ ID NO:31), or (b) the complement of the DNA of (a).
  • Another embodiment is directed to fragments of a PROl 110 polypeptide coding sequence that may find use as hybridization probes.
  • Such nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 19 (SEQ ID NO:30).
  • the invention provides isolated PROl l lO polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention concerns an isolated PROl 110 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 to about 322, inclusive of Figure 20 (SEQ ID NO:31).
  • the invention concerns an isolated PRO 1110 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to about 322, inclusive of Figure 20 (SEQ ID NO:31).
  • the invention concerns an isolated PRO 1110 polypeptide, comprising the sequence of amino acid residues 1 to about 322, inclusive of Figure 20 (SEQ ID NO:31), or a fragment thereof sufficient to provide a binding site for an anti-PROl 110 antibody.
  • the PROl 110 fragment retains a qualitative biological activity of a native PROll lO polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PROlllO polypeptide having the sequence of amino acid residues from about 1 to about 322, inclusive of Figure 20 (SEQ ID NO:31), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PROlllO polypeptide.
  • the agonist or antagonist is an anti-PROl 110 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PROll lO polypeptide by contacting the native PROlllO polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PRO 1110 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA58730-1607) has been identified that encodes a novel secreted polypeptide designated in the present application as "PRO 1378".
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1378 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PRO 1378 polypeptide having the sequence of amino acid residues from 1 or about 16 to about 335, inclusive of Figure 22 (SEQ ID NO:33), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01378 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 1365 and about 2369, inclusive, of Figure 21 (SEQ ID NO:32).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203221 (DNA58730-1607), or (b) the complement ofthe DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203221 (DNA58730-1607).
  • the invention concerns an isolated nucleic acid molecule having at least about 20 nucleotides, preferably at least about 50 nucleotides, and more preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1378 polypeptide having the sequence of amino acid residues from about 16 to about 335, inclusive of Figure 22 (SEQ ID NO:33), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01378 polypeptide, with or without the N-terminal signal sequence, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 15 in the sequence of Figure 22 (SEQ ID NO:33).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 16 to about 335, inclusive of Figure 22 (SEQ ID NO:33), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PRO 1378 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PR01378 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 16 to 335 of Figure 22 (SEQ ID NO: 33).
  • the invention concerns an isolated PR01378 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 16 to about 335, inclusive of Figure 22 (SEQ ID NO:33).
  • the invention concerns an isolated PRO 1378 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 16 to 335 of Figure 22 (SEQ ID NO:33).
  • the invention concerns an isolated PR01378 polypeptide, comprising the sequence of amino acid residues 16 to about 335, inclusive of Figure 22 (SEQ ID NO:33), or a fragment thereof sufficient to provide a binding site for an anti-PRO 1378 antibody.
  • the PRO 1378 fragment retains a qualitative biological activity of a native PR01378 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1378 polypeptide having the sequence of amino acid residues from about 16 to about 335, inclusive of Figure 22 (SEQ ID NO:33), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • a cDNA clone (DNA58732-1650) has been identified that encodes a novel polypeptide designated in the present application as "PR01481.”
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01481 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1481 polypeptide having the sequence of amino acid residues from 1 or about 24 to about 334, inclusive of Figure 24 (SEQ ID NO:41), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PRO 1481 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 88 and about 1321, inclusive, of Figure 23 (SEQ ID NO:40).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203290 (DNA58732-1650), or (b) the complement of the DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203290 (DNA58732-1650).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 24 to about 334, inclusive of Figure 24 (SEQ ID NO:41), or the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1481 polypeptide having the sequence of amino acid residues from about 24 to about 334, inclusive of Figure 24 (SEQ ID NO:41), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01481 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e. transmembrane domain deleted, truncated or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 23 in the sequence of Figure 24 (SEQ ID NO:41).
  • the transmembrane domain has been tentatively identified as extending from about amino acid position 235 through about amino acid position 262 in the PR01481 amino acid sequence ( Figure 24, SEQ ID NO:41).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 24 to about 334, inclusive of Figure 24 (SEQ ID NO:41), or (b) the complement of the DNA of (a).
  • Another embodiment is directed to fragments of a PRO 1481 polypeptide coding sequence that may find use as hybridization probes.
  • Such nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PRO 1481 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PRO 1481 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 24 through 334 of Figure 24 (SEQ ID NO:
  • the invention concerns an isolated PR01481 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 24 to about 334, inclusive of Figure 24 (SEQ ID NO:41).
  • the invention concerns an isolated PR01481 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 24 through 334 of Figure 24 (SEQ ID NO:41).
  • the invention concerns an isolated PRO 1481 polypeptide, comprising the sequence of amino acid residues 24 to about 334, inclusive of Figure 24 (SEQ ID NO:41), or a fragment thereof sufficient to provide a binding site for an anti-PR01481 antibody.
  • the PR01481 fragment retains a qualitative biological activity of a native PRO 1481 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1481 polypeptide having the sequence of amino acid residues from about 24 to about 334, inclusive of Figure 24 (SEQ ID NO:41), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprismg the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PRO 1481 polypeptide.
  • the agonist or antagonist is an anti-PR01481 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PRO 1481 polypeptide, by contacting the native PRO 1481 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition comprising a PRO 1481 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier. 13. PROl 189
  • a cDNA clone (DNA58828-1519) has been identified that encodes a novel polypeptidehaving homology to E25 which is designated in the present application as "PRO 1189.”
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PROl 189 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PROl 189 polypeptide having the sequence of amino acid residues from about 1 to about 263, inclusive of Figure 26 (SEQ ID NO:43), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PROl 189 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 79 and about 867, inclusive, of Figure 25 (SEQ ID NO:42).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203172 (DNA58828-1519), or (b) the complement ofthe DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203172 (DNA58828-1519).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 1 to about 263, inclusive of Figure 26 (SEQ ID NO:43), or the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PROl 189 polypeptide having the sequence of amino acid residues from about 1 to about 263, inclusive of Figure 26 (SEQ ID NO:43), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PROl 189 polypeptide with its transmembrane domain deleted or inactivated, or is complementary to such encoding nucleic acid molecule.
  • the transmembrane domain has been tentatively identified as extending from about amino acid position 53 through about amino acid position 75 in the PROl 189 amino acid sequence ( Figure 26, SEQ ID NO:43).
  • the invention concerns an isolated nucleic acid molecule comprismg (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to about 263, inclusive of Figure 26 (SEQ ID NO:43), or (b) the complement of the DNA of (a).
  • Another embodiment is directed to fragments of a PRO 1189 polypeptide coding sequence that may find use as hybridization probes.
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PROl 189 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PROl 189 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 263 of Figure 26 (SEQ ID NO:43).
  • the invention concerns an isolated PROl 189 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 to about 263, inclusive of Figure 26 (SEQ ID NO:43).
  • the invention concerns an isolated PROl 189 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to 263 of Figure 26 (SEQ ID NO:43).
  • the invention concerns an isolated PRO 1189 polypeptide, comprising the sequence of amino acid residues 1 to about 263, inclusive of Figure 26 (SEQ ID NO:43), or a fragment thereof sufficient to provide a binding site for an anti-PROl 189 antibody.
  • the PROl 189 fragment retains a qualitative biological activity of a native PRO 1189 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1189 polypeptide having the sequence of amino acid residues from about 1 to about 263, inclusive of Figure 26 (SEQ ID NO:43), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PROl 189 polypeptide.
  • the agonist or antagonist is an anti-PROl 189 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PRO 1189 polypeptide, by contacting the native PRO 1189 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition comprising a PRO 1189 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA58852-1637) has been identified that encodes a novel polypeptide, designated in the present application as "PR01415".
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01415 polypeptide.
  • the invention concerns an isolated nucleic acid molecule encoding a PR01415 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 148 or about 223 and about 996, inclusive, of Figure 27 (SEQ ID NO:49).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203271 (DNA58852-1637) or (b) the complement of the nucleic acid molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203271 (DNA58852-1637).
  • the invention concerns an isolated nucleic acid molecule having at least 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR01415 polypeptide having the sequence of amino acid residues from 1 or about 26 to about 283, inclusive of Figure 28 (SEQ ID NO:50), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01415 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e., transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 25 in the sequence of Figure 28 (SEQ ID NO:50).
  • the transmembrane domain has been tentatively identified as extending from about amino acid position 94 to about amino acid position 118 in the PR01415 amino acid sequence ( Figure 28, SEQ ID NO:50).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 26 to about 283, inclusive of Figure 28 (SEQ ID NO:50), or (b) the complement of the DNA of (a).
  • Another embodiment is directed to fragments of a PR01415 polypeptide coding sequence that may find use as hybridization probes.
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 27 (SEQ ID NO:49).
  • the invention provides isolated PR01415 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention provides isolated native sequence PR01415 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 26 to about 283 of Figure 28 (SEQ ID NO:50).
  • the invention concerns an isolated PR01415 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 26 to about 283, inclusive of Figure 28 (SEQ ID NO: 50).
  • the invention concerns an isolated PR01415 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 or about 26 to about 283, inclusive of Figure 28 (SEQ ID NO:50).
  • the invention concerns an isolated PR01415 polypeptide, comprising the sequence of amino acid residues 1 or about 26 to about 283, inclusive of Figure 28 (SEQ ID NO:50), or a fragment thereof sufficient to provide a binding site for an anti-PR01415 antibody.
  • the PR01415 fragment retains a qualitative biological activity of a native PR01415 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1415 polypeptide having the sequence of amino acid residues from about 1 or about 26 to about 283, inclusive of Figure 28 (SEQ ID NO:50), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PR01415 polypeptide.
  • the agonist or antagonist is an anti-PR01415 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PR01415 polypeptide by contacting the native PR01415 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PR01415 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA59212-1627) has been identified that encodes a novel secreted polypeptide designated in the present application as "PRO 1411."
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01411 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PRO 1411 polypeptide having the sequence of amino acid residues from 1 or about 22 to about 440, inclusive of Figure 30 (SEQ ID NO:52), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01411 polypeptide comprising DNA hybridizing to the complement ofthe nucleic acid between about residues 247 and about 1503, inclusive, of Figure 29 (SEQ ID NO:51).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203245 (DNA59212-1627), or (b) the complement ofthe DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203245 (DNA59212-1627).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 22 to about 440, inclusive of Figure 30 (SEQ ID NO:52), or the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1411 polypeptide having the sequence of amino acid residues from about 22 to about 440, inclusive of Figure 30 (SEQ ID NO:52), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 22 to about 440, inclusive of Figure 30 (SEQ ID NO: 52), or (b) the complement of the DNA of (a).
  • Another embodiment is directed to fragments of a PR01411 polypeptide coding sequence that may find use as hybridization probes.
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PRO 1411 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PR01411 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 22 through 440 of Figure 30 (SEQ ID NO:52).
  • the invention concerns an isolated PRO 1411 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 22 to about 440, inclusive of Figure 30 (SEQ ID NO:52).
  • the invention concerns an isolated PRO 1411 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 22 through 440 of Figure 30 (SEQ ID NO:52).
  • the invention concerns an isolated PRO 1411 polypeptide, comprising the sequence of amino acid residues 22 to about 440, inclusive of Figure 30 (SEQ ID NO:52), or a fragment thereof sufficient to provide a binding site for an anti-PR01411 antibody.
  • the PR01411 fragment retains a qualitative biological activity of a native PR01411 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1411 polypeptide having the sequence of amino acid residues from about 22 to about 440, inclusive of Figure 30 (SEQ ID NO:52), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PR01411 polypeptide.
  • the agonist or antagonist is an anti-PRO 1411 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PR01411 polypeptide, by contacting the native PR01411 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PR01411 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • PRQ1295 A cDNA clone (DNA59218-1559) has been identified that encodes a novel secreted polypeptide designated in the present application as "PRO 1295.”
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1295 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PRO 1295 polypeptide having the sequence of amino acid residues from 1 or about 19 to about 280, inclusive of Figure 32 (SEQ ID NO:54), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01295 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 261 and about 1046, inclusive, of Figure 31 (SEQ ID NO:53).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203287 (DNA59218-1559), or (b) the complement of the DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203287 (DNA59218-1559).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 19 to about 280, inclusive of Figure 32 (SEQ ID NO:54), or the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1295 polypeptide having the sequence of amino acid residues from about 19 to about 280, inclusive of Figure 32 (SEQ ID NO:54), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 19 to about 280, inclusive of Figure 32 (SEQ ID NO:54), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PR01295 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PR01295 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 19 through 280 of Figure 32 (SEQ ID NO:54).
  • the invention concerns an isolated PRO 1295 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 19 to about 280, inclusive of Figure 32 (SEQ ID NO:54).
  • the invention concerns an isolated PR01295 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 19 through 280 of Figure 32 (SEQ ID NO:54).
  • the invention concerns an isolated PRO 1295 polypeptide , comprising the sequence of amino acid residues 19 to about 280, inclusive of Figure 32 (SEQ ID NO:54), or a fragment thereof sufficient to provide a binding site for an anti-PR01295 antibody.
  • the PR01295 fragment retains a qualitative biological activity of a native PRO 1295 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1295 polypeptide having the sequence of amino acid residues from about 19 to about 280, inclusive of Figure 32 (SEQ ID NO:54), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PR01295 polypeptide.
  • the agonist or antagonist is an anti-PR01295 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PRO 1295 polypeptide, by contacting the native PRO 1295 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition comprising a PR01295 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA59219-1613) has been identified that encodes a novel polypeptide having sequence identity with sialytransferases and designated in the present application as "PRO 1359” polypeptides.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1359 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1359 polypeptide having the sequence of amino acid residues from 1 or about 32 to about 299, inclusive of Figure 34 (SEQ ID NO:56), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01359 polypeptide comprising DNA hybridizing to the complement ofthe nucleic acid between about residues 277 and about 1080, inclusive, of Figure 33 (SEQ ID NO:55).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203220 (DNA59219-1613), or (b) the complement ofthe DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203220 (DNA59219-1613).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1359 polypeptide having the sequence of amino acid residues from about 32 to about 299, inclusive of Figure 34 (SEQ ID NO:56), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01359 polypeptide in its soluble, i.e. transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the transmembrane domain (type II) has been tentatively identified as extending from about amino acid position 9 through about amino acid position 31 in the
  • PRO 1359 amino acid sequence ( Figure 34, SEQ ID NO: 56).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 32 to about 299, inclusive of Figure 34 (SEQ ID NO:56), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PRO 1359 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PR01359 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 32 through 299 of Figure 34 (SEQ ID NO:56).
  • the invention concerns an isolated PR01359 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 32 to about 299, inclusive of Figure 34 (SEQ ID NO:56).
  • the invention concerns an isolated PR01359 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 32 through 299 of Figure 34 (SEQ ID NO:56).
  • the invention concerns an isolated PR01359 polypeptide, comprising the sequence of amino acid residues 32 to about 299, inclusive of Figure 34 (SEQ ID NO:56), or a fragment thereof sufficient to provide a binding site for an anti-PR01359 antibody.
  • the PR01359 fragment retains a qualitative biological activity of a native PRO 1359 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1359 polypeptide having the sequence of amino acid residues from about 32 to about 299, inclusive of Figure 34 (SEQ ID NO:56), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80 % sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PR01359 polypeptide.
  • the agonist or antagonist is an anti-PR01359 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PRO 1359 polypeptide, by contacting the native PRO 1359 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PRO 1359 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA59586-1520) has been identified that encodes a novel polypeptide designated in the present application as "PRO1190", and which has homology to CDO protein.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1190 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PROl 190 polypeptide having the sequence of amino acid residues from about 1 to about 1115, inclusive of Figure 36 (SEQ ID NO:58), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PROl 190 polypeptide comprising DNA hybridizing to the complement ofthe nucleic acid between about residues 340 and about 3684, inclusive, of Figure 35 (SEQ ID NO:58).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203288 (DNA59586-1520), or (b) the complement of the DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203288 (DNA59586-1520).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 1 to about 1115, inclusive of Figure 36 (SEQ ID NO:58), or the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PROl 190 polypeptide having the sequence of amino acid residues from about 1 to about 1115, inclusive of Figure 36 (SEQ ID NO:58), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PROl 190 polypeptide, with one or more of its transmembrane domains deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the transmembrane domains have been tentatively identified in the PROl 190 amino acid sequence shown in Figure 36 (SEQ ID NO:58) as extending from about amino acid position 16 to about amino acid position 30 and from about amino acid position 854 to about amino acid position 879.
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to about 1115, inclusive of Figure 36 (SEQ ID NO:58), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PROl 190 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PROl 190 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 1115 of Figure 36 (SEQ ID NO:58).
  • the invention concerns an isolated PRO 1190 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 to about 1115, inclusive of Figure 36 (SEQ ID NO:58).
  • the invention concerns an isolated PROl 190 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to 1115 of Figure 36 (SEQ ID NO:58).
  • the invention concerns an isolated PRO 1190 polypeptide, comprising the sequence of amino acid residues 1 to about 1115, inclusive of Figure 36 (SEQ ID NO:58), or a fragment thereof sufficient to provide a binding site for an anti-PROl 190 antibody.
  • the PROl 190 fragment retains a qualitative biological activity of a native PROl 190 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PROl 190 polypeptide having the sequence of amino acid residues from about 1 to about 1115, inclusive of Figure 36 (SEQ ID NO:58), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PROl 190 polypeptide.
  • the agonist or antagonist is an anti-PROl 190 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PROl 190 polypeptide, by contacting the native PROl 190 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PROl 190 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA59817-1703) has been identified, having homology to nucleic acid encoding peptidase enzymes, that encodes a novel polypeptide, designated in the present application as "PR01772".
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01772 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1772 polypeptide having the sequence of amino acid residues from about 1 or about 37 to about 487, inclusive of Figure 38 (SEQ ID NO:63), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01772 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 93 or about 201 and about 1553, inclusive, of Figure 37 (SEQ ID NO:62). Preferably, hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No.
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203470 (DNA59817-1703).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 37 to about 487, inclusive of Figure 38 (SEQ ID NO: 63), or (b) the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least 415 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1772 polypeptide having the sequence of amino acid residues from 1 or about 37 to about 487, inclusive of Figure 38 (SEQ ID NO:63), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encodmg a PR01772 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e., transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 36 in the sequence of Figure 38 (SEQ ID NO:63).
  • the transmembrane domain has been tentatively identified as extending from about amino acid position 313 to about amino acid position 331 in the PR01772 amino acid sequence ( Figure 38, SEQ ID NO:63).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 37 to about 487, inclusive of Figure 38 (SEQ ID NO:63), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 37 (SEQ ID NO: 62).
  • the invention provides isolated PR01772 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention provides isolated native sequence PR01772 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 37 to about 487 of Figure 38 (SEQ ID NO:63).
  • the invention concerns an isolated PR01772 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 37 to about 487, inclusive of Figure 38 (SEQ ID NO:63).
  • the invention concerns an isolated PR01772 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 or about 37 to about 487, inclusive of Figure 38 (SEQ ID NO:63).
  • the invention concerns an isolated PRO 1772 polypeptide , comprising the sequence of amino acid residues 1 or about 37 to about 487, inclusive of Figure 38 (SEQ ID NO:63), or a fragment thereof sufficient to provide a binding site for an anti-PR01772 antibody.
  • the PR01772 fragment retains a qualitative biological activity of a native PRO 1772 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1772 polypeptide having the sequence of amino acid residues from about 1 or about 37 to about 487, inclusive of Figure 38 (SEQ ID NO:63), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an
  • the invention concerns agonists and antagonists of a native PR01772 polypeptide.
  • the agonist or antagonist is an anti-PRO 1772 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PRO 1772 polypeptide by contacting the native PRO 1772 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition comprising a PR01772 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA60278-1530) has been identified, having homology to nucleic acid encoding PUT- 2, that encodes a novel polypeptide, designated in the present application as "PRO 1248".
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01248 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PRO 1248 polypeptide having the sequence of amino acid residues from about 1 or about 21 to about 183, inclusive of Figure 40 (SEQ ID NO: 1).
  • the invention concerns an isolated nucleic acid molecule encoding a PRO 1248 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 122 or about 182 and about 670, inclusive, of Figure 39 (SEQ ID NO:67).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203170 (DNA60278-1530) or (b) the complement of the nucleic acid molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203170 (DNA60278-1530).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 21 to about 183, inclusive of Figure 40 (SEQ ID NO:68), or (b) the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least 10 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1248 polypeptide having the sequence of amino acid residues from 1 or about 21 to about 183, inclusive of Figure 40 (SEQ ID NO:68), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1248 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e., transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 20 in the sequence of Figure 40 (SEQ ID NO: 68).
  • the transmembrane domain has been tentatively identified as extending from about amino acid position 90 to about amino acid position 112 in the PR01248 amino acid sequence ( Figure 40, SEQ ID NO:68).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 21 to about 183, inclusive of Figure 40 (SEQ ID NO: 68), or (b) the complement of the DNA of (a).
  • Another embodiment is directed to fragments of a PRO 1248 polypeptide coding sequence that may find use as hybridization probes.
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 39 (SEQ ID NO:67).
  • the invention provides isolated PRO 1248 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention provides isolated native sequence PR01248 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 21 to about 183 of Figure 40 (SEQ ID NO:68).
  • the invention concerns an isolated PRO 1248 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 21 to about 183, inclusive of Figure 40 (SEQ ID NO:68).
  • the invention concerns an isolated PRO 1248 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 21 to about 183, inclusive of Figure 40 (SEQ ID NO: 68).
  • the invention concerns an isolated PR01248 polypeptide, comprising the sequence of amino acid residues 1 or about 21 to about 183, inclusive of Figure 40 (SEQ ID NO: 68), or a fragment thereof sufficient to provide a binding site for an anti-PR01248 antibody.
  • the PR01248 fragment retains a qualitative biological activity of a native PRO 1248 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1248 polypeptide having the sequence of amino acid residues from about 1 or about 21 to about 183, inclusive of Figure 40 (SEQ ID NO:68), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PRO 1248 polypeptide.
  • the agonist or antagonist is an anti-PR01248 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PR01248 polypeptide by contacting the native PR01248 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PR01248 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA60608-1577) has been identified, having homology to Dickkopf that encodes a novel polypeptide, designated in the present application as "PRO 1316. "
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1316 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1316 polypeptide having the sequence of amino acid residues from 1 or about 26 to about 259, inclusive of Figure 42 (SEQ ID NO:70), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01316 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 281 and about 987, inclusive, of Figure 41 (SEQ ID NO:69).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203126 (DNA60608-1577), or (b) the complement of the DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203126 (DNA60608-1577).
  • the invention concern an isolated nucleic acid molecule having at least 15 nucleotides which hybridizes under stringent conditions with (a) a DNA molecule having a identity with a region spanning either from residues 1-454 or from residues 1095-3130 of the Figure 41 (SEQ ID NO:69), or (b) the complement of the DNA molecule of (a).
  • an isolated nucleic acid molecule having at least 15 nucleotides having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, and most preferably at least about 95% sequence identity to: (a) a DNA molecule having a identity with a region spanning either from residues 1-454 or from residues 1095-3130 ofthe Figure 41 (SEQ ID NO: 69), or (b) the complement of the DNA molecule of (a).
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1316 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e. transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from amino acid position 1 to about amino acid position 25 in the sequence of Figure 42 (SEQ ID NO:70).
  • An N-glycosylation site has been identified at position 52 and a fungal Zn(2)-Cys(6) binuclear cluster has been identified at position 99.
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 26 to about 259, inclusive of Figure 42 (SEQ ID NO:70), or (b) the complement of the DNA of (a).
  • the invention provides isolated PR01316 polypeptide encoded by any of the isolated nucleic acid sequences herein above defined.
  • the invention provides isolated native sequence PRO 1316 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 26 to 259 of Figure 42 (SEQ ID NO:70).
  • the invention concerns an isolated PR01316 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 26 to about 259, inclusive of Figure 42 (SEQ ID NO:70).
  • the invention concerns an isolated PRO 1316 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 26 to 259 of Figure 42 (SEQ ID NO:70).
  • the invention concerns an isolated PRO 1316 polypeptide, comprising the sequence of amino acid residues 26 to about 259, inclusive of Figure 42 (SEQ ID NO:70), or a fragment thereof sufficient to provide a binding site for an anti-PRO 1316 antibody .
  • the PRO 1316 fragment retains a qualitative biological activity of a native PRO 1316 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1316 polypeptide having the sequence of amino acid residues from about 26 to about 259, inclusive of Figure 42 (SEQ ID NO:70), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of the a native PR01316 polypeptide.
  • the agonist or antagonist is an anti-PR01316 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PR01316 polypeptide, by contacting the native PR01316 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PR01316 polypeptide, or an agonist or antagonist as herein above defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA60611-1524) has been identified that encodes a novel secreted polypeptide designated in the present application as "PROl 197.”
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PROl 197 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PROl 197 polypeptide having the sequence of amino acid residues from 1 or about 25 to about 363, inclusive of Figure 44 (SEQ ID NO:72), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PROl 197 polypeptide comprising DNA hybridizing to the complement ofthe nucleic acid between about residues 383 and about 1399, inclusive, of Figure 43 (SEQ ID NO:71).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203175 (DNA60611-1524), or (b) the complement of the DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203175 (DNA60611-1524).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 25 to about 363, inclusive of Figure 44 (SEQ ID NO: 1
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1197 polypeptide having the sequence of amino acid residues from about 25 to about 363, inclusive of Figure 44 (SEQ ID NO:72), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 25 to about 363, inclusive of Figure 44 (SEQ ID NO:72), or (b) the complement of the DNA of (a).
  • Another embodiment is directed to fragments of a PROl 197 polypeptide coding sequence that may find use as hybridization probes.
  • Such nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PROl 197 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PROl 197 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 25 through 363 of Figure 44 (SEQ ID NO:72).
  • the invention concerns an isolated PROl 197 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 25 to about 363, inclusive of Figure 44 (SEQ ID NO:72).
  • the invention concerns an isolated PROl 197 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 25 through 363 of Figure 44 (SEQ ID NO:72).
  • the invention concerns an isolated PRO 1197 polypeptide , comprising the sequence of amino acid residues 25 to about 363, inclusive of Figure 44 (SEQ ID NO:72), or a fragment thereof sufficient to provide a binding site for an anti-PROl 197 antibody.
  • the PROl 197 fragment retains a qualitative biological activity of a native PRO 1197 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1197 polypeptide having the sequence of amino acid residues from about 25 to about 363, inclusive of Figure 44 (SEQ ID NO:72), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PROl 197 polypeptide.
  • the agonist or antagonist is an anti-PROl 197 antibody.
  • a cDNA clone (DNA60618-1557) has been identified, having homology to nucleic acid encoding an immunoglobulin heavy chain variable region protein that encodes a novel polypeptide, designated in the present application as " PRO 1293".
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01293 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1293 polypeptide having the sequence of amino acid residues from about 1 or about 20 to about 341, inclusive of Figure 46 (SEQ ID NO:77), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PRO 1293 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 37 or about 94 and about 1059, inclusive, of Figure 45 (SEQ ID NO:76).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203292
  • nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 20 to about 341, inclusive of Figure 46 (SEQ ID NO: 1
  • the invention concerns an isolated nucleic acid molecule having at least 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1293 polypeptide having the sequence of amino acid residues from 1 or about 20 to about 341, inclusive of Figure 46 (SEQ ID NO:77), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1293 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e., transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 19 in the sequence of Figure 46 (SEQ ID NO:77).
  • the transmembrane domain has been tentatively identified as extending from about amino acid position 237 to about amino acid position 262 in the PR01293 amino acid sequence ( Figure 46, SEQ ID NO:77).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 20 to about 341, inclusive of Figure 46 (SEQ ID NO: 77), or (b) the complement of the DNA of (a).
  • Another embodiment is directed to fragments of a PRO 1293 polypeptide coding sequence that may find use as hybridization probes.
  • Such nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 45 (SEQ ID NO: 76).
  • the invention provides isolated PRO 1293 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention provides isolated native sequence PR01293 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 20 to about 341 of Figure 46 (SEQ ID NO:77).
  • the invention concerns an isolated PR01293 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 20 to about 341, inclusive of Figure 46 (SEQ ID NO: 77).
  • the invention concerns an isolated PR01293 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 or about 20 to about 341, inclusive of Figure 46 (SEQ ID NO:77).
  • the invention concerns an isolated PR01293 polypeptide, comprising the sequence of amino acid residues 1 or about 20 to about 341 , inclusive of Figure 46 (SEQ ID NO: 77), or a fragment thereof sufficient to provide a binding site for an anti-PR01293 antibody.
  • the PR01293 fragment retains a qualitative biological activity of a native PRO 1293 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1293 polypeptide having the sequence of amino acid residues from about 1 or about 20 to about 341, inclusive of Figure 46 (SEQ ID NO:77), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PR01293 polypeptide.
  • the agonist or antagonist is an anti-PR01293 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PRO 1293 polypeptide by contacting the native PRO 1293 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition comprising a PR01293 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA60740-1615) has been identified that encodes a novel multi-span transmembrane polypeptide designated in the present application as "PRO1380".
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1380 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PRO1380 polypeptide having the sequence of amino acid residues from about 1 to about 470, inclusive of Figure 48 (SEQ ID NO:79), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PRO 1380 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 36 and about 1460, inclusive, of Figure 47 (SEQ ID NO:78).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203456 (DNA60740-1615), or (b) the complement of the DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203456 (DNA60740-1615).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 1 to about 470, inclusive of Figure 48 (SEQ ID NO:79), or the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO1380 polypeptide having the sequence of amino acid residues from about 1 to about 470, inclusive of Figure 48 (SEQ ID NO: 79), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encodmg a PRO1380 polypeptide, and its soluble variants (i.e. one or more transmembrane domains deleted or inactivated), or is complementary to such encoding nucleic acid molecule.
  • Transmembrane domains have been tentatively identified at about the following amino acid positions: 50-74, 105-127, 135-153, 163-183, 228-252,
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to about 470, inclusive of Figure 48 (SEQ ID NO:79), or (b) the complement of the DNA of (a).
  • Another embodiment is directed to fragments of a PRO 1380 polypeptide coding sequence that may find use as hybridization probes.
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PRO 1380 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PRO1380 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 to 470 of Figure 48 (SEQ ID NO:79).
  • the invention concerns an isolated PRO1380 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 to about 470, inclusive of Figure 48 (SEQ ID NO:79).
  • the invention concerns an isolated PRO1380 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to 470 of Figure 48 (SEQ ID NO:79).
  • the invention concerns an isolated PRO 1380 polypeptide, comprising the sequence of amino acid residues 1 to about 470, inclusive of Figure 48 (SEQ ID NO:79), or a fragment thereof sufficient to provide a binding site for an anti-PRO1380 antibody.
  • the PRO1380 fragment retains a qualitative biological activity of a native PRO1380 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO1380 polypeptide having the sequence of amino acid residues from about 1 to about 470, inclusive of Figure 48 (SEQ ID NO: 79), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culmring a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • PRQ1265 A cDNA clone (DNA60764-1533) has been identified that encodes a novel polypeptide having homology to the Figl polypeptide and designated in the present application as "PRO 1265.”
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1265 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1265 polypeptide having the sequence of amino acid residues from 1 or about about 22 to about 567, inclusive of Figure 50 (SEQ ID NO:84), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01265 polypeptide comprising DNA hybridizing to the complement ofthe nucleic acid between about residues 142 and about 1779, inclusive, of Figure 49 (SEQ ID NO:83). Preferably, hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No.
  • the nucleic acid comprises a DNA encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203452 (DNA60764-1533).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1265 polypeptide having the sequence of amino acid residues from about 22 to about 567, inclusive of Figure 50 (SEQ ID NO:84), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01265 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 21 in the sequence of Figure 50 (SEQ ID NO: 1
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 22 to about 567, inclusive of Figure 50 (SEQ ID NO:84), or (b) the complement of the DNA of (a).
  • Another embodiment is directed to fragments of a PRO 1265 polypeptide coding sequence that may find use as hybridization probes.
  • Such nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PRO 1265 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PR01265 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 1 or about 22 to 567 of Figure 50 (SEQ ID NO:84).
  • the invention concerns an isolated PR01265 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 22 to about 567, inclusive of Figure 50 (SEQ ID NO:84).
  • the invention concerns an isolated PRO 1265 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 22 to 567 of Figure 50 (SEQ ID NO:84).
  • the invention concerns an isolated PRO 1265 polypeptide, comprising the sequence of amino acid residues 22 to about 567, inclusive of Figure 50 (SEQ ID NO:84), or a fragment thereof sufficient to provide a binding site for an anti-PR01265 antibody.
  • the PR01265 fragment retains a qualitative biological activity of a native PR01265 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR01265 polypeptide having the sequence of amino acid residues from about 22 to about 567, inclusive of Figure 50 (SEQ ID NO: 84), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culmring a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • a cDNA clone (DNA60775-1532) has been identified, having homology to nucleic acid encoding long chain fatty acid CoA ligase that encodes a novel polypeptide, designated in the present application as "PRO1250".
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO1250 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1250 polypeptide having the sequence of amino acid residues from about 1 to about 739, inclusive of Figure 52 (SEQ ID NO:86), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PRO1250 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 74 and about 2290, inclusive, of Figure 51 (SEQ ID NO:85).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203173 (DNA60775-1532) or (b) the complement of the nucleic acid molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203173 (DNA60775-1532).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 to about 739, inclusive of Figure 52 (SEQ ID NO:86), or (b) the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least 10 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO1250 polypeptide having the sequence of amino acid residues from 1 to about 739, inclusive of Figure 52 (SEQ ID NO:86), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO1250 polypeptide, with or without the initiating methionine, and its soluble, i.e., transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the type II transmembrane domain has been tentatively identified as extending from about amino acid position 61 to about amino acid position 80 in the PRO1250 amino acid sequence ( Figure 52, SEQ ID NO:86).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to about 739, inclusive of Figure 52 (SEQ ID NO:86), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 51 (SEQ ID NO: 85).
  • the invention provides isolated PRO1250 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention provides isolated native sequence PRO1250 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 to about 739 of Figure 52 (SEQ ID NO:86).
  • the invention concerns an isolated PRO 1250 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 to about 739, inclusive of Figure 52 (SEQ ID NO:86).
  • the invention concerns an isolated PRO 1250 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 to about 739, inclusive of Figure 52 (SEQ ID NO:86).
  • the invention concerns an isolated PRO 1250 polypeptide , comprising the sequence of amino acid residues 1 to about 739, inclusive of Figure 52 (SEQ ID NO:86), or a fragment thereof sufficient to provide a binding site for an anti-PRO 1250 antibody.
  • the PRO 1250 fragment retains a qualitative biological activity of a native PRO 1250 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1250 polypeptide having the sequence of amino acid residues from about 1 to about 739, inclusive of Figure 52 (SEQ ID NO:86), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b) , (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PRO1250 polypeptide.
  • the agonist or antagonist is an anti-PRO1250 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PRO1250 polypeptide by contacting the native PRO1250 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PRO1250 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA61185-1646) has been identified, having homology to nucleic acid encoding an N-acetylglucosaminyltransferase that encodes a novel polypeptide, designated in the present application as "PR01475".
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01475 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PRO 1475 polypeptide having the sequence of amino acid residues from about 1 to about 660, inclusive of Figure 54 (SEQ ID NO:88), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PRO 1475 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 130 and about 2109, inclusive, of Figure 53 (SEQ ID NO:87).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203464 (DNA61185-1646) or (b) the complement of the nucleic acid molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203464 (DNA61185-1646).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 to about 660, inclusive of Figure 54 (SEQ ID NO:88), or (b) the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least 180 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1475 polypeptide having the sequence of amino acid residues from 1 to about 660, inclusive of Figure 54 (SEQ ID NO:88), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01475 polypeptide, with or without the initiating methionine, and its soluble, i.e., transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the transmembrane domain has been tentatively identified as extending from about amino acid position 38 to about amino acid position 55 in the PR01475 amino acid sequence ( Figure 54, SEQ ID NO:88).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to about 660, inclusive of Figure 54 (SEQ ID NO:88), or (b) the complement of the DNA of (a).
  • Another embodiment is directed to fragments of a PRO 1475 polypeptide coding sequence that may find use as hybridization probes.
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 53 (SEQ ID NO:87).
  • the invention provides isolated PRO 1475 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention provides isolated native sequence PRO 1475 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 to about 660 of Figure 54 (SEQ ID NO:88).
  • the invention concerns an isolated PR01475 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 to about 660, inclusive of Figure 54 (SEQ ID NO: 88).
  • the invention concerns an isolated PR01475 polypeptide, comprising an amino acid sequence scormg at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 to about 660, inclusive of Figure 54 (SEQ ID NO:88).
  • the invention concerns an isolated PRO 1475 polypeptide, comprising the sequence of amino acid residues 1 to about 660, inclusive of Figure 54 (SEQ ID NO:88), or a fragment thereof sufficient to provide a binding site for an anti-PR01475 antibody.
  • the PR01475 fragment retains a qualitative biological activity of a native PR01475 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR01475 polypeptide having the sequence of amino acid residues from about 1 to about 660, inclusive of Figure 54 (SEQ ID NO:88), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PR01475 polypeptide.
  • the agonist or antagonist is an anti-PR01475 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PR01475 polypeptide by contacting the native PR01475 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition comprising a PR01475 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier. 28. PRQ1377
  • a cDNA clone (DNA61608- 1606) has been identified that encodes a novel multi-span transmembrane polypeptide designated in the present application as "PRO 1377.”
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1377 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PRO 1377 polypeptide having the sequence of amino acid residues from 1 or about 19 to about 307, inclusive of Figure 56 (SEQ ID NO:95), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01377 polypeptide comprising DNA hybridizing to the complement ofthe nucleic acid between about residues 203 and about 1069, inclusive, of Figure 55 (SEQ ID NO:94).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203239 (DNA61608- 1606), or (b) the complement of the DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203239 (DNA61608- 1606).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 19 to about 307, inclusive of Figure 56 (SEQ ID NO: 95), or the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1377 polypeptide having the sequence of amino acid residues from about 19 to about 307, inclusive of Figure 56 (SEQ ID NO: 95), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01377 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and one or more of its transmembrane domains deleted or inactivated, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 18 in the sequence of Figure 56 (SEQ ID N0:95).
  • Transmembrane domain has been tentatively identified as extending from about amino acid positions 37-56, 106-122, 211-20, 240-260, and 288-304 in the PRO 1377 amino acid sequence ( Figure 56, SEQ ID NO: 95).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scormg at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 19 to about 307, inclusive of Figure 56 (SEQ ID NO:95), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PRO 1377 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PRO 1377 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 19 to 307 of Figure 56 (SEQ ID NO: 95).
  • the invention concerns an isolated PR01377 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 19 to about 307, inclusive of Figure 56 (SEQ ID NO:95).
  • the invention concerns an isolated PR01377 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 19 to 307 of Figure 56 (SEQ ID NO:95).
  • the invention concerns an isolated PRO 1377 polypeptide, comprising the sequence of amino acid residues 19 to about 307, inclusive of Figure 56 (SEQ ID NO:95), or a fragment thereof sufficient to provide a binding site for an anti-PR01377 antibody.
  • the PR01377 fragment retains a qualitative biological activity of a native PRO 1377 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1377 polypeptide having the sequence of amino acid residues from about 19 to about 307, inclusive of Figure 56 (SEQ ID NO:95), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culmring a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • a cDNA clone (DNA62808-1582) has been identified that encodes a novel secreted polypeptide designated in the present application as "PRO 1326.”
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1326 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1326 polypeptide having the sequence of amino acid residues from 1 or about 30 to about 401 , inclusive of Figure 58 (SEQ ID NO: 100), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01326 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 199 and about 1314, inclusive, of Figure 57 (SEQ ID NO:99).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203358 (DNA62808-1582), or (b) the complement of the DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203358 (DNA62808-1582).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 30 to about 401, inclusive of Figure 58 (SEQ ID NO: 1).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1326 polypeptide having the sequence of amino acid residues from about 30 to about 401, inclusive of Figure 58 (SEQ ID NO: 100), or (b) the complement ofthe DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01326 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 29 in the sequence of Figure 58 (SEQ ID NO: 100).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 30 to about 401, inclusive of Figure 58 (SEQ ID NO: 100), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PRO 1326 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PRO 1326 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 30 to 401 of Figure 58 (SEQ ID NO: 100).
  • the invention concerns an isolated PR01326 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 30 to about 401, inclusive of Figure 58 (SEQ ID NO: 100).
  • the invention concerns an isolated PRO 1326 polypeptide , comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 30 to 401 of Figure 58 (SEQ ID NO: 100).
  • the invention concerns an isolated PRO 1326 polypeptide , comprising the sequence of amino acid residues 30 to about 401, inclusive of Figure 58 (SEQ ID NO: 100), or a fragment thereof sufficient to provide a binding site for an anti-PR01326 antibody.
  • the PR01326 fragment retains a qualitative biological activity of a native PR01326 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1326 polypeptide having the sequence of amino acid residues from about 30 to about 401, inclusive of Figure 58 (SEQ ID NO: 100), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • a cDNA clone (DNA62809-1531) has been identified that encodes a novel transmembrane polypeptide, designated in the present application as "PRO 1249".
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01249 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1249 polypeptide having the sequence of amino acid residues from about 1 or about 17 to about 1089, inclusive of Figure 60 (SEQ ID NO: 102), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01249 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 3 or about 51 and about 3269, inclusive, of Figure 59 (SEQ ID NO: 101).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203237 (DNA62809-1531) or (b) the complement of the nucleic acid molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203237 (DNA62809-1531).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 17 to about 1089, inclusive of Figure 60 (SEQ ID NO: 102), or (b) the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least 10 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1249 polypeptide having the sequence of amino acid residues from 1 or about 17 to about 1089, inclusive of Figure 60 (SEQ ID NO: 102), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01249 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e., transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 16 in the sequence of Figure 60 (SEQ ID NO: 102).
  • transmembrane domains have been tentatively identified as extending from about amino acid position 317 to about amino acid position 341, from about amino acid position 451 to about amino acid position 470, from about amino acid position 481 to about amino acid position 500, from about amino acid position 510 to about amino acid position 527, from about amino acid position 538 to about amino acid position 555, from about amino acid position 831 to about amino acid position 850, from about amino acid position 1016 to about amino acid position 1034 and from about amino acid position 1052 to about amino acid position 1070 in the PR01249 amino acid sequence (Figure 60, SEQ ID NO: 102).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 17 to about 1089, inclusive of Figure 60 (SEQ ID NO: 102), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 59 (SEQ ID NO: 101).
  • the invention provides isolated PR01249 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention provides isolated native sequence PR01249 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 17 to about 1089 of Figure 60 (SEQ ID NO: 102).
  • the invention concerns an isolated PRO 1249 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 17 to about 1089, inclusive of Figure 60 (SEQ ID NO: 102).
  • the invention concerns an isolated PR01249 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 17 to about 1089, inclusive of Figure 60 (SEQ ID NO: 102).
  • the invention concerns an isolated PR01249 polypeptide, comprising the sequence of amino acid residues 1 or about 17 to about 1089, inclusive of Figure 60 (SEQ ID NO: 102), or a fragment thereof sufficient to provide a binding site for an anti-PR01249 antibody.
  • the PR01249 fragment retains a qualitative biological activity of a native PRO 1249 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1249 polypeptide having the sequence of amino acid residues from about 1 or about 17 to about 1089, inclusive of Figure 60 (SEQ ID NO: 102), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culmring a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • PRQ1315 a DNA molecule encoding a PRO 1249 polypeptide having the sequence of amino acid residues from about 1 or about 17 to about 1089, inclusive of Figure 60 (SEQ ID NO: 102), or
  • a cDNA clone (DNA62815-1576) has been identified, having homology to nucleic acid encoding cytokine receptor family -4 proteins that encodes a novel polypeptide, designated in the present application as "PR01315" .
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01315 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1315 polypeptide having the sequence of amino acid residues from about 1 or about 29 to about 442, inclusive of Figure 62 (SEQ ID NO: 104), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01315 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 121 or about 205 and about 1446, inclusive, of Figure 61 (SEQ ID NO: 103). Preferably, hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No.
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203247 (DNA62815-1576).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 29 to about 442, inclusive of Figure 62 (SEQ ID NO: 1).
  • the invention concerns an isolated nucleic acid molecule having at least 500 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encodmg a PRO 1315 polypeptide having the sequence of amino acid residues from 1 or about 29 to about 442, inclusive of Figure 62 (SEQ ID NO: 104), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01315 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e., transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 28 in the sequence of Figure 62 (SEQ ID NO: 104).
  • the transmembrane domain has been tentatively identified as extending from about amino acid position 140 to about amino acid position 163 in the PR01315 amino acid sequence ( Figure 62, SEQ ID NO: 104).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 29 to about 442, inclusive of Figure 62 (SEQ ID NO: 104), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 61 (SEQ ID NO: 103).
  • the invention provides isolated PR01315 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention provides isolated native sequence PR01315 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 29 to about 442 of Figure
  • the invention concerns an isolated PR01315 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 29 to about 442, inclusive of Figure 62 (SEQ ID NO: 104).
  • the invention concerns an isolated PRO 1315 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 29 to about 442, inclusive of Figure 62 (SEQ ID NO: 104).
  • the invention concerns an isolated PRO 1315 polypeptide, comprising the sequence of amino acid residues 1 or about 29 to about 442, inclusive of Figure 62 (SEQ ID NO: 104), or a fragment thereof sufficient to provide a binding site for an anti-PR01315 antibody.
  • the PR01315 fragment retains a qualitative biological activity of a native PRO 1315 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR01315 polypeptide having the sequence of amino acid residues from about 1 or about 29 to about 442, inclusive of Figure 62 (SEQ ID NO: 104), or a fragment thereof sufficient to provide a binding site for an anti-PR01315 antibody.
  • the PR01315 fragment retains a qualitative biological activity of a native PRO 1315 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA
  • the invention concerns agonists and antagonists of a native PR01315 polypeptide.
  • the agonist or antagonist is an anti-PR01315 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PRO 1315 polypeptide by contacting the native PRO 1315 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition comprising a PRO 1315 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA62845-1684)has been identified that encodes a novel polypeptide having homology to Granzyme M and designated in the present application as "PRO 1599.”
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1599 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1599 polypeptide having the sequence of amino acid residues from 1 or about 31 to about 283, inclusive of Figure 64 (SEQ ID NO: 111), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01599 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 159 and about 917, inclusive, of Figure 63 (SEQ ID NO: 110).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203361 (DNA62845-1684), or (b) the complement of the DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203361 (DNA62845-1684).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR01599 polypeptide having the sequence of amino acid residues from about 31 to about 283, inclusive of Figure 64 (SEQ ID NO: 111), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01599 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 30 in the sequence of Figure 64 (SEQ ID NO: 1
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 31 to about 283, inclusive of Figure 64 (SEQ ID NO: 111), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PRO 1599 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PRO 1599 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 31 to 283 of Figure 64 (SEQ ID NO: 111).
  • the invention concerns an isolated PRO 1599 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 31 to about 283, inclusive of Figure 64 (SEQ ID NO: 111).
  • the invention concerns an isolated PR01599 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 31 to 283 of Figure 64 (SEQ ID NO:l l l).
  • the invention concerns an isolated PR01599 polypeptide, comprising the sequence of amino acid residues 31 to about 283, inclusive of Figure 64 (SEQ ID NO: 111), or a fragment thereof sufficient to provide a binding site for an anti-PR01599 antibody.
  • the PR01599 fragment retains a qualitative biological activity of a native PR01599 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1599 polypeptide having the sequence of amino acid residues from about 31 to about 283, inclusive of Figure 64 (SEQ ID NO: 111), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (n) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (in) recovering the polypeptide from the cell culture
  • the invention concerns agonists and antagonists of a native PR01599 polypeptide
  • the agonist or antagonist is an anti-PRO 1599 antibody
  • the invention concerns a method of identifying agonists or antagonists of a native PRO 1599 polypeptide, by contacting the native PRO 1599 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide
  • the invention concerns a composition
  • a composition comprismg a PR01599 polypeptide, or an agonist or antagonist as hereinabove defined, in combmation with a pharmaceutically acceptable carrier
  • a cDN A clone (DNA64842 1632) has been identified that encodes a novel polypeptide having homology to reductase proteins, designated in the present application as "PRO 1430 "
  • the invention provides an isolated nucleic acid molecule comprising DNA encodmg a PRO 1430 polypeptide
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encodmg a PRO 1430 polypeptide having the sequence of ammo acid residues from 1 or about 18 to about 331, inclusive of Figure 66 (SEQ ID NO 116), or (b) the complement of the DNA molecule of (a)
  • the invention concerns an isolated nucleic acid molecule encodmg a PRO 1430 polypeptide comprismg DNA hybridizing to the complement of the nucleic acid between about residues 33 and about 1074, inclusive, of Figure 65 (SEQ ID NO 115) Preferably, hybridization occurs under stringent hybridization and wash conditions
  • the invention concerns an isolated nucleic acid molecule comprismg DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encodmg the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No 203278 (DNA64842-1632), or (b) the complement ofthe DNA molecule of (a)
  • the nucleic acid comprises a DNA encodmg the same mature polypeptide encoded by the human protein cDNA m ATCC Deposit No 203278 (DNA64842-1632)
  • the invention concerns an isolated nucleic acid molecule comprismg (a) DNA encodmg a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of ammo acid residues from about 18 to about 331 , mciusive of Figure 66 (SEQ ID NO: 1).
  • the invention concerns an isolated nucleic acid molecule havmg at least about 50 nucleotides, and preferably at least about 100 and produced by hybridizing a test DNA molecule under strmgent conditions with (a) a DNA molecule encoding a PRO 1430 polypeptide having the sequence of amino acid residues from about 18 to about 331, inclusive of Figure 66 (SEQ ID NO 116), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO1430 polypeptide, with or without the N-terminal signal sequence, or is complementary to such encodmg nucleic acid molecule
  • the signal peptide has been tentatively identified as extendmg from ammo acid position 1 through about amino acid position 17 in the sequence of Figure 66 (SEQ ID NO 116)
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encodmg a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the ammo acid sequence of residues 18 to about 331 , inclusive of Figure 66 (SEQ ID NO 116), or (b) the complement of the DNA of (a) Another embodiment is directed to fragments of a PRO 1430 polypeptide coding sequence that may find use as hybridization probes Such nucleic acid fragments are
  • the invention provides isolated PRO 1430 polypeptide encoded by any of the isolated nucleic acid sequences heremabove defined
  • the mvention provides isolated native sequence PRO 1430 polypeptide, which in one embodiment, includes an ammo acid sequence comprismg residues 18 to 331 of Figure 66 (SEQ ID NO 116)
  • the mvention concerns an isolated PRO 1430 polypeptide, comprising an ammo acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of ammo acid residues 18 to about 331, inclusive of Figure 66 (SEQ ID NO 116)
  • the invention concerns an isolated PRO1430 polypeptide, comprismg an amino acid sequence scormg at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the ammo acid sequence of residues 18 to 331 of Figure 66 (SEQ ID NO 116)
  • the invention concerns an isolated PRO 1430 polypeptide, comprismg the sequence of ammo acid residues 18 to about 331, mciusive of Figure 66 (SEQ ID NO 116), or a fragment thereof sufficient to provide a binding site for an anti-PRO 1430 antibody
  • the PRO 1430 fragment retains a qualitative biological activity of a native PRO 1430 polypeptide
  • the mvention provides a polypeptide produced by (t) hybridizing a test DNA molecule under strmgent conditions with (a) a DNA molecule encodmg a PRO 1430 polypeptide havmg the sequence of ammo acid residues from about 18 to about 331 , inclusive of Figure 66 (SEQ ID NO 116), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 9
  • the invention concerns a method of identifying agonists or antagonists of a native PRO 1430 polypeptide, by contacting the native PRO 1430 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition comprising a PRO1430 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA64849-1604) has been identified that encodes a novel polypeptide having sequence identity with P4HA and designated in the present application as "PRO 1374. "
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1374 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1374 polypeptide having the sequence of amino acid residues from 1 or about 20 to about 544, inclusive of Figure 68 (SEQ ID NO: 118), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01374 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 78 and about 1652, inclusive, of Figure 67 (SEQ ID NO: 117).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203468 (DNA64849-1604), or (b) the complement of the DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203468 (DNA64849-1604).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 20 to about 544, inclusive of Figure 68 (SEQ ID NO: 118), or the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1374 polypeptide having the sequence of amino acid residues from about 20 to about 544, inclusive of Figure 68 (SEQ ID NO: 118), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 20 to about 544, inclusive of Figure 68 (SEQ ID NO: 118), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PR01374 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PRO 1374 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 20 through 544 of Figure 68 (SEQ ID NO: 118).
  • the invention concerns an isolated PR01374 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 20 to about 544, inclusive of Figure 68 (SEQ ID NO: 118).
  • the invention concerns an isolated PR01374 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 20 through 544 of Figure 68 (SEQ ID NO: 118).
  • the invention concerns an isolated PR01374 polypeptide, comprising the sequence of amino acid residues 20 to about 544, inclusive of Figure 68 (SEQ ID NO: 118), or a fragment thereof sufficient to provide a binding site for an anti-PRO 1374 antibody.
  • the PRO 1374 fragment retains a qualitative biological activity of a native PRO 1374 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1374 polypeptide having the sequence of amino acid residues from about 20 to about 544, inclusive of Figure 68 (SEQ ID NO: 118), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (n) culturing a host cell comp ⁇ sing the test DNA molecule under conditions suitable for expression of the polypeptide, and (in) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PRO 1374 polypeptide
  • the agomst or antagonist is an ant ⁇ -PR01374 antibody
  • the invention concerns a method of identifying agonists or antagonists of a native PR01374 polypeptide, by contacting the native PR01374 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide
  • the invention concerns a composition
  • a composition comprismg a PRO 1374 polypeptide , or an agonist or antagonist as hereinabove defined, m combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA64863-1573) has been identified that encodes a novel tetraspan polypeptide designated in the present application as "PR01311 "
  • the invention provides an isolated nucleic acid molecule comprising DNA encodmg a PRO 1311 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encodmg a PR01311 polypeptide having the sequence of ammo acid residues from 1 or about 45 to about 294, inclusive of Figure 70 (SEQ ID NO: 123), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PRO 1311 polypeptide comprismg DNA hybridizmg to the complement ofthe nucleic acid between about residues 327 and about 1076, inclusive, of Figure 69 (SEQ ID NO.122).
  • hybridization occurs under strmgent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprismg DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encodmg the same mamre polypeptide encoded by the human protein cDNA m ATCC Deposit No. 203251 (DNA64863-1573), or (b) the complement ofthe DNA molecule of (a).
  • the nucleic acid comprises a DNA encodmg the same mamre polypeptide encoded by the human protem cDNA in ATCC
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR01311 polypeptide having the sequence of amino acid residues from about 45 to about 294, inclusive of Figure 70 (SEQ ID NO: 123), or (b) the complement ofthe DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1311 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e. transmembrane domains deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 44 in the sequence of Figure 70 (SEQ ID NO: 123).
  • Four transmembrane domains has been tentatively identified as extending from about amino acid 22-42, 57-85, 94-116, and 230-257 in the PR01311 amino acid sequence ( Figure 70, SEQ ID NO: 123).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 45 to about 294, inclusive of Figure 70 (SEQ ID NO: 123), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PRO 1311 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
  • the invention provides isolated native sequence PR01311 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 45 to 294 of Figure 70 (SEQ ID NO: 123).
  • the invention concerns an isolated PR01311 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 45 to about 294, inclusive of Figure 70 (SEQ ID NO: 123).
  • the invention concerns an isolated PR01311 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 45 to 294 of Figure 70 (SEQ ID NO: 123).
  • the invention concerns an isolated PR01311 polypeptide, comprising the sequence of amino acid residues 45 to about 294, inclusive of Figure 70 (SEQ ID NO: 123), or a fragment thereof sufficient to provide a binding site for an anti-PRO 1311 antibody.
  • the PRO 1311 fragment retains a qualitative biological activity of a native PRO 1311 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR01311 polypeptide having the sequence of amino acid residues from about 45 to about 294, inclusive of Figure 70 (SEQ ID NO: 123), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • a cDNA clone (DNA64881-1602) has been identified, having homology to nucleic acid encoding the von Ebner minor salivary gland protein that encodes a novel polypeptide, designated in the present application as "PR01357”.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1357 polypeptide .
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1357 polypeptide having the sequence of amino acid residues from about 1 or about 22 to about 484, inclusive of Figure 72 (SEQ ID NO: 128), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01357 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 74 or about 137 and about 1525, inclusive, of Figure 71 (SEQ ID NO: 127). Preferably, hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No.
  • the nucleic acid comprises a DNA encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203240 (DNA64881-1602).
  • the invention concerns an isolated nucleic acid molecule having at least 40 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR01357 polypeptide having the sequence of amino acid residues from 1 or about 22 to about 484, inclusive of Figure 72 (SEQ ID NO: 128), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encodmg a PR01357 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extendmg from about amino acid position 1 to about amino acid position 21 in the sequence of Figure 72 (SEQ ID NO: 128).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 22 to about 484, inclusive of Figure 72 (SEQ ID NO: 128), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 71 (SEQ ID NO: 127).
  • the invention provides isolated PR01357 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
  • the invention provides isolated native sequence PR01357 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 22 to about 484 of Figure 72 (SEQ ID NO: 128).
  • the invention concerns an isolated PR01357 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 22 to about 484, inclusive of Figure 72 (SEQ ID NO: 128).
  • the invention concerns an isolated PR01357 polypeptide, comprising an amino acid sequence scormg at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 22 to about 484, inclusive of Figure 72 (SEQ ID NO: 128).
  • the invention concerns an isolated PRO 1357 polypeptide, comprising the sequence of amino acid residues 1 or about 22 to about 484, inclusive of Figure 72 (SEQ ID NO: 128), or a fragment thereof sufficient to provide a binding site for an anti-PR01357 antibody.
  • the PR01357 fragment retains a qualitative biological activity of a native PR01357 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1357 polypeptide having the sequence of amino acid residues from about 1 or about 22 to about 484, inclusive of Figure 72 (SEQ ID NO: 128), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PRO 1357 polypeptide.
  • the agonist or antagonist is an anti-PR01357 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PRO 1357 polypeptide by contacting the native PRO 1357 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the mvention concerns a composition comprising a PRO 1357 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA64883- 1526) has been identified that encodes a novel polypeptide having homology to Implantation-Associated Protein and designated in the present application as "PR01244.”
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01244 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1244 polypeptide having the sequence of amino acid residues from 1 or about 30 to about 335, inclusive of Figure 74 (SEQ ID NO: 130), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01244 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 96 and about 1013, inclusive, of Figure 73 (SEQ ID NO: 129). Preferably, hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No.
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203253 (DNA64883-1526).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of ammo acid residues from about 30 to about 335, inclusive of Figure 74 (SEQ ID NO.130), or the complement of the DNA of (a)
  • the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizmg a test DNA molecule under strmgent conditions with (a) a DNA molecule encoding a PRO 1244 polypeptide havmg the sequence of ammo acid residues from about 30 to about 335, inclusive of Figure 74 (SEQ ID NO- 130), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encodmg a PR01244 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionme, and its soluble, l e transmembrane domams deleted or inactivated variants, or is complementary to such encodmg nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from ammo acid position 1 through about ammo acid position 29 m the sequence of Figure 74 (SEQ ID NO.130).
  • the transmembrane domains have been tentatively identified m the PRO 1244 ammo acid sequence at about the following ammo acid regions: 183-205, 217-137, 271-287, and 301-321.
  • the mvention concerns an isolated nucleic acid molecule comprismg (a) DNA encodmg a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the ammo acid sequence of residues 30 to about 335, inclusive of Figure 74 (SEQ ID NO: 130), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides m length, and most preferably from about 20 to about 40 nucleotides in length.
  • the invention provides isolated PR01244 polypeptide encoded by any of the isolated nucleic acid sequences heremabove defined.
  • the invention provides isolated native sequence PR01244 polypeptide, which in one embodiment, includes an ammo acid sequence comprismg residues 30 to 335 of Figure 74 (SEQ ID NO: 130).
  • the invention concerns an isolated PR01244 polypeptide, comprising an ammo acid sequence havmg at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of ammo acid residues 30 to about 335, mciusive of Figure 74 (SEQ ID NO: 130).
  • the invention concerns an isolated PRO 1244 polypeptide, comprismg an amino acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 30 to 335 of Figure 74 (SEQ ID NO 130)
  • the invention provides a polypeptide produced by (l) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR01244 polypeptide having the sequence of ammo acid residues from about 30 to about 335, inclusive of Figure 74 (SEQ ID NO 130), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (n) culmring a host cell comprismg the test DNA molecule under conditions suitable for expression of the polypeptide, and (in) recovering the polypeptide from the cell culture
  • the invention concerns agonists and antagonists of a native PR01244 polypeptide
  • the agonist or antagonist is an ant ⁇ -PR01244 antibody
  • the mvention concerns a method of identifying agonists or antagonists of a native PRO 1244 polypeptide, by contacting the native PRO 1244 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide
  • the invention concerns a composition
  • a composition comprismg a PRO 1244 polypeptide, or an agomst or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier
  • a cDNA clone (DNA64885-1529) has been identified, havmg homology to nucleic acid encoding bone- related sulphatase that encodes a novel polypeptide, designated m the present application as "PRO 1246"
  • the mvention provides an isolated nucleic acid molecule comprismg DNA encodmg a PRO 1246 polypeptide
  • the isolated nucleic acid comprises DNA havmg at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encodmg a PRO 1246 polypeptide havmg the sequence of ammo acid residues from about 1 or about 16 to about 536, mciusive of Figure 76 (SEQ ID NO 132), or (b) the complement of the DNA molecule of (a)
  • the invention concerns an isolated nucleic acid molecule encodmg a PRO 1246 polypeptide comprismg DNA hybridizing to the complement of the nucleic acid between about nucleotides 119 or about 164 and about 1726, inclusive, of Figure 75 (SEQ ID NO 131)
  • hybridization occurs under strmgent hybridization and wash conditions
  • the invention concerns an isolated nucleic acid molecule comprising DNA havmg at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No 203457 (DNA64885-1529) or (b) the complement of the nucleic acid molecule of (a)
  • the nucleic acid comprises a DNA encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No 203457 (DNA64885-1529)
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1
  • the invention provides an isolated nucleic acid molecule comprismg DNA encodmg a PRO 1246 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, or is complementary to such encoding nucleic acid molecule
  • the signal peptide has been tentatively identified as extendmg from about ammo acid position 1 to about ammo acid position 16 in the sequence of Figure 76 (SEQ ID NO: 76).
  • the invention concerns an isolated nucleic acid molecule comprismg (a) DNA encoding a polypeptide scormg at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 16 to about 536, mciusive of Figure 76 (SEQ ID NO.132), or (b) the complement of the DNA of (a)
  • nucleic acid fragments are from about 20 to about 80 nucleotides m length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides m length and most preferably from about 20 to about 40 nucleotides m length and may be derived from the nucleotide sequence shown in Figure 75 (SEQ ID NO: 131).
  • the invention provides isolated PR01246 polypeptide encoded by any of the isolated nucleic acid sequences heremabove identified
  • the invention provides isolated native sequence PRO 1246 polypeptide, which in certain embodiments, mcludes an ammo acid sequence comprismg residues 1 or about 16 to about 536 of Figure 76 (SEQ ID NO 132).
  • the invention concerns an isolated PR01246 polypeptide, comprismg an ammo acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of ammo acid residues 1 or about 16 to about 536, inclusive of Figure 76 (SEQ ID NO: 132)
  • the invention concerns an isolated PR01246 polypeptide, comprismg an ammo acid sequence scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 16 to about 536, inclusive of Figure 76 (SEQ ID NO: 132).
  • the invention concerns an isolated PRO 1246 polypeptide, comprising the sequence of amino acid residues 1 or about 16 to about 536, inclusive of Figure 76 (SEQ ID NO: 132), or a fragment thereof sufficient to provide a binding site for an anti-PR01246 antibody.
  • the PR01246 fragment retains a qualitative biological activity of a native PRO 1246 polypeptide.
  • the invention provides a polypeptide produced by (i) hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PRO 1246 polypeptide having the sequence of amino acid residues from about 1 or about 16 to about 536, inclusive of Figure 76 (SEQ ID NO: 132), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (ii) culturing a host cell comprismg the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
  • the invention concerns agonists and antagonists of a native PR01246 polypeptide.
  • the agonist or antagonist is an anti-PR01246 antibody.
  • the invention concerns a method of identifying agonists or antagonists of a native PRO 1246 polypeptide by contacting the native PRO 1246 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide.
  • the invention concerns a composition
  • a composition comprising a PR01246 polypeptide, or an agonist or antagonist as hereinabove defined, in combination with a pharmaceutically acceptable carrier.
  • a cDNA clone (DNA64886-1601) has been identified, having homology to nucleic acid encoding clostridium perfringens enterotoxin receptor, that encodes a novel polypeptide, designated in the present application as " PRO 1356".
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1356 polypeptide.
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1356 polypeptide having the sequence of amino acid residues from about 1 or about 25 to about 230, inclusive of Figure 78 (SEQ ID NO: 1).
  • the invention concerns an isolated nucleic acid molecule encoding a PRO 1356 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 122 or about 194 and about 811, inclusive, of Figure 77 (SEQ ID NO: 133).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203241 (DNA64886-1601) or (b) the complement of the nucleic acid molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203241 (DNA64886-1601).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 25 to about 230, inclusive of Figure 78 (SEQ ID NO: 134), or (b) the complement of the DNA of (a).
  • the invention concerns an isolated nucleic acid molecule having at least 20 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR01356 polypeptide having the sequence of amino acid residues from 1 or about 25 to about 230, inclusive of Figure 78 (SEQ ID NO: 134), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA molecule.
  • the invention provides an isolated nucleic acid molecule comprising DNA encoding a PRO 1356 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e., transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule.
  • the signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 24 in the sequence of Figure 78 (SEQ ID NO: 134).
  • transmembrane domains have been tentatively identified as extending from about amino acid position 82 to about amino acid position 102, from about amino acid position 117 to about amino acid position 140 and from about amino acid position 163 to about amino acid position 182 in the PR01356 amino acid sequence ( Figure 78, SEQ ID NO: 134).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 25 to about 230, inclusive of Figure 78 (SEQ ID NO: 134), or (b) the complement of the DNA of (a).
  • nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 77 (SEQ ID NO: 133).
  • the invention provides isolated PR01356 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified
  • the invention provides isolated native sequence PR01356 polypeptide, which in certain embodiments, mcludes an amino acid sequence comprising residues 1 or about 25 to about 230 of Figure 78 (SEQ ID NO 134)
  • the invention concerns an isolated PR01356 polypeptide, comprising an amino acid sequence havmg at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of ammo acid residues 1 or about 25 to about 230, inclusive of Figure 78 (SEQ ID NO: 134)
  • the invention concerns an isolated PRO 1356 polypeptide, comprising an ammo acid sequence scormg at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 25 to about 230, inclusive of Figure 78 (SEQ ID NO 134)
  • the invention concerns an isolated PRO 1356 polypeptide, comprising the sequence of ammo acid residues 1 or about 25 to about 230, inclusive of Figure 78 (SEQ ID NO 134), or a fragment thereof sufficient to provide a binding site for an ant ⁇ -PR01356 antibody
  • the PR01356 fragment retains a qualitative biological activity of a native PRO 1356 polypeptide
  • the invention provides a polypeptide produced by (1) hybridizmg a test DNA molecule under strmgent conditions with (a) a DNA molecule encoding a PRO 1356 polypeptide havmg the sequence of ammo acid residues from about 1 or about 25 to about 230, inclusive of Figure 78 (SEQ ID NO: 134), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), (n) culmring a host cell comprismg the test DNA molecule under conditions suitable for expression of the polypeptide, and (in) recovering the polypeptide from the cell culture
  • the invention concerns agonists and antagonists of a native PR01356 polypeptide.
  • the agomst or antagonist is an ant ⁇ -PR01356 antibody.
  • the mvention concerns a method of identifymg agomsts or antagonists of a native PR01356 polypeptide by contactmg the native PR01356 polypeptide with a candidate molecule and monitoring a biological activity mediated by said polypeptide
  • the invention concerns a composition
  • a composition comprising a PR01356 polypeptide, or an agonist or antagonist as hereinabove defined, in combmation with a pharmaceutically acceptable carrier
  • a cDNA clone (DNA64888-1542) has been identified that encodes a novel secreted polypeptide designated in the present application as "PRO 1275 "
  • the invention provides an isolated nucleic acid molecule comprismg DNA encoding a PRO 1275 polypeptide
  • the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding a PRO 1275 polypeptide having the sequence of amino acid residues from about 26 to about 119, inclusive of Figure 80 (SEQ ID NO: 136), or (b) the complement of the DNA molecule of (a).
  • the invention concerns an isolated nucleic acid molecule encoding a PR01275 polypeptide comprising DNA hybridizing to the complement ofthe nucleic acid between about residues 112 and about 393, inclusive, of Figure 79 (SEQ ID NO: 135).
  • hybridization occurs under stringent hybridization and wash conditions.
  • the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mamre polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203249 (DNA64888-1542), or (b) the complement of the DNA molecule of (a).
  • the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203249 (DNA64888-1542).
  • the invention concerns an isolated nucleic acid molecule comprising (a) DNA encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 26 to about 119, inclusive of Figure 80 (SEQ ID NO: 136), or the complement of the DNA of (a).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Les protéines membranaires et les molécules de récepteur possèdent différentes applications industrielles ; elles peuvent notamment servir d'agent pharmaceutique et d'agent diagnostique. Les immunoadhésines récepteurs, par exemple, peuvent servir d'agents thérapeutiques afin de bloquer les interactions récepteur-ligand. Les protéines membranaires peuvent également servir à cribler de potentiels inhibiteurs peptidiques ou inhibiteurs de petites molécules de l'interaction récepteur-ligand pertinente. Des recherches sont menées dans les domaines industriel et universitaire afin d'identifier de nouvelles protéines natives de récepteur ou membranaires. Nombre de ces recherches se concentrent sur le criblage des bibliothèques d'ADN recombinant de mammifère afin d'identifier les séquences de codage pour de nouvelles protéines de récepteur ou membranaires. L'invention concerne de nouveaux polypeptides et des molécules d'acide nucléique codant pour ces polypeptides. L'invention concerne également des vecteurs et des cellules hôtes contenant lesdites séquences d'acide nucléique, des molécules de polypeptides chimères contenant les polypeptides selon l'invention fusionnées à des séquences de polypeptides hétérologues, des anticorps qui se lient aux polypeptides selon l'invention ainsi que des méthodes de production de ces polypeptides.
PCT/US1999/020111 1997-03-31 1999-09-01 Nouveaux pro-polypeptides et sequences correspondantes WO2000012708A2 (fr)

Priority Applications (739)

Application Number Priority Date Filing Date Title
IL14142099A IL141420A0 (en) 1998-09-01 1999-09-01 Polypeptides and sequences thereof
AU55908/99A AU759150B2 (en) 1998-09-01 1999-09-01 Further pro polypeptides and sequences thereof
EP99942557A EP1144629A3 (fr) 1998-09-01 1999-09-01 Nouveaux pro-polypeptides et sequences correspondantes
JP2000567695A JP2003518361A (ja) 1998-09-01 1999-09-01 更なるｐｒｏポリペプチドとその配列
JP2000584912A JP3695642B2 (ja) 1998-12-01 1999-11-30 血管形成及び心臓血管新生の促進又は阻害
KR1020047012987A KR100543857B1 (ko) 1999-09-01 1999-11-30 혈관신생 및 심혈관형성의 촉진 또는 억제
CA002347835A CA2347835A1 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
MXPA01005169A MXPA01005169A (es) 1998-12-01 1999-11-30 Promocion o inhibicion deangiogenesis y cardiovascularizacion.
PCT/US1999/028313 WO2000032221A2 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
AU17482/00A AU771751C (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization
AT99960624T ATE458050T1 (de) 1998-12-01 1999-11-30 Promotion oder inhibition von angiogenese und kardiovaskularisation
EP06014175A EP1734051A3 (fr) 1998-12-01 1999-11-30 Composition et procédés de diagnostic de tumeurs
KR10-2001-7006818A KR100529270B1 (ko) 1998-12-01 1999-11-30 혈관신생 및 심혈관형성의 촉진 또는 억제
CA002503475A CA2503475A1 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
NZ535590A NZ535590A (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization
IL14274299A IL142742A0 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization
EP99960624A EP1135485B1 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
ES05019849T ES2324876T3 (es) 1999-03-08 1999-12-02 Composiciones y metodos para el diagnostico de tumores.
AT05019849T ATE427319T1 (de) 1999-03-08 1999-12-02 Zusammensetzung und verfahren zur diagnose von tumoren
JP2000603371A JP2003525585A (ja) 1999-03-08 1999-12-02 腫瘍治療のための組成物及び方法
CA002367334A CA2367334A1 (fr) 1999-03-08 1999-12-02 Compositions et procedes pour le traitement de tumeurs
EP05019846A EP1642967A3 (fr) 1999-03-08 1999-12-02 Composition et procédés de diagnostic de tumeurs
EP05019850A EP1634892A3 (fr) 1999-03-08 1999-12-02 Composition et procédés de diagnostic de tumeurs
ES05019847T ES2329689T3 (es) 1999-03-08 1999-12-02 Composiciones y procedimientos para el diagnostico de tumores.
AT05019847T ATE439431T1 (de) 1999-03-08 1999-12-02 Zusammenstellung und verfahren zur diagnose von tumoren
EP05019849A EP1642907B1 (fr) 1999-03-08 1999-12-02 Composition et procédés de diagnostic de tumeurs
KR1020017011361A KR100566839B1 (ko) 1999-03-08 1999-12-02 종양 치료용 조성물 및 방법
EP99965090A EP1159422A1 (fr) 1999-03-08 1999-12-02 Compositions et procedes pour le traitement de tumeurs
EP05019848A EP1642906A3 (fr) 1999-03-08 1999-12-02 Composition et procédés de diagnostic de tumeurs
EP05019847A EP1642968B1 (fr) 1999-03-08 1999-12-02 Composition et procédé de diagnostic de tumeurs
DE69941273T DE69941273D1 (de) 1999-03-08 1999-12-02 Zusammenstellung und Verfahren zur Diagnose von Tumoren
DE69940681T DE69940681D1 (de) 1999-03-08 1999-12-02 Zusammensetzung und Verfahren zur Diagnose von Tumoren
PCT/US1999/028551 WO2000053750A1 (fr) 1999-03-08 1999-12-02 Compositions et procedes pour le traitement de tumeurs
AU31077/00A AU773055C (en) 1999-03-08 1999-12-02 Compositions and methods for the treatment of tumors
MXPA01006345A MXPA01006345A (es) 1998-12-22 1999-12-16 Composiciones y metodos para el tratamiento de un tumor.
KR1020017007877A KR20010102960A (ko) 1998-12-22 1999-12-16 종양 치료용 조성물 및 방법
EP99966374A EP1141289A2 (fr) 1998-12-22 1999-12-16 Compositions et methodes de traitement d'une tumeur
IL14321299A IL143212A0 (en) 1998-12-22 1999-12-16 Compositions and methods for the treatment of tumor
PCT/US1999/030095 WO2000037640A2 (fr) 1998-12-22 1999-12-16 Compositions et methodes de traitement d'une tumeur
AU21928/00A AU2192800A (en) 1998-12-22 1999-12-16 Compositions and methods for the treatment of tumor
CA002353775A CA2353775A1 (fr) 1998-12-22 1999-12-16 Compositions et methodes de traitement d'une tumeur
JP2000589694A JP2003524390A (ja) 1998-12-22 1999-12-16 腫瘍治療のための組成物及び方法
PCT/US2000/000219 WO2000053753A2 (fr) 1999-03-08 2000-01-05 Activation ou inhibition de l'angiogenese et de la cardiovascularisation
AU26008/00A AU2600800A (en) 1999-03-08 2000-01-05 Promotion or inhibition of angiogenesis and cardiovascularization
EP05018353A EP1626084B1 (fr) 1999-03-08 2000-02-11 Compositions et méthodes pour le diagnostic de tumeurs
ES05018355T ES2289630T3 (es) 1999-03-08 2000-02-11 Composiciones y procedimientos para el diagnostico de tumores.
EP05018354A EP1632499B9 (fr) 1999-03-08 2000-02-11 Séquences des gènes amplifiés dans des tumeurs et leurs utilisations diagnostiques
AT05018355T ATE364628T1 (de) 1999-03-08 2000-02-11 Verfahren und zusammensetzungen zur diagnose von tumoren
AU28794/00A AU756400B2 (en) 1999-03-08 2000-02-11 Compositions and methods for the treatment of tumor
PT05018355T PT1623989E (pt) 1999-03-08 2000-02-11 ''composições e métodos para o diagnóstico de tumores''
AT05018353T ATE422536T1 (de) 1999-03-08 2000-02-11 Zusammensetzungen und methoden zur diagnose von tumoren
CA002365610A CA2365610A1 (fr) 1999-03-08 2000-02-11 Compositions et procedes destines au traitement de tumeur
EP00907270A EP1173563A1 (fr) 1999-03-08 2000-02-11 Compositions et procedes destines au traitement de tumeur
ES05018353T ES2321954T3 (es) 1999-03-08 2000-02-11 Composiciones y procedimientos para el diagnostico de tumores.
ES05018356T ES2279473T3 (es) 1999-03-08 2000-02-11 Procedimiento de diagnosis de tumores.
AT05018356T ATE348108T1 (de) 1999-03-08 2000-02-11 Methode zum nachweis von tumoren
AT05018358T ATE380195T1 (de) 1999-03-08 2000-02-11 Zusammensetzungen und verfahren zur behandlung von tumoren
PCT/US2000/003565 WO2001053486A1 (fr) 1999-03-08 2000-02-11 Compositions et procedes destines au traitement de tumeur
CA002479494A CA2479494C (fr) 1999-03-08 2000-02-11 Compositions et methodes associees au gene pro5725 et son application aux diagnostics d'une tumeur broncho-pulmonaire et d'une tumeur du colon
DK05018358T DK1623990T3 (da) 1999-03-08 2000-02-11 Sammensætninger og fremgangsmåder til tumorbehandling
KR10-2001-7011391A KR100512819B1 (ko) 1999-03-08 2000-02-11 종양 치료용 조성물 및 방법
DK05018354T DK1632499T3 (da) 1999-03-08 2000-02-11 Gensekvenser amplificeret i tumorer og diagnistiske anvendelser deraf
PT05018356T PT1607402E (pt) 1999-03-08 2000-02-11 Método para o diagnóstico de tumores
EP05018356A EP1607402B1 (fr) 1999-03-08 2000-02-11 Méthode de diagnostic de tumeurs
AT05018354T ATE363489T1 (de) 1999-03-08 2000-02-11 In tumoren vervielfältigte gensequenzen und deren diagnostische verwendungen
CA002479498A CA2479498A1 (fr) 1999-03-08 2000-02-11 Compositions et procedes destines au traitement de tumeur
PT05018354T PT1632499E (pt) 1999-03-08 2000-02-11 Dispositivo de detecção de impacto para automóveis.
CA002479476A CA2479476C (fr) 1999-03-08 2000-02-11 Compositions et procedes destines au traitement de tumeur
AT05018357T ATE377025T1 (de) 1999-03-08 2000-02-11 Zusammensetzungen und verfahren zur diagnose von tumoren
EP05018355A EP1623989B1 (fr) 1999-03-08 2000-02-11 Compositions et méthodes de diagnostique de tumeurs
CA002479511A CA2479511A1 (fr) 1999-03-08 2000-02-11 Compositions et procedes destines au traitement de tumeur
DK05018356T DK1607402T3 (da) 1999-03-08 2000-02-11 Sammensætninger og fremgangsmåder til tumorbehandling
EP05018358A EP1623990B1 (fr) 1999-03-08 2000-02-11 Compositions et procédures pour le traitement de tumeurs
ES05018354T ES2290834T3 (es) 1999-03-08 2000-02-11 Secuencias de genes amplificados en tumores y sus usos diagnosticos.
PT05018358T PT1623990E (pt) 1999-03-08 2000-02-11 Composições e métodos para o tratamento de tumores
ES05018357T ES2296029T3 (es) 1999-03-08 2000-02-11 Composiciones y procedimientos para el diagnostico de tumores.
JP2001553947A JP2004520003A (ja) 1999-03-08 2000-02-11 腫瘍治療のための組成物及び方法
PT05018357T PT1626058E (pt) 1999-03-08 2000-02-11 Composições e métodos para o diagnóstico de tumores
DK05018355T DK1623989T3 (da) 1999-03-08 2000-02-11 Sammensætninger og fremgangsmåder til diagnosticering af tumorer
ES05018358T ES2298896T3 (es) 1999-03-08 2000-02-11 Composiciones y procedimientos para el tratamiento de tumores.
DK05018357T DK1626058T3 (da) 1999-03-08 2000-02-11 Sammensætninger og fremgangsmåder til diagnosticering af tumor
EP05018357A EP1626058B1 (fr) 1999-03-08 2000-02-11 Compositions et méthodes pour le diagnostique de tumeurs
AU28837/00A AU2883700A (en) 1999-06-23 2000-02-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/004342 WO2000078961A1 (fr) 1999-06-23 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
PCT/US2000/005004 WO2000053757A2 (fr) 1999-03-08 2000-02-24 Activation et inhibition de l'angiogenese et de la cardiovascularisation
KR1020017011378A KR100553300B1 (ko) 1999-03-08 2000-02-24 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
KR1020017011378D KR20010104373A (ko) 1999-03-08 2000-02-24 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
EP00912015A EP1159419A1 (fr) 1999-03-08 2000-02-24 Activation et inhibition de l'angiogenese et de la cardiovascularisation
JP2000603378A JP2003531811A (ja) 1999-03-08 2000-02-24 血管形成及び心臓血管新生の促進又は阻害
CA002361849A CA2361849A1 (fr) 1999-03-08 2000-02-24 Activation et inhibition de l'angiogenese et de la cardiovascularisation
AU33816/00A AU768694B2 (en) 1999-03-08 2000-02-24 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US2000/005841 WO2000053758A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires
KR1020017011406A KR20010103046A (ko) 1999-03-08 2000-03-02 면역 관련 질환 치료용 조성물 및 치료 방법
EP00913764A EP1220905A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes pour le traitement de maladies immunitaires
AU35144/00A AU3514400A (en) 1999-03-08 2000-03-02 Compositions and methods for the treatment of immune related diseases
JP2000603379A JP2004516227A (ja) 1999-03-08 2000-03-02 免疫関連疾患を治療するための組成物と方法
CA002362427A CA2362427A1 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires
CA002376116A CA2376116A1 (fr) 1999-06-02 2000-05-17 Promotion ou inhibition de l'angiogenese et de la cardiovascularisation
AT00939307T ATE393825T1 (de) 1999-06-02 2000-05-17 Stimulierung oder hemmung von angiogenese und herzvaskularisierung
ES00939307T ES2307515T3 (es) 1999-06-02 2000-05-17 Activacion o inhibicion de la angiogenesis y la cardiovascularizacion.
AU54412/00A AU5441200A (en) 1999-06-02 2000-05-17 Promotion or inhibition of angiogenesis and cardiovascularization
DE60038740T DE60038740T2 (de) 1999-06-02 2000-05-17 Stimulierung oder hemmung von angiogenese und herzvaskularisierung
DK00939307T DK1212417T3 (da) 1999-06-02 2000-05-17 Fremmelse eller inhibering af angiogenese og vaskularisering
PCT/US2000/013705 WO2000073445A2 (fr) 1999-06-02 2000-05-17 Promotion ou inhibition de l'angiogenese et de la cardiovascularisation
EP00939307A EP1212417B1 (fr) 1999-06-02 2000-05-17 Activation ou inhibition de l'angiogenèse et de la cardiovascularisation
PT00939307T PT1212417E (pt) 1999-06-02 2000-05-17 Promoção ou inibição de angiogénese e cardiovascularização
JP2001500757A JP4297317B2 (ja) 1999-06-02 2000-05-17 血管形成及び心臓血管新生の促進又は阻害
EP07025118A EP1956030B1 (fr) 1999-06-15 2000-05-22 Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
AT07025116T ATE449109T1 (de) 1999-06-15 2000-05-22 Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
AU51527/00A AU5152700A (en) 1999-06-15 2000-05-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/014042 WO2000077037A2 (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant
CA2372511A CA2372511C (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant
JP2001503894A JP2003529324A (ja) 1999-06-15 2000-05-22 分泌及び膜貫通ポリペプチドとそれをコードする核酸
AT07025118T ATE448246T1 (de) 1999-06-15 2000-05-22 Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
DE60043322T DE60043322D1 (de) 1999-06-15 2000-05-22 Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
EP07025117A EP1978029A3 (fr) 1999-06-15 2000-05-22 Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
DE60043367T DE60043367D1 (de) 1999-06-15 2000-05-22 Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
EP07025116A EP1953173B1 (fr) 1999-06-15 2000-05-22 Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
EP00936172A EP1208195A2 (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
AT00941164T ATE357518T1 (de) 1999-06-02 2000-05-30 Verfahren und zusammensetzungen zur inhibierung des neoplastischen zellwachstums
ES00941164T ES2287020T3 (es) 1999-06-02 2000-05-30 Procedimiento y composiciones para inhibir el crecimiento de celulas neoplasicas.
DK00941164T DK1185648T3 (da) 1999-06-02 2000-05-30 Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst
JP2001500672A JP2003524406A (ja) 1999-06-02 2000-05-30 腫瘍細胞成長阻害のための組成物及び方法
EP07005022A EP1870464A3 (fr) 1999-06-02 2000-05-30 Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
DE60034036T DE60034036T2 (de) 1999-06-02 2000-05-30 Verfahren und zusammensetzungen zur inhibierung des neoplastischen zellwachstums
AU55911/00A AU5591100A (en) 1999-06-02 2000-05-30 Methods and compositions for inhibiting neoplastic cell growth
EP07005023A EP1867719A3 (fr) 1999-06-02 2000-05-30 Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
EP07005021A EP1873244A3 (fr) 1999-06-02 2000-05-30 Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
CA002373915A CA2373915A1 (fr) 1999-06-02 2000-05-30 Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
PCT/US2000/014941 WO2000073348A2 (fr) 1999-06-02 2000-05-30 Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
EP07004855A EP1820860A3 (fr) 1999-06-02 2000-05-30 Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
EP00941164A EP1185648B1 (fr) 1999-06-02 2000-05-30 Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
PCT/US2000/015264 WO2000073452A2 (fr) 1999-06-02 2000-06-02 Compositions et methodes de traitement de maladies liees a l'immunite
AU54601/00A AU5460100A (en) 1999-06-02 2000-06-02 Compositions and methods for the treatment of immune related diseases
EP00959474A EP1208201B9 (fr) 1999-08-31 2000-08-23 Compositions et procedes pour le traitement de maladies d'ordre immunologique
DE60041266T DE60041266D1 (de) 1999-08-31 2000-08-23 Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
AT00959474T ATE419348T1 (de) 1999-08-31 2000-08-23 Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ES00959474T ES2317847T3 (es) 1999-08-31 2000-08-23 Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.
AU70793/00A AU7079300A (en) 1999-08-31 2000-08-23 Compositions and methods for the treatment of immune related diseases
CA002384055A CA2384055A1 (fr) 1999-08-31 2000-08-23 Compositions et procedes pour le traitement de maladies d'ordre immunologique
JP2001520865A JP3988821B2 (ja) 1999-08-31 2000-08-23 免疫関連疾患を治療するための組成物及び方法
PCT/US2000/023522 WO2001016319A2 (fr) 1999-08-31 2000-08-23 Compositions et procedes pour le traitement de maladies d'ordre immunologique
EP05019537A EP1637541B1 (fr) 1999-09-01 2000-08-24 Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
ES05019537T ES2341257T3 (es) 1999-09-01 2000-08-24 Polipeptidos secretados y transmembrana y acidos nucleicos que los codifican.
EP07019808A EP1892249A1 (fr) 1999-09-01 2000-08-24 Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
EP05019538A EP1623992A3 (fr) 1999-09-01 2000-08-24 Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP05019539A EP1623993A3 (fr) 1999-09-01 2000-08-24 Protéines sécrétées et transmembranaire et acides nucléiques les codant
CA002645727A CA2645727A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481691A CA2481691A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
AT05019537T ATE459645T1 (de) 1999-09-01 2000-08-24 Ausgeschiedene polypeptide und transmembranpolypeptide und dafür kodierende nukleinsäuren
CA002481685A CA2481685A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481756A CA2481756A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002380355A CA2380355A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
EP05019540A EP1621620A3 (fr) 1999-09-01 2000-08-24 Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
EP00964919A EP1208202A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA2481731A CA2481731C (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
JP2001520864A JP3951035B2 (ja) 1999-09-01 2000-08-24 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
DE60043951T DE60043951D1 (de) 1999-09-01 2000-08-24 Ausgeschiedene Polypeptide und Transmembranpolypeptide und dafür kodierende Nukleinsäuren
CA002481788A CA2481788A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
PCT/US2000/023328 WO2001016318A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
EP05019536A EP1623991A3 (fr) 1999-09-01 2000-08-24 Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
AU75730/00A AU7573000A (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/888,257 US20030060612A1 (en) 1997-10-28 2001-06-22 Compositions and methods for the diagnosis and treatment of tumor
US09/929,769 US6914130B2 (en) 1998-06-17 2001-08-14 Compositions and methods for the diagnosis and treatment of tumor
US09/938,418 US20020161199A1 (en) 1998-04-08 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor
US09/946,374 US20030073129A1 (en) 1998-09-01 2001-09-04 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/990,456 US20020137890A1 (en) 1997-03-31 2001-11-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/002,796 US20030032057A1 (en) 1997-08-26 2001-11-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/001,054 US20020192209A1 (en) 1997-09-17 2001-11-30 Methods and compositions for inhibiting neoplastic cell growth
US10/006,130 US7098312B2 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,041 US6951921B2 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,172 US7081514B2 (en) 1998-09-01 2001-12-06 PRO1347 polypeptides
US10/006,485 US7026448B2 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,867 US7160985B2 (en) 1997-10-29 2001-12-06 Pro180 polypeptide
US10/006,063 US20030114652A1 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/007,194 US7041805B2 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,768 US6936697B2 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,818 US20030054406A1 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,117 US7071304B2 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/006,116 US20030082626A1 (en) 1998-09-01 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/007,236 US7034123B2 (en) 1998-09-01 2001-12-06 Anti-PRO1347 antibodies
US10/006,856 US7538086B2 (en) 1998-09-01 2001-12-06 PRO1303 polypeptides
US10/006,746 US7026449B2 (en) 1999-01-05 2001-12-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/011,833 US6951920B2 (en) 1998-09-01 2001-12-07 PRO1340 polypeptides
US10/012,753 US7488796B2 (en) 1998-09-01 2001-12-07 PRO1269 polypeptides
US10/012,752 US7026455B2 (en) 1998-09-01 2001-12-07 Anti-pro 1343 antibodies
US10/012,755 US20030096955A1 (en) 1998-09-01 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/012,137 US20030187189A1 (en) 1998-09-01 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/011,692 US20030109672A1 (en) 1998-09-01 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/011,671 US20030096954A1 (en) 1998-09-01 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/012,237 US20030191281A1 (en) 1998-09-01 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/012,149 US7038019B2 (en) 1998-09-01 2001-12-07 Antibodies to PRO1410
US10/012,121 US7022817B2 (en) 1998-09-01 2001-12-07 PRO1325 polypeptides
US10/012,101 US20030187239A1 (en) 1998-09-01 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/012,754 US7375184B2 (en) 1998-09-01 2001-12-07 PRO1382 polypeptides
US10/011,795 US7012131B2 (en) 1998-09-01 2001-12-07 Pro1410 polypeptides
US10/012,064 US6953841B2 (en) 1999-01-05 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/012,231 US6924355B2 (en) 1998-09-01 2001-12-07 PRO1343 polypeptides
US10/012,754 US20030187191A1 (en) 1998-09-01 2001-12-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,907 US20030064925A1 (en) 1998-09-01 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,913 US20030083462A1 (en) 1999-01-05 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,911 US20030187193A1 (en) 1998-09-01 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,912 US7399834B2 (en) 1998-10-07 2001-12-10 Anti-PRO1558 antibodies
US10/013,910 US7057018B2 (en) 1999-01-05 2001-12-10 Pro 1474 polypeptides
US10/013,430 US20030092883A1 (en) 1998-09-01 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,915 US20030204053A1 (en) 1998-09-01 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,906 US20030191282A1 (en) 1998-09-01 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/013,909 US20030186318A1 (en) 1999-01-05 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,822 US20030130491A1 (en) 1998-09-01 2001-12-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,519 US7033785B2 (en) 1998-09-01 2001-12-11 PRO1347 nucleic acids
US10/015,869 US7189530B2 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,389 US6936436B2 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,653 US20030187195A1 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,869 US20030073130A1 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,671 US6946263B2 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,480 US7074912B2 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,393 US6951737B2 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,499 US20030065142A1 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,388 US20030191299A1 (en) 1998-09-01 2001-12-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,386 US7022498B2 (en) 1998-09-01 2001-12-12 Pro 1325 nucleic acids
US10/015,387 US20030135034A1 (en) 1998-09-01 2001-12-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,385 US20030195347A1 (en) 1998-09-01 2001-12-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,390 US20030216562A1 (en) 1998-09-01 2001-12-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,610 US7087404B2 (en) 1998-09-15 2001-12-12 PRO1306 nucleic acids
US10/015,391 US20030120053A1 (en) 1998-09-01 2001-12-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,715 US7033786B2 (en) 1998-09-01 2001-12-12 Pro1340 nucleic acids
US10/015,392 US6972186B2 (en) 1998-09-23 2001-12-12 Nucleic acid encoding pro 1410 polypeptides
US10/015,395 US7083946B2 (en) 1998-09-23 2001-12-12 PRO1343 nucleic acids
US10/017,527 US20030082628A1 (en) 1998-09-01 2001-12-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,867 US20030180792A1 (en) 1998-09-01 2001-12-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,306 US20030170718A1 (en) 1998-09-01 2001-12-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,407 US20030125535A1 (en) 1998-09-01 2001-12-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,610 US20030113795A1 (en) 1998-09-01 2001-12-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/020,063 US20030119097A1 (en) 1999-01-05 2001-12-13 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/017,253 US7029875B2 (en) 1998-09-24 2001-12-14 PRO1343 nucleic acids
US10/028,072 US20030004311A1 (en) 1997-06-18 2001-12-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/052,586 US20020127584A1 (en) 1997-09-18 2002-01-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/053,107 US20020192752A1 (en) 1998-09-09 2002-01-17 Compositions and methods for the treatment of immune related diseases
US10/066,198 US20030170721A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,211 US20030044844A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,500 US20020177165A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding
US10/066,273 US7317092B2 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,269 US20030040014A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,193 US20030044902A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,203 US20030180796A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/066,494 US20030032063A1 (en) 1997-08-26 2002-02-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/081,056 US20040043927A1 (en) 1997-09-19 2002-02-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US10/119,480 US20040087769A1 (en) 1998-09-10 2002-04-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,044 US20030190717A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,042 US20030096386A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,059 US20030190721A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,040 US20030082759A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,045 US20030073210A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,041 US20030077776A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,046 US20030194791A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,047 US20030077778A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,051 US20030092147A1 (en) 1997-03-31 2002-04-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,061 US20030082761A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,052 US20030199052A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,043 US7220831B2 (en) 1997-03-31 2002-04-12 PRO235 polypeptides
US10/121,050 US20030054516A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,056 US20030082760A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,048 US20030199051A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,055 US20030190718A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,058 US20030190720A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,063 US20030199055A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,054 US20030199054A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,062 US20030077779A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,060 US20030190722A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,049 US20030022239A1 (en) 1997-06-18 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,053 US20030199053A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/121,057 US20030190719A1 (en) 1997-03-31 2002-04-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,213 US7193048B2 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,154 US20030190724A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,156 US20030194792A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,261 US20030068796A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,109 US20030190723A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,235 US20030082762A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,771 US20030199060A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,292 US20030073211A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,212 US7276577B2 (en) 1997-03-31 2002-04-15 PRO1866 polypeptides
US10/123,291 US20030199058A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,262 US20030049816A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,236 US20030068795A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,213 US20030199057A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,215 US7291329B2 (en) 1997-03-31 2002-04-15 Antibodies against PRO4406
US10/123,108 US7635478B2 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,322 US20030199059A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,157 US20030190725A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,214 US7343721B2 (en) 1997-03-31 2002-04-15 PRO4406 polypeptide
US10/123,155 US20030068794A1 (en) 1997-03-31 2002-04-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,905 US7285625B2 (en) 1997-06-18 2002-04-16 PRO536 polypeptides
US10/123,904 US20030022328A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,913 US20030203462A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,902 US20030077781A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,903 US20030073212A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,905 US20030087344A1 (en) 1997-06-18 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,907 US7084258B2 (en) 1997-03-31 2002-04-16 Antibodies against the PRO862 polypeptides
US10/123,912 US20030100087A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,908 US7335728B2 (en) 1997-03-31 2002-04-16 PRO1310 polypeptides
US10/123,906 US20030190726A1 (en) 1997-03-31 2002-04-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/123,910 US7329404B2 (en) 1997-03-31 2002-04-16 Antibodies against PRO1310
US10/123,911 US7408032B2 (en) 1997-03-31 2002-04-16 PRO1188 polypeptides
US10/123,909 US7193049B2 (en) 1997-03-31 2002-04-16 PRO862 polypeptides
US10/125,795 US7304131B2 (en) 1997-03-31 2002-04-17 PRO1483 polypeptides
US10/124,818 US20030082763A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,820 US20030190729A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,814 US7105335B2 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,819 US7285626B2 (en) 1997-03-31 2002-04-17 PRO1076 polypeptides
US10/124,823 US20030199062A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,805 US20030194794A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,821 US20030199023A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,704 US7357926B2 (en) 1997-03-31 2002-04-17 Antibodies against PRO1879 and the use thereof
US10/124,822 US7109305B2 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,816 US20030190728A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,817 US20030077786A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,824 US20030077659A1 (en) 1997-03-31 2002-04-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/124,813 US7312307B2 (en) 1997-03-31 2002-04-17 PRO1056 polypeptides
US10/125,932 US7317079B2 (en) 1997-03-31 2002-04-19 PRO812 polypeptides
US10/125,927 US20030190731A1 (en) 1997-03-31 2002-04-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,931 US20030199063A1 (en) 1997-03-31 2002-04-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/125,922 US7309762B2 (en) 1997-03-31 2002-04-19 PRO1360 polypeptides
US10/125,924 US7342097B2 (en) 1997-03-31 2002-04-19 PRO1309 polypeptides
US10/127,831 US20030082689A1 (en) 1997-03-31 2002-04-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/128,689 US20030087365A1 (en) 1997-03-31 2002-04-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/131,833 US7141652B1 (en) 1998-10-07 2002-04-24 Antibodies to PRO1561 polypeptide
US10/131,820 US7312314B2 (en) 1998-10-28 2002-04-24 Antibody that binds a pro1693 polypeptide
US10/131,825 US7282566B2 (en) 1997-03-31 2002-04-24 PRO1779 polypeptide
US10/131,828 US7309777B2 (en) 1998-10-07 2002-04-24 Antibodies against the PRO1556 polypeptide
US10/131,823 US7304132B2 (en) 1997-03-31 2002-04-24 PRO1693 polypeptides
US10/131,817 US7291701B2 (en) 1997-03-31 2002-04-24 PRO1777 polypeptides
US10/063,612 US7399828B2 (en) 1998-09-24 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/137,865 US20030032155A1 (en) 1997-03-31 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,586 US7244817B2 (en) 1998-09-10 2002-05-03 Pro1357 polypeptide
US10/063,587 US7244428B2 (en) 1998-09-10 2002-05-03 PRO1357 antibodies
US10/063,591 US7196174B2 (en) 1998-10-27 2002-05-03 PRO1557 polypeptide encoded by a nucleic acid highly expressed in esophageal and kidney tumors
US10/137,867 US20030207349A1 (en) 1997-03-31 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,615 US7405269B2 (en) 1998-10-08 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,609 US7402661B2 (en) 1998-10-06 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/137,868 US20030082764A1 (en) 1997-03-31 2002-05-03 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,592 US7220841B2 (en) 1998-10-27 2002-05-03 Antibody to PRO1557 polypeptide encoded by a nucleic acid highly expressed in esophageal and kidney tumors
US10/140,474 US20030032156A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,023 US20030207416A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,020 US20030207415A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/139,980 US7247710B2 (en) 1997-03-31 2002-05-06 PRO4395 antibodies
US10/140,024 US20040058424A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,470 US20030022331A1 (en) 1997-03-31 2002-05-06 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/139,963 US7288625B2 (en) 1997-03-31 2002-05-06 PRO4395 polypeptides
US10/063,647 US7193046B2 (en) 1998-10-20 2002-05-07 Polypeptide encoded by a nucleic acid overexpressed in esophageal and lung tumor, and underexpressesd in kidney tumor and melanoma
US10/140,921 US7317080B2 (en) 1997-03-31 2002-05-07 PRO4303 polypeptides
US10/140,865 US20030207420A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,805 US20030207417A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,639 US7081520B2 (en) 1998-10-08 2002-05-07 Anti-pro 1570 antibodies
US10/140,860 US7307151B2 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,644 US7196167B2 (en) 1998-10-20 2002-05-07 Polypeptide underexpressed in lung tumor
US10/063,648 US7193062B2 (en) 1998-10-20 2002-05-07 Antibodies to a polypeptide encoded by a nucleic acid over expressed in esoprageal and lung tumor, and under expressed in kidney tumor and melanoma
US10/140,864 US20030207419A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,925 US20030073215A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/140,808 US7425621B2 (en) 1997-03-31 2002-05-07 Antibodies against the PRO4401 polypeptide
US10/063,646 US7189821B2 (en) 1998-10-20 2002-05-07 Antibodies to a polypeptide encoded by a nucleic acid underexpressed in lung tumor
US10/140,809 US20030207418A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/063,651 US7193057B2 (en) 1997-10-29 2002-05-07 Antibodies to a polypeptide encoded by a nucleic acid underexpressed in rectal tumor
US10/140,928 US20030068798A1 (en) 1997-03-31 2002-05-07 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/141,754 US7361732B2 (en) 1997-03-31 2002-05-08 PRO4400 polypeptides
US10/141,756 US7488586B2 (en) 1997-03-31 2002-05-08 PRO4409 polypeptides
US10/141,755 US7297764B2 (en) 1997-03-31 2002-05-08 PRO4318 polypeptides
US10/141,701 US20030207421A1 (en) 1997-03-31 2002-05-08 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/141,760 US7342104B2 (en) 1997-03-31 2002-05-08 Antibodies against the PRO4320 polypeptide
US10/142,417 US7304133B2 (en) 1997-03-31 2002-05-09 PRO4389 polypeptides
US10/143,113 US7329730B2 (en) 1997-03-31 2002-05-09 PRO4348 polypeptides
US10/142,425 US20030207424A1 (en) 1997-03-31 2002-05-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/143,114 US20030036180A1 (en) 1997-03-31 2002-05-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/142,430 US7309766B2 (en) 1997-03-31 2002-05-09 PRO5774 polypeptides
US10/142,419 US7153941B2 (en) 1997-03-31 2002-05-10 Antibodies that bind PRO4994 polypeptides
US10/142,423 US20030049817A1 (en) 1997-03-31 2002-05-10 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/143,032 US7408033B2 (en) 1997-03-31 2002-05-10 PRO5995 polypeptides
US10/142,431 US7285629B2 (en) 1997-03-31 2002-05-10 Pro5005 polypeptides
US10/146,792 US20030207428A1 (en) 1997-03-31 2002-05-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/146,730 US20030207427A1 (en) 1997-03-31 2002-05-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,528 US20030219885A1 (en) 1997-03-31 2002-05-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,492 US20030082765A1 (en) 1997-03-31 2002-05-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,536 US20040077064A1 (en) 1997-03-31 2002-05-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/147,519 US20030077791A1 (en) 1997-03-31 2002-05-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/152,395 US7189534B2 (en) 1997-03-31 2002-05-21 PRO4320 polynucleotide
US10/153,934 US20030129695A1 (en) 1997-03-31 2002-05-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/156,843 US20030207805A1 (en) 1997-06-18 2002-05-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/157,782 US20030077792A1 (en) 1997-03-31 2002-05-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/157,786 US20030208055A1 (en) 1997-03-31 2002-05-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/158,782 US20030082766A1 (en) 1997-03-31 2002-05-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/160,498 US20030073216A1 (en) 1997-03-31 2002-05-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/158,791 US20030207429A1 (en) 1997-03-31 2002-05-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,707 US20030166110A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,708 US20030040053A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,706 US20030022293A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,690 US20030166105A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,699 US20030166109A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,691 US20030166106A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,698 US20030166108A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,704 US20030170795A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,695 US20030032101A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,701 US20030104538A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,694 US20030166107A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,692 US20030166188A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,705 US20030032103A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,697 US20030032102A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,702 US20030170793A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,696 US20030082767A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,700 US20030027262A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,689 US20030166104A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,703 US20030170794A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/173,693 US20030073169A1 (en) 1997-09-18 2002-06-17 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,590 US20030008352A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,578 US20030073170A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,586 US20030032106A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,569 US20030166111A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,581 US7153939B2 (en) 1997-09-18 2002-06-18 PRO354 antibodies
US10/174,585 US20030032105A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,579 US20030027264A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,574 US20030170796A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,591 US20030166115A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,588 US20030027266A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,570 US20030211572A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,583 US7211645B2 (en) 1997-09-18 2002-06-18 PRO268 polypeptides
US10/174,582 US20030027265A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,740 US20030027268A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,589 US20030166114A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,587 US20030166113A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/174,576 US7125962B2 (en) 1997-09-18 2002-06-18 Anti-Pro268 antibodies
US10/174,572 US20030027263A1 (en) 1997-09-18 2002-06-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,739 US20030027267A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,746 US20030027270A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,743 US20030027269A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,744 US20030166119A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,754 US20030166123A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,736 US20030166117A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,750 US20030073172A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,752 US20030022295A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,738 US20030022294A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,742 US20030166118A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,748 US20030166121A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,741 US20030073171A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,747 US20030032107A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,753 US20030077732A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,751 US20030166122A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,735 US20030082715A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,737 US20030013153A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,749 US20050196832A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/175,745 US20030166120A1 (en) 1997-09-18 2002-06-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,914 US20030017543A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,990 US20030036119A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,759 US20030166128A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,483 US20030017541A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,921 US20030027276A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,482 US20030022296A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,490 US20030170798A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,484 US20030059876A9 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,919 US20030032114A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,920 US20030166129A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,981 US20030170800A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,487 US20030032110A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,993 US20030027280A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,757 US7317082B2 (en) 1997-09-18 2002-06-20 PRO1018 polypeptides
US10/176,749 US20030017542A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,479 US20030040054A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,746 US20030068680A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,913 US20030022298A1 (en) 1997-09-15 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,988 US20030170802A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,747 US20030027273A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,989 US20030170803A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,911 US20030032113A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,917 US20030044918A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,493 US20030032111A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,754 US7709602B2 (en) 1997-09-18 2002-06-20 PRO1078 polypeptides
US10/176,485 US20030032109A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,918 US7495083B2 (en) 1997-09-18 2002-06-20 PRO940 antibodies
US10/176,753 US20030044917A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,491 US20030087373A1 (en) 1997-09-18 2002-06-20 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,752 US20030170799A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,760 US7339033B2 (en) 1998-06-26 2002-06-21 Pro1481
US10/176,481 US20030032108A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,923 US20030068681A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,480 US20030166124A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,922 US20030166130A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,489 US20030166125A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,486 US7354999B2 (en) 1997-09-18 2002-06-21 PRO1481 polypeptides
US10/176,979 US20030087374A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,985 US20030027277A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,924 US20030166131A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,982 US20030044919A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,925 US20030032115A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,492 US20030027272A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,755 US20030166127A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,983 US20030170801A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,758 US20030008353A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,915 US20030017544A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,986 US20030073173A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,978 US20030032116A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,756 US20030032112A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,987 US20030027278A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,751 US20030036117A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,992 US20030027279A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,916 US20030040056A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,488 US20030027271A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,748 US20030040055A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,991 US20030027324A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/176,750 US20030027274A1 (en) 1997-09-18 2002-06-21 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,507 US20030040057A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,510 US20030032117A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,506 US20030044920A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,512 US20030166134A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,513 US20030044921A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,520 US20030096353A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,519 US7339024B2 (en) 1997-09-18 2002-06-24 PRO1772 polypeptides
US10/179,526 US20030100061A1 (en) 1998-06-26 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,514 US20030044922A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,517 US20030170805A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,525 US20030040060A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,518 US20030104540A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,508 US20030166133A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,522 US20030044923A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,515 US20030166135A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,509 US20030207392A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,521 US20030170806A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,516 US20030040058A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,523 US20030215909A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/179,511 US20030104539A1 (en) 1997-09-18 2002-06-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,546 US20030032120A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,552 US7348415B2 (en) 1997-09-18 2002-06-25 PRO1316 antibodies
US10/180,559 US20030032124A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,548 US7696319B2 (en) 1997-09-18 2002-06-25 PRO1772 antibodies
US10/180,560 US20030044925A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,545 US20030040062A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,540 US20030040061A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,553 US7365156B2 (en) 1997-09-18 2002-06-25 PRO1316 polypeptides
US10/180,555 US20030032123A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,544 US20030032119A1 (en) 1998-06-26 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,541 US20030036120A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,543 US20030032118A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,542 US20030036121A1 (en) 1998-06-26 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,554 US20050202526A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,557 US20030022301A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,547 US20030032121A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,549 US20030032122A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,556 US7355000B2 (en) 1997-09-18 2002-06-25 PRO1380 polypeptides
US10/180,550 US20030064440A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,551 US20030036123A1 (en) 1997-09-18 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,011 US20030068682A1 (en) 1998-06-26 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,019 US7425605B2 (en) 1997-09-18 2002-06-26 PRO1486 polypeptides
US10/183,012 US7718770B2 (en) 1997-09-18 2002-06-26 PRO1305-polypeptides
US10/183,005 US7317093B2 (en) 1997-09-18 2002-06-26 PRO1339 antibodies
US10/180,999 US7297767B2 (en) 1997-09-18 2002-06-26 PRO1374 polypeptides
US10/183,013 US7309769B2 (en) 1997-09-18 2002-06-26 PRO1487 polypeptides
US10/183,006 US7297776B2 (en) 1997-09-18 2002-06-26 PRO1374 antibodies
US10/183,002 US20030054454A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,008 US20030040064A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,003 US20030082716A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,010 US20030032126A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,998 US7087421B2 (en) 1997-09-18 2002-06-26 Pro1278 polypeptides
US10/183,009 US7339034B2 (en) 1997-09-18 2002-06-26 PRO1305 antibodies
US10/183,018 US20030104541A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,015 US20030044926A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,001 US7084255B2 (en) 1997-09-18 2002-06-26 PRO1278 polypeptides
US10/183,017 US20030040065A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/181,000 US7319137B2 (en) 1997-09-18 2002-06-26 PRO1339 polypeptides
US10/183,014 US20030064441A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/183,016 US20030082717A1 (en) 1997-09-18 2002-06-26 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,619 US20030049738A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,642 US7332573B2 (en) 1997-09-18 2002-06-27 PRO1571 polypeptides
US10/184,639 US7291703B2 (en) 1998-10-08 2002-06-27 PRO1508 polypeptides
US10/184,618 US7393917B2 (en) 1997-09-18 2002-06-27 PRO1482 polypeptides
US10/184,613 US20030119105A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,641 US20030073174A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,615 US20030044927A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,614 US20030032128A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,627 US20030040070A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,612 US20030036127A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,640 US7271250B2 (en) 1998-06-26 2002-06-27 PRO1757 antibodies
US10/184,652 US20030032134A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,631 US20030036134A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,651 US7291704B2 (en) 1997-09-18 2002-06-27 PRO1758 polypeptides
US10/184,616 US20030036128A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,633 US20030068683A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,630 US7304143B2 (en) 1997-09-18 2002-06-27 PRO1571 antibodies
US10/184,654 US7378486B2 (en) 1997-09-18 2002-06-27 PRO1482 antibodies
US10/184,630 US20030036133A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,627 US7282569B2 (en) 1997-09-18 2002-06-27 PRO1508 antibodies
US10/184,638 US20030054456A1 (en) 1997-09-18 2002-06-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,628 US7309770B2 (en) 1997-09-18 2002-06-27 PRO1757 polypeptides
US10/184,635 US20030032130A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,637 US20030032131A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,624 US20030104542A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,657 US20030104543A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,645 US7291718B2 (en) 1998-06-26 2002-06-28 PRO1758 antibodies
US10/184,629 US20030036132A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,644 US20030044930A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,647 US20030032133A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,621 US20030054455A1 (en) 1998-06-26 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,626 US20030040069A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,655 US20030040073A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,656 US20030044931A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,634 US20030068684A1 (en) 1998-06-26 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,617 US20030036129A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,646 US20030032132A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,658 US20030027281A1 (en) 1998-06-26 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,625 US20030040068A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,643 US20030044929A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,632 US20030036135A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,636 US20030036136A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,650 US20030036138A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,623 US20030032129A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,620 US20030044928A1 (en) 1997-09-18 2002-06-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/184,622 US20030036130A1 (en) 1997-09-18 2002-06-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,591 US7709603B2 (en) 1998-09-29 2002-07-01 PRO1190 polypeptides
US10/187,588 US7351795B2 (en) 1998-06-26 2002-07-01 PRO19563 polypeptides
US10/187,887 US7285645B2 (en) 1997-09-18 2002-07-01 PRO4356 antibodies
US10/187,886 US7291708B2 (en) 1997-09-18 2002-07-01 PRO1785 polypeptides
US10/187,739 US7291706B2 (en) 1998-06-26 2002-07-01 PRO4352 polypeptides
US10/187,884 US20030036155A1 (en) 1997-09-18 2002-07-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,597 US20030036141A1 (en) 1997-09-18 2002-07-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,747 US7291707B2 (en) 1997-09-18 2002-07-01 PRO1337 polypeptides
US10/187,601 US7291705B2 (en) 1997-09-18 2002-07-01 PRO19645 polypeptides
US10/187,594 US7294335B2 (en) 1998-06-26 2002-07-01 PRO19645 antibodies
US10/187,598 US20030036142A1 (en) 1997-09-18 2002-07-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,767 US7312310B2 (en) 1997-09-18 2002-07-02 PRO6015 polypeptides
US10/187,745 US7250490B2 (en) 1997-09-18 2002-07-02 PRO1480 polypeptides
US10/188,766 US7351804B2 (en) 1998-06-26 2002-07-02 Antibodies against PRO4421
US10/187,741 US20030036147A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,780 US7268217B2 (en) 1998-06-26 2002-07-02 PRO4421 polypeptides
US10/187,753 US20030036152A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,602 US20030036145A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,743 US20030036148A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,770 US7358340B2 (en) 1997-09-18 2002-07-02 PRO19563 antibodies
US10/187,754 US20030036153A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,885 US20030032138A1 (en) 1998-06-24 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,747 US20030036150A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,746 US20030036149A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,603 US20030036146A1 (en) 1998-06-26 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,774 US20030040074A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,600 US20030036143A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,769 US20030036157A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,781 US20030036160A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,596 US20030032136A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,773 US20030036159A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/188,775 US20030040075A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/187,757 US7276578B2 (en) 1997-09-18 2002-07-02 PRO4334 polypeptides
US10/187,751 US20030036151A1 (en) 1997-09-18 2002-07-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2002194555A JP2003274977A (ja) 1999-03-08 2002-07-03 腫瘍治療のための組成物及び方法
JP2002194919A JP2003274980A (ja) 1999-03-08 2002-07-03 腫瘍治療のための組成物及び方法
JP2002194814A JP2003274979A (ja) 1999-03-08 2002-07-03 腫瘍治療のための組成物及び方法
JP2002194702A JP2003274978A (ja) 1999-03-08 2002-07-03 腫瘍治療のための組成物及び方法
US10/192,010 US20030044932A1 (en) 1997-09-18 2002-07-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,423 US7339025B2 (en) 1998-06-26 2002-07-12 PRO6246 polypeptides
US10/194,462 US7388073B2 (en) 1998-06-26 2002-07-12 PRO9835 polypeptides
US10/194,365 US7381791B2 (en) 1998-06-26 2002-07-12 PRO9739 polypeptides
US10/194,461 US20030054459A1 (en) 1998-06-26 2002-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/194,361 US20030036161A1 (en) 1998-06-26 2002-07-12 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,889 US7534856B2 (en) 1998-06-26 2002-07-15 PRO19624 antibodies
US10/195,893 US20030206188A1 (en) 1998-06-26 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,897 US20030036164A1 (en) 1997-09-18 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,892 US7385033B2 (en) 1998-06-26 2002-07-15 PRO12970 polypeptides
US10/195,894 US20030043176A1 (en) 1998-06-26 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,902 US20030038826A1 (en) 1998-06-26 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,883 US20060073544A1 (en) 1998-06-26 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,901 US20030036165A1 (en) 1998-06-26 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/195,888 US20060073545A1 (en) 1998-06-26 2002-07-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/196,756 US7304145B2 (en) 1998-06-26 2002-07-16 PRO19646 antibodies
US10/196,762 US20030040078A1 (en) 1998-06-26 2002-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/196,759 US20030071835A1 (en) 1998-06-26 2002-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/196,745 US7423120B2 (en) 1997-09-18 2002-07-16 PRO19814 polypeptides
US10/196,743 US20030038827A1 (en) 1998-06-26 2002-07-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/196,760 US7408034B2 (en) 1998-06-26 2002-07-16 PRO20025 polypeptides
US10/197,942 US20030175882A1 (en) 1998-09-10 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/198,768 US20030049756A1 (en) 1998-06-26 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,316 US20030068726A1 (en) 1998-06-26 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,464 US20030032140A1 (en) 1997-09-18 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/199,462 US20030054468A1 (en) 1998-06-26 2002-07-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/205,904 US20030073813A1 (en) 1998-06-26 2002-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/213,181 US7282570B2 (en) 1999-04-20 2002-08-05 Compositions and methods for the treatment of immune related diseases
US10/213,199 US7381809B2 (en) 1998-09-09 2002-08-05 Compositions and methods for the treatment of immune related diseases
US10/212,912 US7344880B2 (en) 1998-04-24 2002-08-05 Nucleic acid encoding PRO9912 polypeptides
US10/219,528 US20030096963A1 (en) 1998-11-18 2002-08-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/219,471 US20030100720A1 (en) 1998-11-18 2002-08-14 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/226,739 US7390879B2 (en) 1999-06-15 2002-08-23 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/272,051 US20030108544A1 (en) 1999-09-01 2002-10-16 Compositions and methods for the diagnosis and treatment of tumor
JP2002378692A JP2004201653A (ja) 1999-03-08 2002-12-26 腫瘍治療のための組成物及び方法
JP2002378517A JP2004201652A (ja) 1999-03-08 2002-12-26 腫瘍治療のための組成物及び方法
JP2002379406A JP2004229503A (ja) 1999-03-08 2002-12-27 腫瘍治療のための組成物及び方法
JP2002380537A JP2004229504A (ja) 1999-03-08 2002-12-27 腫瘍治療のための組成物及び方法
JP2002379711A JP2004201654A (ja) 1999-03-08 2002-12-27 腫瘍治療のための組成物及び方法
AU2003200731A AU2003200731C1 (en) 1999-03-08 2003-02-25 Compositions and methods for the treatment of tumor
AU2003200740A AU2003200740C1 (en) 1999-03-08 2003-02-26 Compositions and methods for the treatment of tumor
JP2003420475A JP2004154140A (ja) 1999-03-08 2003-12-18 血管形成及び心血管新生の促進又は阻害
US10/758,377 US20040126807A1 (en) 1999-06-02 2004-01-15 Compositions and methods for the diagnosis and treatment of tumor
JP2004212340A JP3803681B2 (ja) 1998-12-01 2004-07-20 血管形成及び心臓血管新生の促進又は阻害
US10/972,317 US7208321B2 (en) 1998-06-02 2004-10-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/021,329 US20050159591A1 (en) 1999-06-02 2004-12-21 Compositions and methods for the diagnosis and treatment of tumor
US11/021,330 US20050159588A1 (en) 1999-06-02 2004-12-21 Compositions and methods for the diagnosis and treatment of tumor
US11/025,607 US20050181478A1 (en) 1998-09-01 2004-12-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/038,549 US20060246461A1 (en) 1998-10-27 2005-01-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/042,889 US20050272058A1 (en) 1998-09-02 2005-01-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/060,652 US20050136475A1 (en) 1998-10-22 2005-02-16 Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2005054646A JP2005224245A (ja) 1999-09-01 2005-02-28 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
US11/090,729 US20060068413A1 (en) 1998-09-18 2005-03-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2005118817A JP2005245460A (ja) 1999-09-01 2005-04-15 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
JP2005118968A JP2005270107A (ja) 1999-09-01 2005-04-15 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
JP2005118579A JP2005253468A (ja) 1999-09-01 2005-04-15 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
JP2005118701A JP2005253469A (ja) 1999-09-01 2005-04-15 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
JP2005119030A JP2005261437A (ja) 1999-09-01 2005-04-15 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
JP2005180188A JP4358159B2 (ja) 1998-12-01 2005-06-21 血管形成及び心臓血管新生の促進又は阻害
US11/189,442 US20060246465A1 (en) 1998-06-04 2005-07-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/191,669 US7414112B2 (en) 1998-10-08 2005-07-27 Antibodies to PRO1550 polypeptides
JP2005229454A JP4145314B2 (ja) 1999-06-02 2005-08-08 腫瘍細胞成長阻害のための組成物及び方法
JP2005235120A JP2006068006A (ja) 1999-06-15 2005-08-15 分泌及び膜貫通ポリペプチドとそれをコードする核酸
JP2005238244A JP2006061156A (ja) 1999-06-15 2005-08-19 分泌及び膜貫通ポリペプチドとそれをコードする核酸
JP2005238274A JP2006051032A (ja) 1999-06-15 2005-08-19 分泌及び膜貫通ポリペプチドとそれをコードする核酸
JP2005238266A JP2006025795A (ja) 1999-06-15 2005-08-19 分泌及び膜貫通ポリペプチドとそれをコードする核酸
JP2005238217A JP2006051031A (ja) 1999-06-15 2005-08-19 分泌及び膜貫通ポリペプチドとそれをコードする核酸
US11/240,891 US20060246540A1 (en) 1997-08-26 2005-09-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/258,348 US7462692B2 (en) 1998-09-30 2005-10-24 PRO1477 polypeptides
US11/258,349 US7470774B2 (en) 1998-09-30 2005-10-24 Anti-pro1477 antibodies
US11/323,117 US20070092941A1 (en) 1998-09-16 2005-12-29 PRO1298 polypeptides
US11/341,175 US7468427B2 (en) 1997-03-31 2006-01-27 Antibodies to PRO1275 polypeptide
US11/367,172 US20060257897A1 (en) 1998-10-28 2006-03-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/457,750 US20070031901A1 (en) 1999-03-08 2006-07-14 Compositions and methods for the diagnosis and treatment of tumor
JP2006225771A JP4074645B2 (ja) 1999-06-02 2006-08-22 腫瘍細胞成長阻害のための組成物及び方法
JP2006225772A JP2007029098A (ja) 1999-06-02 2006-08-22 腫瘍細胞成長阻害のための組成物及び方法
JP2006225770A JP4072181B2 (ja) 1999-06-02 2006-08-22 腫瘍細胞成長阻害のための組成物及び方法
JP2006225879A JP2007037552A (ja) 1999-08-31 2006-08-22 免疫関連疾患を治療するための組成物及び方法
US11/537,235 US7504484B2 (en) 1998-10-07 2006-09-29 Antibodies to the PRO1561 polypeptide
US11/538,754 US20070098634A1 (en) 1999-09-01 2006-10-04 Compositions and methods for the diagnosis and treatment of tumor
US11/796,725 US20090197301A1 (en) 1998-09-01 2007-04-27 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/929,190 US20080050758A1 (en) 1998-09-09 2007-10-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US11/929,465 US7728108B2 (en) 1998-10-08 2007-10-30 PRO1550 polypeptides
JP2008145176A JP2009019032A (ja) 1999-06-02 2008-06-02 血管形成及び心臓血管新生の促進又は阻害
JP2008163394A JP2009039097A (ja) 1999-03-08 2008-06-23 腫瘍治療のための組成物及び方法
JP2008166460A JP2009000114A (ja) 1999-03-08 2008-06-25 腫瘍治療のための組成物及び方法
JP2008256822A JP2009095345A (ja) 1999-09-01 2008-10-01 分泌及び膜貫通ポリペプチドとそれをコードしている核酸
US12/364,329 US20090142786A1 (en) 1998-10-07 2009-02-02 Secreted and transmembrane polypeptides and nucleic acids encoding the same
IL202176A IL202176A0 (en) 1998-12-01 2009-11-17 Promotion or inhibition of angiogenesis and cardiovascularization

Applications Claiming Priority (223)

Application Number Priority Date Filing Date Title
US9874998P 1998-09-01 1998-09-01
US9875098P 1998-09-01 1998-09-01
US9871698P 1998-09-01 1998-09-01
US60/098,716 1998-09-01
US60/098,749 1998-09-01
US60/098,750 1998-09-01
US9882198P 1998-09-02 1998-09-02
US9880398P 1998-09-02 1998-09-02
US9884398P 1998-09-02 1998-09-02
US60/098,803 1998-09-02
US60/098,821 1998-09-02
US60/098,843 1998-09-02
US9964298P 1998-09-09 1998-09-09
US9959898P 1998-09-09 1998-09-09
US9959698P 1998-09-09 1998-09-09
US9960298P 1998-09-09 1998-09-09
US9953698P 1998-09-09 1998-09-09
US60/099,536 1998-09-09
US60/099,596 1998-09-09
US60/099,602 1998-09-09
US60/099,642 1998-09-09
US60/099,598 1998-09-09
US9979298P 1998-09-10 1998-09-10
US9976398P 1998-09-10 1998-09-10
US9981598P 1998-09-10 1998-09-10
US9980898P 1998-09-10 1998-09-10
US9981698P 1998-09-10 1998-09-10
US9981298P 1998-09-10 1998-09-10
US9975498P 1998-09-10 1998-09-10
US9974198P 1998-09-10 1998-09-10
US60/099,815 1998-09-10
US60/099,792 1998-09-10
US60/099,812 1998-09-10
US60/099,808 1998-09-10
US60/099,741 1998-09-10
US60/099,754 1998-09-10
US60/099,763 1998-09-10
US60/099,816 1998-09-10
US10038598P 1998-09-15 1998-09-15
US10039098P 1998-09-15 1998-09-15
US10038898P 1998-09-15 1998-09-15
US60/100,385 1998-09-15
US60/100,388 1998-09-15
US60/100,390 1998-09-15
US10066298P 1998-09-16 1998-09-16
US10066198P 1998-09-16 1998-09-16
US10058498P 1998-09-16 1998-09-16
US10066498P 1998-09-16 1998-09-16
US10062798P 1998-09-16 1998-09-16
US60/100,584 1998-09-16
US60/100,627 1998-09-16
US60/100,664 1998-09-16
US60/100,661 1998-09-16
US60/100,662 1998-09-16
US10068498P 1998-09-17 1998-09-17
US10071098P 1998-09-17 1998-09-17
US10093098P 1998-09-17 1998-09-17
US10091998P 1998-09-17 1998-09-17
US10068398P 1998-09-17 1998-09-17
US10071198P 1998-09-17 1998-09-17
US60/100,684 1998-09-17
US60/100,930 1998-09-17
US60/100,683 1998-09-17
US60/100,919 1998-09-17
US60/100,711 1998-09-17
US60/100,710 1998-09-17
US10106898P 1998-09-18 1998-09-18
US10084998P 1998-09-18 1998-09-18
US10107198P 1998-09-18 1998-09-18
US10084898P 1998-09-18 1998-09-18
US10101498P 1998-09-18 1998-09-18
US60/101,071 1998-09-18
US60/101,014 1998-09-18
US60/101,068 1998-09-18
US60/100,848 1998-09-18
US60/100,849 1998-09-18
US10127998P 1998-09-22 1998-09-22
US60/101,279 1998-09-22
US10147698P 1998-09-23 1998-09-23
US10147298P 1998-09-23 1998-09-23
US10147198P 1998-09-23 1998-09-23
US10147498P 1998-09-23 1998-09-23
US10147798P 1998-09-23 1998-09-23
US10147598P 1998-09-23 1998-09-23
US10147998P 1998-09-23 1998-09-23
US60/101,472 1998-09-23
US60/101,479 1998-09-23
US60/101,474 1998-09-23
US60/101,475 1998-09-23
US60/101,476 1998-09-23
US60/101,477 1998-09-23
US60/101,471 1998-09-23
US10174398P 1998-09-24 1998-09-24
US10173898P 1998-09-24 1998-09-24
US10174198P 1998-09-24 1998-09-24
US10191598P 1998-09-24 1998-09-24
US10191698P 1998-09-24 1998-09-24
US60/101,738 1998-09-24
US60/101,915 1998-09-24
US60/101,916 1998-09-24
US60/101,743 1998-09-24
US60/101,741 1998-09-24
US10224098P 1998-09-29 1998-09-29
US10230798P 1998-09-29 1998-09-29
US10220798P 1998-09-29 1998-09-29
US10233198P 1998-09-29 1998-09-29
US10233098P 1998-09-29 1998-09-29
US60/102,330 1998-09-29
US60/102,331 1998-09-29
US60/102,207 1998-09-29
US60/102,307 1998-09-29
US60/102,240 1998-09-29
US10248498P 1998-09-30 1998-09-30
US10248798P 1998-09-30 1998-09-30
US10257198P 1998-09-30 1998-09-30
US10257098P 1998-09-30 1998-09-30
US60/102,484 1998-09-30
US60/102,570 1998-09-30
US60/102,571 1998-09-30
US60/102,487 1998-09-30
US10268498P 1998-10-01 1998-10-01
US10268798P 1998-10-01 1998-10-01
US60/102,687 1998-10-01
US60/102,684 1998-10-01
US10296598P 1998-10-02 1998-10-02
US60/102,965 1998-10-02
US10344998P 1998-10-06 1998-10-06
US10325898P 1998-10-06 1998-10-06
US60/103,258 1998-10-06
US60/103,449 1998-10-06
US10331598P 1998-10-07 1998-10-07
US10340198P 1998-10-07 1998-10-07
US10332898P 1998-10-07 1998-10-07
US10339598P 1998-10-07 1998-10-07
US10339698P 1998-10-07 1998-10-07
US10331498P 1998-10-07 1998-10-07
US60/103,314 1998-10-07
US60/103,401 1998-10-07
US60/103,328 1998-10-07
US60/103,395 1998-10-07
US60/103,396 1998-10-07
US60/103,315 1998-10-07
US10371198P 1998-10-08 1998-10-08
US10367898P 1998-10-08 1998-10-08
US10367998P 1998-10-08 1998-10-08
US10363398P 1998-10-08 1998-10-08
US60/103,679 1998-10-08
US60/103,678 1998-10-08
US60/103,711 1998-10-08
US60/103,633 1998-10-08
US10425798P 1998-10-14 1998-10-14
US60/104,257 1998-10-14
US10500298P 1998-10-20 1998-10-20
US10500098P 1998-10-20 1998-10-20
US10498798P 1998-10-20 1998-10-20
US60/104,987 1998-10-20
US60/105,000 1998-10-20
US60/105,002 1998-10-20
US10510498P 1998-10-21 1998-10-21
US60/105,104 1998-10-21
US10526698P 1998-10-22 1998-10-22
US10516998P 1998-10-22 1998-10-22
US60/105,169 1998-10-22
US60/105,266 1998-10-22
US10569498P 1998-10-26 1998-10-26
US10569398P 1998-10-26 1998-10-26
US60/105,694 1998-10-26
US60/105,693 1998-10-26
US10588298P 1998-10-27 1998-10-27
US10588198P 1998-10-27 1998-10-27
US10606298P 1998-10-27 1998-10-27
US10580798P 1998-10-27 1998-10-27
US60/105,807 1998-10-27
US60/105,881 1998-10-27
US60/105,882 1998-10-27
US60/106,062 1998-10-27
US10602998P 1998-10-28 1998-10-28
US10617898P 1998-10-28 1998-10-28
US10603398P 1998-10-28 1998-10-28
US10603098P 1998-10-28 1998-10-28
US10602398P 1998-10-28 1998-10-28
US10603298P 1998-10-28 1998-10-28
US60/106,178 1998-10-28
US60/106,033 1998-10-28
US60/106,029 1998-10-28
US60/106,030 1998-10-28
US60/106,032 1998-10-28
US60/106,023 1998-10-28
US10850098P 1998-10-29 1998-10-29
US10624898P 1998-10-29 1998-10-29
US10638498P 1998-10-29 1998-10-29
US60/106,248 1998-10-29
US60/106,384 1998-10-29
US60/108,500 1998-10-29
US10646498P 1998-10-30 1998-10-30
US60/106,464 1998-10-30
US10685698P 1998-11-03 1998-11-03
US60/106,856 1998-11-03
US60/106,905 1998-11-03
US60/106,932 1998-11-03
US60/106,919 1998-11-03
US60/106,934 1998-11-03
US60/106,902 1998-11-03
US60/107,783 1998-11-10
US60/108,801 1998-11-17
US60/108,787 1998-11-17
US60/108,807 1998-11-17
US60/108,788 1998-11-17
US60/108,775 1998-11-17
US60/108,925 1998-11-17
US60/108,779 1998-11-17
US60/108,806 1998-11-17
US60/108,867 1998-11-17
US60/108,802 1998-11-17
US60/108,852 1998-11-18
US60/108,851 1998-11-18
US60/108,848 1998-11-18
US60/108,904 1998-11-18
US60/108,850 1998-11-18
US60/108,858 1998-11-18
US60/108,849 1998-11-18
US09/946,374 US20030073129A1 (en) 1998-09-01 2001-09-04 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/015,480 US7074912B2 (en) 1998-09-01 2001-12-11 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Related Parent Applications (8)

Application Number Title Priority Date Filing Date
PCT/US1998/019330 Continuation-In-Part WO1999014328A2 (fr) 1994-09-08 1998-09-16 Polypeptides secretes et transmembranaires et acides nucleiques les codant
PCT/US1999/000106 Continuation-In-Part WO1999035170A2 (fr) 1996-11-06 1999-01-05 Compositions et methodes pour le traitement des tumeurs
US28429199A Continuation-In-Part 1996-11-06 1999-04-12
US38014299A Continuation 1997-09-15 1999-08-25
US09380139 Continuation-In-Part 1999-08-25
US38013899A Continuation-In-Part 1996-11-06 1999-08-25
PCT/US1999/021194 Continuation-In-Part WO2000017353A1 (fr) 1997-10-29 1999-09-15 Ucp4
US40329799A Continuation-In-Part 1997-08-26 1999-10-18

Related Child Applications (32)

Application Number Title Priority Date Filing Date
PCT/US1999/020594 Continuation-In-Part WO2000015666A2 (fr) 1994-09-08 1999-09-08 Compositions et methodes de traitement des tumeurs
PCT/US1999/021547 Continuation-In-Part WO2000015797A2 (fr) 1994-09-08 1999-09-15 Compositions et methodes de traitement des maladies relatives au syteme immunitaire
US39734299A Continuation 1997-10-29 1999-09-15
PCT/US1999/021194 Continuation-In-Part WO2000017353A1 (fr) 1997-10-29 1999-09-15 Ucp4
US40329799A A-371-Of-International 1997-08-26 1999-10-18
US40329799A Continuation-In-Part 1997-08-26 1999-10-18
US40329699A Continuation-In-Part 1996-11-06 1999-10-18
PCT/US1999/028313 Continuation-In-Part WO2000032221A2 (fr) 1994-09-08 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
PCT/US2000/003565 Continuation-In-Part WO2001053486A1 (fr) 1994-09-08 2000-02-11 Compositions et procedes destines au traitement de tumeur
PCT/US2000/004342 Continuation WO2000078961A1 (fr) 1997-03-31 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
PCT/US2000/004342 Continuation-In-Part WO2000078961A1 (fr) 1997-03-31 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
PCT/US2000/014042 Continuation-In-Part WO2000077037A2 (fr) 1994-09-08 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant
PCT/US2000/014941 Continuation-In-Part WO2000073348A2 (fr) 1996-11-06 2000-05-30 Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
PCT/US2000/023328 Continuation WO2001016318A2 (fr) 1994-09-08 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
PCT/US2000/023328 Continuation-In-Part WO2001016318A2 (fr) 1994-09-08 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
PCT/US2000/030952 Continuation-In-Part WO2001049715A2 (fr) 1996-11-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
PCT/US2001/004342 Continuation-In-Part WO2001059984A1 (fr) 2000-02-11 2001-02-12 Procede et systeme de prevention de contrefaçon
PCT/US2001/006520 Continuation-In-Part WO2001068848A2 (fr) 1996-11-06 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US09/888,257 Continuation US20030060612A1 (en) 1997-10-28 2001-06-22 Compositions and methods for the diagnosis and treatment of tumor
US09/938,418 Continuation-In-Part US20020161199A1 (en) 1998-04-08 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor
US09/938,418 Continuation US20020161199A1 (en) 1998-04-08 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor
PCT/US2001/027099 Continuation-In-Part WO2002024888A2 (fr) 1997-09-15 2001-08-29 Polypeptides secretes transmembranaires et acides nucleiques codant pour ceux-ci
US09/946,374 Continuation US20030073129A1 (en) 1997-09-15 2001-09-04 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US09/946,374 Continuation-In-Part US20030073129A1 (en) 1997-09-15 2001-09-04 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/028,072 Continuation US20030004311A1 (en) 1997-03-31 2001-12-19 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/052,586 Continuation US20020127584A1 (en) 1997-09-15 2002-01-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/081,056 Continuation US20040043927A1 (en) 1997-09-19 2002-02-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US10/119,480 Continuation US20040087769A1 (en) 1998-09-10 2002-04-09 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/180,542 Continuation US20030036121A1 (en) 1998-06-26 2002-06-25 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/197,942 Continuation US20030175882A1 (en) 1998-03-27 2002-07-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US10/272,051 Continuation-In-Part US20030108544A1 (en) 1999-09-01 2002-10-16 Compositions and methods for the diagnosis and treatment of tumor
US10/758,377 Continuation US20040126807A1 (en) 1999-06-02 2004-01-15 Compositions and methods for the diagnosis and treatment of tumor

Publications (2)

Publication Number Publication Date
WO2000012708A2 true WO2000012708A2 (fr) 2000-03-09
WO2000012708A3 WO2000012708A3 (fr) 2001-10-04

Family

ID=56289939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/020111 WO2000012708A2 (fr) 1997-03-31 1999-09-01 Nouveaux pro-polypeptides et sequences correspondantes

Country Status (3)

Country Link
CA (1) CA2339043A1 (fr)
NZ (2) NZ510464A (fr)
WO (1) WO2000012708A2 (fr)

Cited By (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036550A2 (fr) 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Molecules de proteases humaines
WO2000043512A1 (fr) * 1999-01-25 2000-07-27 Zymogenetics, Inc. Polypeptide humain avec multiples domaines du type facteur de croissance epidermique (egf), denomme zntr2
WO2000053747A1 (fr) * 1999-03-11 2000-09-14 Mount Sinai Hospital Gene de la lectine du type immunoglobuline de liaison de l'acide sialique (siglec) ; proteine du type proteine de liaison de ob
EP1043333A1 (fr) * 1997-12-26 2000-10-11 Ono Pharmaceutical Co., Ltd. NOUVEAUX POLYPEPTIDES, ADNc CODANT CES POLYPEPTIDES ET UTILISATION DE CEUX-CI
WO2000061610A2 (fr) * 1999-04-12 2000-10-19 Agensys, Inc. Nouveau gene specifique de la prostate exprime dans le cancer de la prostate
WO2000061754A2 (fr) * 1999-04-09 2000-10-19 Curagen Corporation Nouvelles proteines humaines et polypeptides codant pour ces proteines
WO2001002586A1 (fr) * 1999-06-29 2001-01-11 Mcgill University Alpha 1,2-mannosidase humaine
WO2001004141A2 (fr) * 1999-07-12 2001-01-18 Merck Patent Gmbh Seripancrine
EP1070121A1 (fr) * 1998-03-20 2001-01-24 Smithkline Beecham Corporation Ef-7 un membre de la famille des cytokines
WO2001016319A2 (fr) * 1999-08-31 2001-03-08 Genentech, Inc. Compositions et procedes pour le traitement de maladies d'ordre immunologique
WO2001023557A1 (fr) * 1999-09-29 2001-04-05 Teijin Limited Polypeptides et genes les codant
WO2001027277A2 (fr) * 1999-10-13 2001-04-19 Curagen Corporation Proteines et polynucleotides codes par ces proteines
WO2001029084A2 (fr) * 1999-10-18 2001-04-26 Lexicon Genetics Incorporated Nouvelles proteines humaines et polynucleotides codant pour ces memes proteines
WO2001034796A1 (fr) * 1999-11-10 2001-05-17 Compugen Ltd. Homologues de type chordine
WO2001036440A1 (fr) * 1999-11-19 2001-05-25 Human Genome Sciences, Inc. 23 proteines humaines secretees
WO2001038505A2 (fr) * 1999-11-23 2001-05-31 Zymogenetics, Inc. Proteine secretee, zalpha37
EP1111058A1 (fr) * 1998-08-31 2001-06-27 Yu, Long Nouveau gene de lysozyme humain, son polypeptide de codage et leur procede de preparation
WO2001048203A1 (fr) * 1999-12-27 2001-07-05 Takeda Chemical Industries, Ltd. Nouvelle proteine et adn associe
WO2001053344A2 (fr) * 2000-01-19 2001-07-26 Amgen, Inc. Peptide apparente a la chondromoduline-i
WO2001055390A1 (fr) * 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Polynucleotides, polypeptides, et anticorps serpiniques humains
WO2001064885A1 (fr) * 2000-03-02 2001-09-07 Amgen, Inc. Molecules de type chordine 2 et utilisations de celles-ci
WO2001066720A1 (fr) * 2000-03-10 2001-09-13 Toshio Kitamura Genes de souris d'origine adipocyte
WO2001066740A2 (fr) * 2000-03-03 2001-09-13 Genentech, Inc. Compositions et methodes de traitement de maladies d'origine immune
WO2001068868A2 (fr) * 2000-03-15 2001-09-20 Fibrogen, Inc. Sous-unite alpha(iii) de prolyl-4-hydroxylase
EP1137656A1 (fr) * 1998-11-12 2001-10-04 Human Genome Sciences, Inc. 31 proteines humaines secretees
WO2001073074A2 (fr) * 2000-03-24 2001-10-04 Millennium Pharmaceuticals, Inc. 18806, une nouvelle molecule de type serine-protease de trypsine et ses utilisations
EP1143005A1 (fr) * 1998-12-09 2001-10-10 Shionogi & Co., Ltd. Phospholipase a 2? secretoire humaine
WO2001074851A2 (fr) * 2000-03-30 2001-10-11 Curagen Corporation Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2001080879A2 (fr) * 2000-04-20 2001-11-01 Smithkline Beecham Biologicals S.A. Compositions
WO2001036604A3 (fr) * 1999-11-18 2001-11-01 Corvas Int Inc Acides nucleiques codant pour des endotheliases, endotheliases et leurs utilisations
WO2002000709A2 (fr) * 2000-06-23 2002-01-03 Eli Lilly And Company Polypeptides homologues de la cerebelline et utilisations therapeutiques de ces polypeptides
WO2002002011A1 (fr) * 2000-06-30 2002-01-10 Ortho-Mcneil Pharmaceutical, Inc. And codant une serine protease d-g humaine
WO2002008260A2 (fr) * 2000-07-26 2002-01-31 Stanford University Proteine bstp-ecg1 et reactifs associes et procedes d'utilisation de ceux-ci
WO2002008277A2 (fr) * 2000-07-19 2002-01-31 Eli Lilly And Company Acides nucleiques, vecteurs, cellules hotes, polypeptides et leurs utilisations
WO2002016581A2 (fr) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions et methodes pour le diagnostic et le traitement de tumeurs
WO2002016429A2 (fr) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions et procedes de diagnostic et traitement de tumeurs
WO2002016602A2 (fr) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions et procedes conçus pour le diagnostic et le traitement de tumeur
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
WO2001053352A3 (fr) * 2000-01-19 2002-04-04 Univ Virginia Proteines specifiques du sperme
WO2002031159A1 (fr) * 2000-10-06 2002-04-18 Kirin Beer Kabushiki Kaisha Nouvelle n-acetylglucosaminyltransferase et polynucleotide codant pour celle-ci
EP1206233A2 (fr) * 1999-08-03 2002-05-22 Human Genome Sciences, Inc. Serine proteases
EP1224201A1 (fr) * 1999-10-29 2002-07-24 Human Genome Sciences 32 proteines humaines secretees
US6441131B1 (en) 1997-12-22 2002-08-27 Ono Pharmaceutical Co., Ltd. Peptides, method for assaying human pepsinogen II or human pepsin II, and assaying kit
WO2002002774A3 (fr) * 2000-06-30 2002-08-29 Millennium Pharm Inc Nouvelle udp-glycosyltransferase humaine appelee 32626, et ses utilisations
EP1235843A1 (fr) * 1999-10-29 2002-09-04 Human Genome Sciences, Inc. 26 proteines humaines secretees
WO2002068595A2 (fr) * 2001-02-23 2002-09-06 The Regents Of The University Of California Mono et diacyglycerol acyltransferases et methodes d'utilisation
EP1251863A1 (fr) * 2000-01-31 2002-10-30 Human Genome Sciences, Inc. 22 proteines humaines secretees
WO2002088363A2 (fr) * 2001-05-02 2002-11-07 Bayer Healthcare Ag Regulation de nouvelles prolyl 4-hydroxylases humaines
WO2003012099A1 (fr) * 2001-08-01 2003-02-13 The New Industry Research Organization Synthase de chondroitine
US20030036124A1 (en) 1997-09-18 2003-02-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6573068B1 (en) 1997-11-13 2003-06-03 Genset, S. A. Claudin-50 protein
WO2004016636A1 (fr) * 2002-08-14 2004-02-26 Lg Life Sciences Ltd. Familles de genes liees au cancer gastrique
WO2004035627A1 (fr) * 2002-10-21 2004-04-29 Cambridge University Technical Services Limited Modulation de parcours de signalisation de type beta tgf
WO2004058817A1 (fr) * 2002-12-26 2004-07-15 Takeda Pharmaceutical Company Limited Nouvelles proteines et leur utilisation
WO2004060867A2 (fr) * 2003-01-02 2004-07-22 Timothy Kirk Gallaher Facteur proteine secrete et variant d'epissure membranaire
WO2003024392A3 (fr) * 2001-09-18 2004-10-21 Genentech Inc Compositions et procedes pour le diagnostic et le traitement des tumeurs
WO2004106503A1 (fr) * 2003-05-27 2004-12-09 Applied Research Systems Ars Holding N.V. Nouveaux polypeptides de type il-8
US6855811B2 (en) 1998-01-16 2005-02-15 Incyte Pharmaceuticals, Inc. Human protease molecules
US6914130B2 (en) 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005061704A1 (fr) * 2003-12-24 2005-07-07 Takeda Pharmaceutical Company Limited Substance destinee a la prevention et au traitement du cancer
US6924356B2 (en) 1998-02-09 2005-08-02 Human Genome Sciences, Inc. Human protein HHEPU32
US6949339B1 (en) 1998-05-21 2005-09-27 Diadexus, Inc. Method of diagnosing, monitoring, and staging colon cancer
US6951920B2 (en) * 1998-09-01 2005-10-04 Genentech, Inc. PRO1340 polypeptides
JP2005536190A (ja) * 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
WO2005118631A1 (fr) 2004-06-03 2005-12-15 Takeda Pharmaceutical Company Limited Nouveau complexe protéinique et utilisation de ce complexe
JP2006512903A (ja) * 2002-09-11 2006-04-20 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
EP1652924A2 (fr) * 1998-05-14 2006-05-03 Ono Pharmaceutical Co., Ltd. Polypeptide, l'ADNc qui la code et leur utilisation
US7048923B2 (en) 1998-11-10 2006-05-23 Emory University Antibodies to mitogenic oxygenases
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
AU2002318371B2 (en) * 2001-06-20 2006-06-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7084255B2 (en) 1997-09-18 2006-08-01 Genentech, Inc. PRO1278 polypeptides
US7087737B2 (en) 1998-10-06 2006-08-08 Genentech, Inc. Pro1278 nucleic acids
US7101539B2 (en) 2001-02-28 2006-09-05 Eli Lilly And Company Use of LP82 to treat hematopoietic disorders
US7166427B1 (en) 1999-02-26 2007-01-23 The Ohio University Research Foundation Detecting the expression of the DESC1 gene in squamous cell carcinoma
JP2007077155A (ja) * 2000-08-24 2007-03-29 Genentech Inc 腫瘍の診断と治療のための組成物と方法
US7244428B2 (en) * 1998-09-10 2007-07-17 Genentech, Inc. PRO1357 antibodies
US7244817B2 (en) * 1998-09-10 2007-07-17 Genentech, Inc. Pro1357 polypeptide
US7247717B2 (en) 2000-11-14 2007-07-24 Bristol-Myers Squibb Company Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
WO2007100211A1 (fr) * 2006-02-28 2007-09-07 Curonix Co., Ltd Sisp-1, un nouveau gène cible p53 et son utilisation
US7273610B2 (en) 2003-08-14 2007-09-25 Dyax Corp. Endotheliase-2 ligands
US7282562B2 (en) 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1115863B1 (fr) * 1998-09-22 2007-11-28 Genentech, Inc. Ucp4
WO2007136226A1 (fr) * 2006-05-24 2007-11-29 Industry-Academic Cooperation Foundation, Yonsei Unuversity Procédé de stimulation d'angiogénèse faisant intervenir dkk2 et composition comprenant dkk2
WO2007145466A1 (fr) * 2006-06-14 2007-12-21 Lg Life Sciences Ltd. Famille de gène (lbfl313) associée au cancer du pancréas
WO2008014410A2 (fr) * 2006-07-26 2008-01-31 Zymogenetics, Inc. Polynucléotides et polypeptides zimlig2 et leurs procédés d'utilisation
US7351793B2 (en) * 1998-09-15 2008-04-01 Genentech, Inc. PRO1286 polypeptide
US7381809B2 (en) 1998-09-09 2008-06-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7393684B2 (en) 2003-11-21 2008-07-01 Zymogenetics, Inc. Immunoconjugates of anti-IL-20 antibodies and hybridoma cell lines expressing anti-IL-20 antibodies
US7414112B2 (en) 1998-10-08 2008-08-19 Genentech, Inc. Antibodies to PRO1550 polypeptides
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
US7527933B2 (en) 2002-11-22 2009-05-05 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US7582287B2 (en) 2001-12-17 2009-09-01 Zymogenetics, Inc. Method for treating cervical cancer
AU2003302386B2 (en) * 2002-11-26 2010-04-01 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7704950B2 (en) 2001-03-09 2010-04-27 Zymogenetics, Inc. Methods of using soluble heterodimeric cytokine receptor
US7709611B2 (en) 2004-08-04 2010-05-04 Amgen Inc. Antibodies to Dkk-1
US7723478B2 (en) 1998-09-25 2010-05-25 Amgen Inc. DKR polypeptides
US7737255B1 (en) 1998-09-02 2010-06-15 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating various cancers
US7799898B2 (en) 2000-03-07 2010-09-21 Millennium Pharmaceuticals, Inc. Human transferase family members and uses thereof
US7799899B2 (en) 2003-04-16 2010-09-21 Genentech, Inc. Compositions and methods relating to STOP-1
AU2004241446B2 (en) * 2003-05-16 2010-12-02 Diadexus, Inc. Ovr115 antibody composition and methods of use
US7855269B2 (en) 2000-09-15 2010-12-21 Zymogenetics, Inc. Method for treating inflammation
US7862819B2 (en) 2001-02-23 2011-01-04 The J. David Gladstone Institutes Diacylglycerol O-acyltransferase 2α (DGAT2α)
EP2333112A2 (fr) 2004-02-20 2011-06-15 Veridex, LLC Pronostics de cancer du sein
US8124088B2 (en) 2004-10-22 2012-02-28 Zymogenetics, Inc. Methods of treatment using anti-IL-22RA antibodies
US8163878B2 (en) * 2001-10-12 2012-04-24 Amgen Inc. Tumor Endothelial Marker 5-α molecules and uses thereof
US8163286B2 (en) 2003-03-24 2012-04-24 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
US8287866B2 (en) 2000-08-08 2012-10-16 Zymogenetics, Inc. Methods of treating IL-TIF associated inflammatory or immune diseases using antibodies against soluble zcytor 11 cytokine receptors
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
WO2015004248A2 (fr) * 2013-07-12 2015-01-15 B.R.A.H.M.S Gmbh Dosage immunologique d'augurin
US9044382B2 (en) 2004-05-18 2015-06-02 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9433675B2 (en) 2012-05-23 2016-09-06 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US9487584B2 (en) 2009-11-11 2016-11-08 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis
US9770487B2 (en) 2013-02-20 2017-09-26 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinoma
US9809815B2 (en) 2009-02-20 2017-11-07 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
US9902778B2 (en) 2010-07-06 2018-02-27 Ganymed Pharmaceuticals Ag Cancer therapy using CLDN6 target-directed antibodies in vivo
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US10137195B2 (en) 2013-03-18 2018-11-27 Ganymed Pharmaceuticals Gmbh Therapy involving antibodies against Claudin 18.2 for treatment of cancer
US10233253B2 (en) 2011-05-13 2019-03-19 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
US10604568B2 (en) 2013-07-31 2020-03-31 BioN Tech AG Diagnosis and therapy of cancer involving cancer stem cells
US11306150B2 (en) 2017-01-11 2022-04-19 Bristol-Myers Squibb Company Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist
US11603406B2 (en) 2017-03-14 2023-03-14 Five Prime Therapeutics, Inc. Antibodies binding to VISTA at acidic pH
US12091462B2 (en) 2018-07-11 2024-09-17 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic pH
US12173069B2 (en) 2018-03-21 2024-12-24 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic pH

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
EP1539942A4 (fr) 2001-05-14 2005-10-19 Dendreon Corp Molecules d'acides nucleiques codant pour une serine protease transmembranaire 10, polypeptides codes et methodes associees

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031799A2 (fr) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Polynucleotides et polypeptides codant des recepteurs
WO1999035165A1 (fr) * 1998-01-08 1999-07-15 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031799A2 (fr) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Polynucleotides et polypeptides codant des recepteurs
WO1999035165A1 (fr) * 1998-01-08 1999-07-15 Genetics Institute, Inc. Proteines secretees et polynucleotides les codant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KLEIN R D ET AL: "Selection for genes encoding secreted proteins and receptors" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, no. 93, 1 July 1996 (1996-07-01), pages 7108-7113, XP002061411 ISSN: 0027-8424 cited in the application *
MAECKER H T ET AL: "THE TETRASPANIN SUPERFAMILY: MOLECULAR FACILITATORS" FASEB JOURNAL,US,FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, vol. 11, no. 6, 1 May 1997 (1997-05-01), pages 428-442, XP002037857 ISSN: 0892-6638 cited in the application *

Cited By (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468427B2 (en) 1997-03-31 2008-12-23 Genentech, Inc. Antibodies to PRO1275 polypeptide
US8202966B2 (en) 1997-04-16 2012-06-19 Millennium Pharmaceuticals, Inc. Human Dickkopf-related protein and nucleic acid molecules and uses therefor
US7645451B2 (en) 1997-04-16 2010-01-12 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
US7579168B2 (en) 1997-04-16 2009-08-25 Millennium Pharmaceuticals, Inc. Human Dickkopf-related nucleic acid molecules
US7087421B2 (en) 1997-09-18 2006-08-08 Genentech, Inc. Pro1278 polypeptides
US20030036124A1 (en) 1997-09-18 2003-02-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7084255B2 (en) 1997-09-18 2006-08-01 Genentech, Inc. PRO1278 polypeptides
US7056680B2 (en) 1997-11-13 2006-06-06 Serono Genetics Institute S.A. Antibodies to claudin-50 polypeptide
US6573068B1 (en) 1997-11-13 2003-06-03 Genset, S. A. Claudin-50 protein
US6441131B1 (en) 1997-12-22 2002-08-27 Ono Pharmaceutical Co., Ltd. Peptides, method for assaying human pepsinogen II or human pepsin II, and assaying kit
EP1043333A4 (fr) * 1997-12-26 2001-11-28 Ono Pharmaceutical Co NOUVEAUX POLYPEPTIDES, ADNc CODANT CES POLYPEPTIDES ET UTILISATION DE CEUX-CI
EP1043333A1 (fr) * 1997-12-26 2000-10-11 Ono Pharmaceutical Co., Ltd. NOUVEAUX POLYPEPTIDES, ADNc CODANT CES POLYPEPTIDES ET UTILISATION DE CEUX-CI
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
US8043818B2 (en) 1998-01-16 2011-10-25 Incyte Corporation Methods for detecting expression of human protease molecules
WO1999036550A2 (fr) 1998-01-16 1999-07-22 Incyte Pharmaceuticals, Inc. Molecules de proteases humaines
US6855811B2 (en) 1998-01-16 2005-02-15 Incyte Pharmaceuticals, Inc. Human protease molecules
US6924356B2 (en) 1998-02-09 2005-08-02 Human Genome Sciences, Inc. Human protein HHEPU32
EP1070121A4 (fr) * 1998-03-20 2005-01-05 Smithkline Beecham Corp Ef-7 un membre de la famille des cytokines
EP1070121A1 (fr) * 1998-03-20 2001-01-24 Smithkline Beecham Corporation Ef-7 un membre de la famille des cytokines
US6365369B1 (en) 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
EP1652924A2 (fr) * 1998-05-14 2006-05-03 Ono Pharmaceutical Co., Ltd. Polypeptide, l'ADNc qui la code et leur utilisation
EP1652924A3 (fr) * 1998-05-14 2006-09-13 Ono Pharmaceutical Co., Ltd. Polypeptide, l'ADNc qui la code et leur utilisation
US6949339B1 (en) 1998-05-21 2005-09-27 Diadexus, Inc. Method of diagnosing, monitoring, and staging colon cancer
US6914130B2 (en) 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1111058A4 (fr) * 1998-08-31 2003-01-02 Long Yu Nouveau gene de lysozyme humain, son polypeptide de codage et leur procede de preparation
EP1111058A1 (fr) * 1998-08-31 2001-06-27 Yu, Long Nouveau gene de lysozyme humain, son polypeptide de codage et leur procede de preparation
US7033786B2 (en) * 1998-09-01 2006-04-25 Genentech, Inc. Pro1340 nucleic acids
US6951920B2 (en) * 1998-09-01 2005-10-04 Genentech, Inc. PRO1340 polypeptides
US7737255B1 (en) 1998-09-02 2010-06-15 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating various cancers
US8029787B2 (en) 1998-09-02 2011-10-04 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating various cancers
US7381809B2 (en) 1998-09-09 2008-06-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7244428B2 (en) * 1998-09-10 2007-07-17 Genentech, Inc. PRO1357 antibodies
US7244817B2 (en) * 1998-09-10 2007-07-17 Genentech, Inc. Pro1357 polypeptide
US7351793B2 (en) * 1998-09-15 2008-04-01 Genentech, Inc. PRO1286 polypeptide
EP1115863B1 (fr) * 1998-09-22 2007-11-28 Genentech, Inc. Ucp4
US7723478B2 (en) 1998-09-25 2010-05-25 Amgen Inc. DKR polypeptides
US7087737B2 (en) 1998-10-06 2006-08-08 Genentech, Inc. Pro1278 nucleic acids
US7728108B2 (en) 1998-10-08 2010-06-01 Genentech Inc. PRO1550 polypeptides
US7414112B2 (en) 1998-10-08 2008-08-19 Genentech, Inc. Antibodies to PRO1550 polypeptides
US7247709B2 (en) 1998-11-10 2007-07-24 Emory University Mitogenic oxygenases
US7048923B2 (en) 1998-11-10 2006-05-23 Emory University Antibodies to mitogenic oxygenases
EP1137656A4 (fr) * 1998-11-12 2003-08-06 Human Genome Sciences Inc 31 proteines humaines secretees
EP1137656A1 (fr) * 1998-11-12 2001-10-04 Human Genome Sciences, Inc. 31 proteines humaines secretees
US7432345B2 (en) 1998-11-17 2008-10-07 Genentech, Inc. PRO1475 polypeptide
EP1143005A4 (fr) * 1998-12-09 2002-11-06 Shionogi & Co Phospholipase a 2? secretoire humaine
EP1143005A1 (fr) * 1998-12-09 2001-10-10 Shionogi & Co., Ltd. Phospholipase a 2? secretoire humaine
WO2000043512A1 (fr) * 1999-01-25 2000-07-27 Zymogenetics, Inc. Polypeptide humain avec multiples domaines du type facteur de croissance epidermique (egf), denomme zntr2
US7166427B1 (en) 1999-02-26 2007-01-23 The Ohio University Research Foundation Detecting the expression of the DESC1 gene in squamous cell carcinoma
WO2000053747A1 (fr) * 1999-03-11 2000-09-14 Mount Sinai Hospital Gene de la lectine du type immunoglobuline de liaison de l'acide sialique (siglec) ; proteine du type proteine de liaison de ob
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
WO2000061754A3 (fr) * 1999-04-09 2001-05-31 Curagen Corp Nouvelles proteines humaines et polypeptides codant pour ces proteines
WO2000061754A2 (fr) * 1999-04-09 2000-10-19 Curagen Corporation Nouvelles proteines humaines et polypeptides codant pour ces proteines
WO2000061610A3 (fr) * 1999-04-12 2001-03-15 Urogenesys Inc Nouveau gene specifique de la prostate exprime dans le cancer de la prostate
WO2000061610A2 (fr) * 1999-04-12 2000-10-19 Agensys, Inc. Nouveau gene specifique de la prostate exprime dans le cancer de la prostate
WO2001002586A1 (fr) * 1999-06-29 2001-01-11 Mcgill University Alpha 1,2-mannosidase humaine
WO2001004141A2 (fr) * 1999-07-12 2001-01-18 Merck Patent Gmbh Seripancrine
US7011967B1 (en) 1999-07-12 2006-03-14 Merck Patent Gmbh Seripancrin
WO2001004141A3 (fr) * 1999-07-12 2001-05-25 Merck Patent Gmbh Seripancrine
EP1206233A2 (fr) * 1999-08-03 2002-05-22 Human Genome Sciences, Inc. Serine proteases
EP1206233A4 (fr) * 1999-08-03 2004-04-14 Human Genome Sciences Inc Serine proteases
WO2001016319A2 (fr) * 1999-08-31 2001-03-08 Genentech, Inc. Compositions et procedes pour le traitement de maladies d'ordre immunologique
WO2001016319A3 (fr) * 1999-08-31 2001-10-04 Genentech Inc Compositions et procedes pour le traitement de maladies d'ordre immunologique
US7576182B1 (en) 1999-08-31 2009-08-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7282562B2 (en) 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2001023557A1 (fr) * 1999-09-29 2001-04-05 Teijin Limited Polypeptides et genes les codant
US7575922B2 (en) 1999-09-29 2009-08-18 Teijin Limited Polypeptide and gene encoding the same
US8030277B2 (en) 1999-09-29 2011-10-04 Teijin Limited Polypeptide and gene encoding the same
WO2001027277A2 (fr) * 1999-10-13 2001-04-19 Curagen Corporation Proteines et polynucleotides codes par ces proteines
WO2001027277A3 (fr) * 1999-10-13 2002-04-18 Curagen Corp Proteines et polynucleotides codes par ces proteines
WO2001029084A3 (fr) * 1999-10-18 2001-11-01 Lexicon Genetics Inc Nouvelles proteines humaines et polynucleotides codant pour ces memes proteines
WO2001029084A2 (fr) * 1999-10-18 2001-04-26 Lexicon Genetics Incorporated Nouvelles proteines humaines et polynucleotides codant pour ces memes proteines
EP1224201A1 (fr) * 1999-10-29 2002-07-24 Human Genome Sciences 32 proteines humaines secretees
EP1235843A1 (fr) * 1999-10-29 2002-09-04 Human Genome Sciences, Inc. 26 proteines humaines secretees
EP1235843A4 (fr) * 1999-10-29 2005-04-20 Human Genome Sciences Inc 26 proteines humaines secretees
EP1224201A4 (fr) * 1999-10-29 2005-03-02 Human Genome Sciences Inc 32 proteines humaines secretees
WO2001034796A1 (fr) * 1999-11-10 2001-05-17 Compugen Ltd. Homologues de type chordine
US7276364B1 (en) 1999-11-18 2007-10-02 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
WO2001036604A3 (fr) * 1999-11-18 2001-11-01 Corvas Int Inc Acides nucleiques codant pour des endotheliases, endotheliases et leurs utilisations
WO2001036440A1 (fr) * 1999-11-19 2001-05-25 Human Genome Sciences, Inc. 23 proteines humaines secretees
WO2001038505A3 (fr) * 1999-11-23 2001-11-22 Zymogenetics Inc Proteine secretee, zalpha37
WO2001038505A2 (fr) * 1999-11-23 2001-05-31 Zymogenetics, Inc. Proteine secretee, zalpha37
WO2001048203A1 (fr) * 1999-12-27 2001-07-05 Takeda Chemical Industries, Ltd. Nouvelle proteine et adn associe
WO2001053352A3 (fr) * 2000-01-19 2002-04-04 Univ Virginia Proteines specifiques du sperme
US7094547B2 (en) 2000-01-19 2006-08-22 University Of Virginia Patent Foundation Sperm specific proteins
US6924121B2 (en) 2000-01-19 2005-08-02 University Of Virginia Patent Foundation Sperm specific proteins
WO2001053344A3 (fr) * 2000-01-19 2002-01-03 Amgen Inc Peptide apparente a la chondromoduline-i
WO2001053344A2 (fr) * 2000-01-19 2001-07-26 Amgen, Inc. Peptide apparente a la chondromoduline-i
WO2001055390A1 (fr) * 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Polynucleotides, polypeptides, et anticorps serpiniques humains
EP1251863A1 (fr) * 2000-01-31 2002-10-30 Human Genome Sciences, Inc. 22 proteines humaines secretees
EP1251863A4 (fr) * 2000-01-31 2005-03-02 Human Genome Sciences Inc 22 proteines humaines secretees
WO2001064885A1 (fr) * 2000-03-02 2001-09-07 Amgen, Inc. Molecules de type chordine 2 et utilisations de celles-ci
WO2001066740A2 (fr) * 2000-03-03 2001-09-13 Genentech, Inc. Compositions et methodes de traitement de maladies d'origine immune
WO2001066740A3 (fr) * 2000-03-03 2002-09-19 Genentech Inc Compositions et methodes de traitement de maladies d'origine immune
US8252915B2 (en) 2000-03-07 2012-08-28 Millennium Pharmaceuticals, Inc. Human transferase family members and uses thereof
US7799898B2 (en) 2000-03-07 2010-09-21 Millennium Pharmaceuticals, Inc. Human transferase family members and uses thereof
WO2001066720A1 (fr) * 2000-03-10 2001-09-13 Toshio Kitamura Genes de souris d'origine adipocyte
WO2001068868A3 (fr) * 2000-03-15 2002-01-31 Fibrogen Inc Sous-unite alpha(iii) de prolyl-4-hydroxylase
WO2001068868A2 (fr) * 2000-03-15 2001-09-20 Fibrogen, Inc. Sous-unite alpha(iii) de prolyl-4-hydroxylase
WO2001073074A2 (fr) * 2000-03-24 2001-10-04 Millennium Pharmaceuticals, Inc. 18806, une nouvelle molecule de type serine-protease de trypsine et ses utilisations
WO2001073074A3 (fr) * 2000-03-24 2003-03-13 Millennium Pharm Inc 18806, une nouvelle molecule de type serine-protease de trypsine et ses utilisations
WO2001074851A3 (fr) * 2000-03-30 2002-10-17 Curagen Corp Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2001074851A2 (fr) * 2000-03-30 2001-10-11 Curagen Corporation Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2001080879A2 (fr) * 2000-04-20 2001-11-01 Smithkline Beecham Biologicals S.A. Compositions
WO2001080879A3 (fr) * 2000-04-20 2002-05-16 Smithkline Beecham Biolog Compositions
WO2002000709A3 (fr) * 2000-06-23 2002-06-20 Lilly Co Eli Polypeptides homologues de la cerebelline et utilisations therapeutiques de ces polypeptides
WO2002000709A2 (fr) * 2000-06-23 2002-01-03 Eli Lilly And Company Polypeptides homologues de la cerebelline et utilisations therapeutiques de ces polypeptides
WO2002002011A1 (fr) * 2000-06-30 2002-01-10 Ortho-Mcneil Pharmaceutical, Inc. And codant une serine protease d-g humaine
US7070977B2 (en) 2000-06-30 2006-07-04 Ortho-Mcneil Pharmaceutical, Inc. Human serine protease D-G polypeptide
WO2002002774A3 (fr) * 2000-06-30 2002-08-29 Millennium Pharm Inc Nouvelle udp-glycosyltransferase humaine appelee 32626, et ses utilisations
US6750034B1 (en) 2000-06-30 2004-06-15 Ortho-Mcneil Pharmaceutical, Inc. DNA encoding human serine protease D-G
WO2002008277A3 (fr) * 2000-07-19 2003-01-30 Lilly Co Eli Acides nucleiques, vecteurs, cellules hotes, polypeptides et leurs utilisations
WO2002008277A2 (fr) * 2000-07-19 2002-01-31 Eli Lilly And Company Acides nucleiques, vecteurs, cellules hotes, polypeptides et leurs utilisations
WO2002008260A2 (fr) * 2000-07-26 2002-01-31 Stanford University Proteine bstp-ecg1 et reactifs associes et procedes d'utilisation de ceux-ci
WO2002008260A3 (fr) * 2000-07-26 2002-10-17 Univ Stanford Proteine bstp-ecg1 et reactifs associes et procedes d'utilisation de ceux-ci
US8287866B2 (en) 2000-08-08 2012-10-16 Zymogenetics, Inc. Methods of treating IL-TIF associated inflammatory or immune diseases using antibodies against soluble zcytor 11 cytokine receptors
WO2002016581A3 (fr) * 2000-08-24 2003-01-16 Genentech Inc Compositions et methodes pour le diagnostic et le traitement de tumeurs
WO2002016602A3 (fr) * 2000-08-24 2003-02-06 Genentech Inc Compositions et procedes conçus pour le diagnostic et le traitement de tumeur
JP2007077155A (ja) * 2000-08-24 2007-03-29 Genentech Inc 腫瘍の診断と治療のための組成物と方法
AU2001286785B2 (en) * 2000-08-24 2006-08-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2002016429A3 (fr) * 2000-08-24 2003-01-03 Genentech Inc Compositions et procedes de diagnostic et traitement de tumeurs
WO2002016602A2 (fr) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions et procedes conçus pour le diagnostic et le traitement de tumeur
WO2002016429A2 (fr) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions et procedes de diagnostic et traitement de tumeurs
WO2002016581A2 (fr) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions et methodes pour le diagnostic et le traitement de tumeurs
US7855269B2 (en) 2000-09-15 2010-12-21 Zymogenetics, Inc. Method for treating inflammation
US7217548B2 (en) 2000-10-06 2007-05-15 National Institute Of Advanced Industrial Science And Technology N-acetylglucosaminlytransferase and polynucleotide encoding the same
WO2002031159A1 (fr) * 2000-10-06 2002-04-18 Kirin Beer Kabushiki Kaisha Nouvelle n-acetylglucosaminyltransferase et polynucleotide codant pour celle-ci
US7256267B2 (en) 2000-11-14 2007-08-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
US7247717B2 (en) 2000-11-14 2007-07-24 Bristol-Myers Squibb Company Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
US7045326B2 (en) 2001-02-23 2006-05-16 The Regents Of The University Of California Mono- and diacylglycerol acyltransferases and methods of use thereof
WO2002068595A2 (fr) * 2001-02-23 2002-09-06 The Regents Of The University Of California Mono et diacyglycerol acyltransferases et methodes d'utilisation
US7862819B2 (en) 2001-02-23 2011-01-04 The J. David Gladstone Institutes Diacylglycerol O-acyltransferase 2α (DGAT2α)
WO2002068595A3 (fr) * 2001-02-23 2002-10-31 Univ California Mono et diacyglycerol acyltransferases et methodes d'utilisation
US7101539B2 (en) 2001-02-28 2006-09-05 Eli Lilly And Company Use of LP82 to treat hematopoietic disorders
US8133487B2 (en) 2001-03-09 2012-03-13 Zymogenetics, Inc. Soluble heterodimeric cytokine receptor
US7704950B2 (en) 2001-03-09 2010-04-27 Zymogenetics, Inc. Methods of using soluble heterodimeric cytokine receptor
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
US7285633B2 (en) 2001-04-26 2007-10-23 Bristol-Myers Squibb Company Metalloprotease highly expressed in the testis, MMP-29
WO2002088363A3 (fr) * 2001-05-02 2003-07-31 Bayer Ag Regulation de nouvelles prolyl 4-hydroxylases humaines
WO2002088363A2 (fr) * 2001-05-02 2002-11-07 Bayer Healthcare Ag Regulation de nouvelles prolyl 4-hydroxylases humaines
AU2002318371B2 (en) * 2001-06-20 2006-06-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7354741B2 (en) 2001-08-01 2008-04-08 Otsuka Chemical Co., Ltd. Method for producing saccharide chain-extended chondroitin
WO2003012099A1 (fr) * 2001-08-01 2003-02-13 The New Industry Research Organization Synthase de chondroitine
AU2002323753B2 (en) * 2001-08-01 2007-12-13 Glytech, Inc. Chondroitin synthase
US8334115B2 (en) 2001-08-01 2012-12-18 Glytech, Inc. Chondroitin synthase, method for producing the same and method for producing saccharide chain-extended chondroitin
US8685674B2 (en) 2001-08-01 2014-04-01 Glytech, Inc. Chondroitin synthase, method for producing the same and method for producing saccharide chain-extended chondroitin
JP2003047467A (ja) * 2001-08-01 2003-02-18 New Industry Research Organization コンドロイチン合成酵素
US7947481B2 (en) 2001-08-01 2011-05-24 Otsuka Chemical Co., Ltd. Chondroitin synthase, method for producing the same and method for producing saccharide chain-extended chondroitin
AU2002330015B2 (en) * 2001-09-18 2008-02-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003024392A3 (fr) * 2001-09-18 2004-10-21 Genentech Inc Compositions et procedes pour le diagnostic et le traitement des tumeurs
US7951546B2 (en) 2001-09-18 2011-05-31 Genetech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7939268B2 (en) 2001-09-18 2011-05-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8163878B2 (en) * 2001-10-12 2012-04-24 Amgen Inc. Tumor Endothelial Marker 5-α molecules and uses thereof
US8420332B2 (en) 2001-10-12 2013-04-16 Amgen Inc. Tumor endothelial marker 5-α molecules and uses thereof
US7582287B2 (en) 2001-12-17 2009-09-01 Zymogenetics, Inc. Method for treating cervical cancer
US8486382B2 (en) 2001-12-17 2013-07-16 Zymogenetics, Inc. Method for treating cervical cancer
JP2005536190A (ja) * 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
WO2004016636A1 (fr) * 2002-08-14 2004-02-26 Lg Life Sciences Ltd. Familles de genes liees au cancer gastrique
JP2006512903A (ja) * 2002-09-11 2006-04-20 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
WO2004035627A1 (fr) * 2002-10-21 2004-04-29 Cambridge University Technical Services Limited Modulation de parcours de signalisation de type beta tgf
US7527933B2 (en) 2002-11-22 2009-05-05 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US8088588B2 (en) 2002-11-22 2012-01-03 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use of thereof
US10414824B2 (en) 2002-11-22 2019-09-17 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US8586047B2 (en) 2002-11-22 2013-11-19 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US8637012B2 (en) 2002-11-22 2014-01-28 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
AU2003302386B2 (en) * 2002-11-26 2010-04-01 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004058817A1 (fr) * 2002-12-26 2004-07-15 Takeda Pharmaceutical Company Limited Nouvelles proteines et leur utilisation
WO2004060867A2 (fr) * 2003-01-02 2004-07-22 Timothy Kirk Gallaher Facteur proteine secrete et variant d'epissure membranaire
WO2004060867A3 (fr) * 2003-01-02 2006-08-03 Timothy Kirk Gallaher Facteur proteine secrete et variant d'epissure membranaire
US8163286B2 (en) 2003-03-24 2012-04-24 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
US7799899B2 (en) 2003-04-16 2010-09-21 Genentech, Inc. Compositions and methods relating to STOP-1
AU2004241446B2 (en) * 2003-05-16 2010-12-02 Diadexus, Inc. Ovr115 antibody composition and methods of use
WO2004106503A1 (fr) * 2003-05-27 2004-12-09 Applied Research Systems Ars Holding N.V. Nouveaux polypeptides de type il-8
US7273610B2 (en) 2003-08-14 2007-09-25 Dyax Corp. Endotheliase-2 ligands
US8907068B2 (en) 2003-11-21 2014-12-09 Zymogenetics, Inc. Anti-IL-20 antibodies and binding partners and methods of using in inflammation
US7393684B2 (en) 2003-11-21 2008-07-01 Zymogenetics, Inc. Immunoconjugates of anti-IL-20 antibodies and hybridoma cell lines expressing anti-IL-20 antibodies
WO2005061704A1 (fr) * 2003-12-24 2005-07-07 Takeda Pharmaceutical Company Limited Substance destinee a la prevention et au traitement du cancer
EP2333112A2 (fr) 2004-02-20 2011-06-15 Veridex, LLC Pronostics de cancer du sein
US9044382B2 (en) 2004-05-18 2015-06-02 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
US9775785B2 (en) 2004-05-18 2017-10-03 Ganymed Pharmaceuticals Ag Antibody to genetic products differentially expressed in tumors and the use thereof
WO2005118631A1 (fr) 2004-06-03 2005-12-15 Takeda Pharmaceutical Company Limited Nouveau complexe protéinique et utilisation de ce complexe
US7709611B2 (en) 2004-08-04 2010-05-04 Amgen Inc. Antibodies to Dkk-1
US8101184B2 (en) 2004-08-04 2012-01-24 Amgen Inc. Treatment methods using Dkk-1 antibodies
US8124088B2 (en) 2004-10-22 2012-02-28 Zymogenetics, Inc. Methods of treatment using anti-IL-22RA antibodies
US8536309B2 (en) 2004-10-22 2013-09-17 Zymogenetics, Inc. Methods of producing anti-IL-22RA antibodies
US9212228B2 (en) 2005-11-24 2015-12-15 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US9499609B2 (en) 2005-11-24 2016-11-22 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US10017564B2 (en) 2005-11-24 2018-07-10 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US9751934B2 (en) 2005-11-24 2017-09-05 Ganymed Pharmaceuticals Ag Monoclonal antibodies against claudin-18 for treatment of cancer
US10738108B2 (en) 2005-11-24 2020-08-11 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
US11739139B2 (en) 2005-11-24 2023-08-29 Astellas Pharma Inc. Monoclonal antibodies against Claudin-18 for treatment of cancer
US10174104B2 (en) 2005-11-24 2019-01-08 Ganymed Pharmaceuticals Gmbh Monoclonal antibodies against claudin-18 for treatment of cancer
US7655778B2 (en) 2006-02-28 2010-02-02 Curonix Co., Ltd. SISP-1, a novel p53 target gene and use thereof
WO2007100211A1 (fr) * 2006-02-28 2007-09-07 Curonix Co., Ltd Sisp-1, un nouveau gène cible p53 et son utilisation
US8067387B2 (en) 2006-05-24 2011-11-29 Theragen Etex Co., Ltd Method for stimulating angiogenesis using DKK2 and composition comprising the same
WO2007136226A1 (fr) * 2006-05-24 2007-11-29 Industry-Academic Cooperation Foundation, Yonsei Unuversity Procédé de stimulation d'angiogénèse faisant intervenir dkk2 et composition comprenant dkk2
WO2007145466A1 (fr) * 2006-06-14 2007-12-21 Lg Life Sciences Ltd. Famille de gène (lbfl313) associée au cancer du pancréas
WO2008014410A2 (fr) * 2006-07-26 2008-01-31 Zymogenetics, Inc. Polynucléotides et polypeptides zimlig2 et leurs procédés d'utilisation
WO2008014410A3 (fr) * 2006-07-26 2008-05-02 Zymogenetics Inc Polynucléotides et polypeptides zimlig2 et leurs procédés d'utilisation
US11473085B2 (en) 2009-02-20 2022-10-18 Ganymed Pharmaceuticals Gmbh Methods and compositions for diagnosis and treatment of cancer
US9809815B2 (en) 2009-02-20 2017-11-07 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
US9487584B2 (en) 2009-11-11 2016-11-08 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
US9932401B2 (en) 2009-11-11 2018-04-03 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (CLDN6)
US10745477B2 (en) 2009-11-11 2020-08-18 Ganymed Pharmaceuticals Gmbh Antibodies specific for claudin 6 (CLDN6)
US11858988B2 (en) 2009-11-11 2024-01-02 Ganymed Pharmaceuticals Gmbh Antibodies specific for claudin 6 (CLDN6)
US10844133B2 (en) 2010-07-06 2020-11-24 Ganymed Pharmaceuticals Gmbh Cancer therapy using CLDN6 target-directed antibodies in vivo
US9902778B2 (en) 2010-07-06 2018-02-27 Ganymed Pharmaceuticals Ag Cancer therapy using CLDN6 target-directed antibodies in vivo
US10233253B2 (en) 2011-05-13 2019-03-19 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
US11859008B2 (en) 2011-05-13 2024-01-02 Ganymed Pharmaceuticals Gmbh Antibodies for treatment of cancer expressing claudin 6
US10919974B2 (en) 2011-05-13 2021-02-16 Ganymed Pharmaceuticals Gmbh Antibodies for treatment of cancer expressing claudin 6
US9512232B2 (en) 2012-05-09 2016-12-06 Ganymed Pharmaceuticals Ag Antibodies against Claudin 18.2 useful in cancer diagnosis
US10053512B2 (en) 2012-05-09 2018-08-21 Ganymed Pharmaceuticals Ag Antibodies against claudin 18.2 useful in cancer diagnosis
US11976130B2 (en) 2012-05-09 2024-05-07 Astellas Pharma Inc. Antibodies against claudin 18.2 useful in cancer diagnosis
US10022444B2 (en) 2012-05-23 2018-07-17 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
US10813996B2 (en) 2012-05-23 2020-10-27 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
US12059464B2 (en) 2012-05-23 2024-08-13 Astellas Pharma Inc. Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
US9433675B2 (en) 2012-05-23 2016-09-06 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US10093736B2 (en) 2012-11-13 2018-10-09 Biontech Ag Agents for treatment of claudin expressing cancer diseases
US9770487B2 (en) 2013-02-20 2017-09-26 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinoma
US11826402B2 (en) 2013-02-20 2023-11-28 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma
US10946069B2 (en) 2013-02-20 2021-03-16 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
US10314890B2 (en) 2013-02-20 2019-06-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
US10137195B2 (en) 2013-03-18 2018-11-27 Ganymed Pharmaceuticals Gmbh Therapy involving antibodies against Claudin 18.2 for treatment of cancer
US11395852B2 (en) 2013-03-18 2022-07-26 Astellas Pharma Inc. Therapy involving antibodies against Claudin 18.2 for treatment of cancer
US10024872B2 (en) 2013-07-12 2018-07-17 B.R.A.H.M.S Gmbh Augurin immunoassay
WO2015004248A3 (fr) * 2013-07-12 2015-03-19 B.R.A.H.M.S Gmbh Dosage immunologique d'augurin
WO2015004248A2 (fr) * 2013-07-12 2015-01-15 B.R.A.H.M.S Gmbh Dosage immunologique d'augurin
US11795218B2 (en) 2013-07-31 2023-10-24 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
US10604568B2 (en) 2013-07-31 2020-03-31 BioN Tech AG Diagnosis and therapy of cancer involving cancer stem cells
US11306150B2 (en) 2017-01-11 2022-04-19 Bristol-Myers Squibb Company Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist
US11603406B2 (en) 2017-03-14 2023-03-14 Five Prime Therapeutics, Inc. Antibodies binding to VISTA at acidic pH
US12195535B2 (en) 2017-03-14 2025-01-14 Five Prime Therapeutics, Inc. Antibodies binding to VISTA at acidic pH
US12173069B2 (en) 2018-03-21 2024-12-24 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic pH
US12091462B2 (en) 2018-07-11 2024-09-17 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic pH

Also Published As

Publication number Publication date
NZ531664A (en) 2005-07-29
WO2000012708A3 (fr) 2001-10-04
CA2339043A1 (fr) 2000-03-09
NZ510464A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
US7538086B2 (en) PRO1303 polypeptides
US6924355B2 (en) PRO1343 polypeptides
WO2000012708A2 (fr) Nouveaux pro-polypeptides et sequences correspondantes
WO2000078961A1 (fr) Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
US20030073129A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030119097A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7488796B2 (en) PRO1269 polypeptides
US20090197301A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7399834B2 (en) Anti-PRO1558 antibodies
US20040073015A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7029875B2 (en) PRO1343 nucleic acids
EP1144629A2 (fr) Nouveaux pro-polypeptides et sequences correspondantes
AU759150B2 (en) Further pro polypeptides and sequences thereof
US20030166901A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003518361A (ja) 更なるｐｒｏポリペプチドとその配列
US20030224478A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR20030000010A (ko) 추가적인 ｐｒｏ 폴리펩티드 및 그의 서열

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09403297

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 55908/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001/01180

Country of ref document: ZA

Ref document number: 200101180

Country of ref document: ZA

ENP Entry into the national phase in:

Ref document number: 2339043

Country of ref document: CA

Ref country code: CA

Ref document number: 2339043

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 141420

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1999942557

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020017002587

Country of ref document: KR

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 567695

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/002238

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 510464

Country of ref document: NZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1999942557

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10226739

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020017002587

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1020017002587

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999942557

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载